deoxycytidine has been researched along with Carcinoma, Non-Small Cell Lung in 1678 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 175 (10.43) | 18.2507 |
| 2000's | 875 (52.15) | 29.6817 |
| 2010's | 572 (34.09) | 24.3611 |
| 2020's | 56 (3.34) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, Y; Fukuoka, M; Higashiyama, M; Iked, N; Katakami, N; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Negoro, S; Nomori, H; Oda, M; Ohta, M; Saka, H; Sawa, T; Semba, H; Seto, T; Shimokawa, M; Tada, H; Yamaguchi, M; Yamashita, M; Yokoi, K | 1 |
| Chen, X; Guo, S; Li, Y; Meng, M; Mo, G; Su, H; Xi, J | 1 |
| Dong, Z; Feng, Q; Gong, J; Liu, Q; Zhang, H | 1 |
| Björn, N; Brandén, E; De Petris, L; Gréen, H; Jakobsen, I; Koyi, H; Lewensohn, R; Udagawa, C; Zembutsu, H | 1 |
| Chen, P; Guo, N; Li, J; Li, S; Liu, B; Tang, J; Zhang, W; Zhao, Y | 1 |
| Pandit, B; Royzen, M | 1 |
| He, Y; Huang, M; Yi, C; Zhang, L | 1 |
| Chen, W; Fang, Z; Tan, X; Xu, Y; Yang, Q | 1 |
| Guo, B; Meng, F; Sun, Y; Wang, J; Wei, J; Yuan, J; Zhong, Z | 1 |
| Du, H; Gong, Y; Lan, J; Na, F; Shao, B; Wang, Y; Wu, S; Xiang, L; Xie, G | 1 |
| Atri, P; Batra, SK; Bessho, M; Bessho, T; Chirravuri, R; Cox, JL; Foster, JM; Ganguly, K; Ganti, AK; Lakshmanan, I; Nallasamy, P; Nimmakayala, RK; Ogunleye, AO; Parte, S; Ponnusamy, MP; Rauth, S; Talmon, GA; Varadharaj, V; Vengoji, R | 1 |
| Geater, SL; Jirapongsak, J; Raungrut, P; Tanyapattrapong, S; Thongsuksai, P | 1 |
| Hasegawa, Y; Hirabayashi, M; Hirai, T; Ikeda, S; Ishida, T; Kaneda, T; Komaki, C; Morita, M; Nakano, Y; Niwa, T; Noguchi, T; Sakaguchi, C; Sone, N; Tomioka, H; Yokoyama, T; Yoshimura, K; Yoshioka, H | 1 |
| Chen, C; Chen, T; Fu, S; He, LN; Hong, S; Li, H; Lin, Z; Wang, Y; Zhang, L; Zhang, X; Zhou, Y | 1 |
| Dubray, B; Ganem, J; Gouel, P; Salaun, M; Texte, E; Thureau, S; Vera, P | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Apellániz-Ruiz, M; Björn, N; Brandén, E; de Petris, L; Gréen, H; Koyi, H; Lewensohn, R; Lundeberg, J; Pradhananga, S; Rodríguez-Antona, C; Sigurgeirsson, B; Svedberg, A | 2 |
| Fang, C; Hu, WW; Ji, M; Wu, J; Zhang, C; Zhao, WQ | 1 |
| Ishiki, H; Kubo, E; Satomi, E; Tateishi, A | 1 |
| Wu, YL; Yan, HH; Zhong, WZ | 1 |
| He, Z; Li, Y; Liu, Y; Niu, Y; Shi, H; Xu, M; Xu, Q; Zhang, Y; Zhu, J | 1 |
| Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L | 1 |
| Cao, W; Hu, X; Li, H; Liang, L; Liu, J; Wang, W; Wang, Z; Xiao, X; Yang, Q; Yuan, Z; Zhang, B; Zhou, P | 1 |
| Georgoulias, V; Ioannidis, G; Lagoudaki, E; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tzardi, M | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Chen, J; Fan, Y; He, T; Li, W; Liu, Y; Wang, Q; Wang, Y; Wang, Z | 1 |
| Han, J; Liang, Y; Svirskis, D; Tian, B; Wu, Z; Zhang, J | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| Akamine, S; Ebi, N; Ichiki, M; Matsumoto, T; Nakanishi, Y; Takayama, K; Tokunaga, S; Uchino, J; Yamada, T | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Ilbasmis-Tamer, S; Takka, S; Yalcin, TE | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Blasi, M; Bozorgmehr, F; Hommertgen, A; Kieser, M; Krisam, J; Kuon, J; Lasitschka, F; Maenz, M; Schneider, M; Stenzinger, A; Thomas, M | 1 |
| Fujita, M; Harada, T; Ichiki, M; Inoue, K; Shiraishi, Y; Sugio, K; Takayama, K; Takeshita, M; Tokunaga, S; Uchino, J; Wataya, H; Yamada, T | 1 |
| Esim, O; Ozkan, CK; Ozkan, Y; Sarper, M; Savaser, A | 1 |
| Feng, Y; Wang, L; Wu, Y; Zhang, Y; Zhou, Y | 1 |
| Liu, JM; Wang, WJ; Ye, CY; Zhao, FC | 1 |
| Akie, K; Amano, T; Dosaka-Akita, H; Fujita, Y; Fuke, S; Fukumoto, SI; Harada, M; Harada, T; Isobe, H; Ito, K; Kinoshita, I; Nakano, K; Nishigaki, Y; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J; Sukoh, N; Takamura, K | 1 |
| Li, J; Liu, TT; Xu, BW; Zhu, GH | 1 |
| Bao, C; Cai, S; Chen, Q; Kong, J; Liu, S; Lu, H; Luo, J; Xie, X | 1 |
| Chauhan, SC; Hatami, E; Jaggi, M; Nagesh, PKB; Yallapu, MM | 1 |
| He, L; Huang, X; Li, Y; Lou, Y; Wang, L; Yang, H; Zhang, Y | 1 |
| Badam, TVS; Björn, N; Brandén, E; De Petris, L; Gréen, H; Gustafsson, M; Koyi, H; Lewensohn, R; Lubovac-Pilav, Z; Lundeberg, J; Sahlén, P; Spalinskas, R | 1 |
| Chen, F; Gou, S; Wang, X | 1 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Ge, C; Shen, F; Yuan, P | 1 |
| Cui, M; Guo, C; Liu, Z; Tang, J; Wang, C; Xie, G; Ye, X | 1 |
| Andric, Z; Barrios, CH; de Marinis, F; Deng, Y; Enquist, I; Felip, E; Geater, S; Giaccone, G; Herbst, RS; Jassem, J; Komatsubara, K; Kuriki, H; McCleland, M; Mocci, S; Morise, M; Özgüroğlu, M; Reinmuth, N; Sandler, A; Spigel, DR; Vergnenegre, A; Wen, X; Zou, W | 1 |
| Atari, M; Imai, K; Matsuo, T; Minamiya, Y; Motoyama, S; Nakayama, K; Nomura, K; Sato, Y; Shibata, H; Takashima, S | 1 |
| Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| GrØnberg, BH; Halvorsen, TO; Jacobsen, KA; SjØgren, K | 1 |
| Ahmad, Z; Cambron, DA; Chen, S; Dillenburg, M; Jacobson, BA; Kratzke, RA; Patel, AJ; Patel, MR; Stoian, E; Wagner, CR; Waldusky, G | 1 |
| Du, W; Hu, C | 1 |
| Ding, J; Gao, L; Shao, T; Zheng, W | 1 |
| Bentsion, D; Bondarenko, I; Chen, CI; Cicin, I; Clingan, P; Gao, B; Gladkov, O; Gogishvili, M; Gullo, G; Gümüş, M; Kilickap, S; Lee, S; Li, S; Lowy, I; Makharadze, T; McGuire, K; Nechaeva, M; Özgüroğlu, M; Paydas, S; Rietschel, P; Rizvi, N; Seebach, F; Sezer, A; Sriuranpong, V; Turk, HM; Weinreich, DM; Yancopoulos, GD | 1 |
| Gao, Q; Guo, H; Jia, W; Liu, Q; Sun, J; Tan, F; Yu, J; Zhu, H | 1 |
| Gao, C; Hu, L; Li, C; Lv, D; Mao, X; Wang, T; Xu, Y | 1 |
| Bao, PT; Lin, H; Liu, XF; Mu, M; Pan, P; Tian, FF; Wang, Q; Zhang, R; Zhao, WG | 1 |
| Berezowska, S; Deng, H; Dorn, P; Gao, Y; Gemperli, CA; Hall, SRR; Marti, TM; Peng, RW; Schmid, RA; Su, M; Wang, W; Xu, D; Yang, H; Yang, Z; Zens, P | 1 |
| Cao, M; Chen, C; Chen, G; Chen, Y; Fan, J; Feng, Q; Guo, Y; Lai, C; Lin, S; Mi, J; Tian, J; Tian, L; Xi, N; Yu, L; Zhang, F; Zhang, Y | 1 |
| Huang, J; Li, Z; Shen, X; Wang, Y; Zhi, Q; Zhou, J | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, JY; Kim, TM; Lee, SH; Park, S; Suh, B | 1 |
| Li, J; Liu, Y; Wang, Z; Yang, L; Zhai, X; Zheng, Q; Zhu, Y | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Chigutsa, E; Long, AJ; Wallin, JE | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Malkoski, SP; Nolan, K; Patil, T; Tippimanchai, D; Ziemke, M | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Anile, G; Banna, GL; Castaing, M; Conte, P; Dieci, MV; Guarneri, V; Lal, R; Marletta, F; Nicolosi, M; Parra, HJS; Strano, S | 1 |
| Ding, L; Dong, X; Geng, L; Li, N; Li, Y; Liu, Y; Luo, Q; Ma, C; Wei, F; Zhang, L; Zhang, Y; Zhou, T | 1 |
| Benes, C; Gao, P; Gray, NS; Li, F; Li, Y; Liu, F; Liu, Q; Liu, Y; Merlino, AA; Quinn, MM; Wang, X; Wong, KK | 1 |
| Miller, PJE; Ravelo, A; Schwartzberg, LS; Walker, MS; Wong, W | 1 |
| Bai, C; Feng, J; Gao, B; Hua, D; Huang, J; Jian, H; Li, W; Lu, S; Ma, S; Ma, Z; Pan, H; Qin, S; Song, Y; Tao, M; Yu, Y; Zhu, H | 1 |
| Dhande, R; Sharma, RK; Thakkar, H; Tyagi, A | 1 |
| Gao, Y; Li, J; Mao, S; Ru, Y; Zhang, R | 1 |
| Arkenau, HT; Blackhall, F; Califano, R; Dean, E; Dymond, AW; Ghiorghiu, D; Greystoke, A; Hossack, S; Lindsay, CR; Md Haris, N; Plummer, R; So, K; Steele, N; Summers, Y; Voskoboynik, M | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Andolfi, M; Balloni, S; Bellezza, G; Bodo, M; Cagini, L; Ludovini, V; Marinucci, L; Matricardi, A; Potenza, R; Puma, F; Siggillino, A; Tofanetti, FR; Vannucci, J | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Hisada, T; Kaira, K; Kawashima, O; Miura, Y; Saito, R; Sakurai, R; Sunaga, N; Tomizawa, Y; Tsurumaki, H; Yamada, M; Yoshii, A | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Benguigui, M; Beyar-Katz, O; Bronshtein, T; Kotsofruk, R; Letko-Khait, N; Machluf, M; Rachman-Tzemah, C; Raviv, Z; Shaked, Y; Timaner, M | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Danter, WR; Koropatnick, J; Maleki Vareki, S; Salim, KY | 1 |
| Bruno, A; Cipollina, C; Di Vincenzo, S; Ferraro, M; Gjomarkaj, M; Pace, E; Siena, L | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Balmaña, J; Cedrés, S; Cruz, C; Felip, E; Llop-Guevara, A; Mancuso, F; Martinez de Castro, A; Martinez-Marti, A; Miquel, JM; Navarro, A; Nuciforo, P; Pardo, N; Remon, J; Sansano, I; Serra, V; Vivancos, A; Zeron-Medina, J | 1 |
| Dehua, Z; Jisheng, W; Mingming, C | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH; Theiss, N | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Curtis, LT; Frieboes, HB; van Berkel, VH | 1 |
| Barrios, CH; Boyer, M; Chih-Hsin Yang, J; Geater, SL; Hirsh, V; Kato, T; Lee, KH; Märten, A; Mok, T; O'Byrne, K; Orlov, S; Park, K; Paz-Ares, L; Peil, B; Schuler, M; Sequist, LV; Tan, EH; Tsai, CM; Wu, YL; Yamamoto, N; Zhang, L | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Eisenhaber, F; Jenjaroenpun, P; Konishi, F; Kremenska, Y; Lee, SC; Limviphuvadh, V; Maurer-Stroh, S; Mu, YS; Soo, RA; Syn, N; Tan, CS; Xiang, JS; Yong, WP | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Cheng, CS; Du, T; Guo, J; Hu, BD; Jiang, Q; Liu, RN; Ye, YZ; Zhang, YB | 1 |
| Bly, CA; Brown, J; Carter, GC; Cinfio, FN; Klein, RW; Molife, C; Tawney, MK | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Le-Rademacher, JG; Lilenbaum, R; McMurray, R; Muss, H; Zemla, T | 1 |
| Chen, K; Chen, P; Chen, YJ; Li, J; Li, XQ; Ren, J; Wu, M; Wu, Y | 1 |
| Andreas, S; Czapiewski, P; Fischer, JR; Kortsik, C; Neuser, P; Reinmuth, N; Reuss, A; Schnabel, PA; Serke, M; Thomas, M; Villalobos, M; Wolf, M | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Chen, H; Ding, X; Hua, CS; Ma, DC; Wang, WS; Wu, F; Zhang, CD; Zhao, J | 1 |
| Artioli, F; Bianco, R; Bilancia, D; Bonanno, L; Bordonaro, R; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Cortinovis, D; Costanzo, R; Daniele, G; di Isernia, G; Filipazzi, V; Fregoni, V; Gallo, C; Gebbia, V; Gridelli, C; Leo, S; Luciani, A; Maione, P; Mencoboni, M; Morabito, A; Nelli, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rocco, G; Rosetti, F; Signoriello, S | 1 |
| Ahn, S; Jang, JS; Kim, JH; Kim, SH; Kim, YJ; Lee, H; Lee, JH; Lee, JS; Lee, YG | 1 |
| Ciesielka, M; Homa-Mlak, I; Kozioł, P; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Fløtten, Ø; Grønberg, BH; Kristensen, A; Solheim, TS | 1 |
| Bria, E; Caccese, M; D'Argento, E; di Noia, V; Grizzi, G; Iacovelli, R; Pilotto, S; Tortora, G | 1 |
| Dai, H; Guo, S; Jiang, Y; Li, Y; Lin, SY; McGrail, DJ; Yin, J | 1 |
| Hack, E; Karanth, N; Thachil, T | 1 |
| Cai, XJ; Chen, LY; Cheng, B; Lei, L; Lin, NM; Shi, L; Wang, Z; Ye, LQ | 1 |
| Han, Z; Hao, W; Jiang, Y; Wang, Y | 1 |
| Baldini, E; Barbieri, F; Boni, L; Brighenti, M; Camerini, A; Chartoire, M; Gilli, A; Giovannetti, E; Honeywell, R; Mazzoni, F; Peters, GJ; Tibaldi, C; Tiseo, M; Vittimberga, I | 1 |
| Adamowicz, K; Janiszewska, J; Lichodziejewska-Niemierko, M | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Huang, P; Li, Y; Shi, L; Tong, B; Wang, Z; Xing, W; Xu, G; Yu, T; Zheng, Y; Zhou, C; Zhou, J | 1 |
| Díaz-Serrano, A; Paz-Ares, L; Sánchez-Torre, A | 1 |
| Appius, A; Button, P; Hooper, G; Lee, V; Liam, CK; Lu, S; Mok, T; Palma, JF; Park, K; Schulze, K; Scudder, S; Shames, DS; Srimuninnimit, V; Wang, J; Wu, YL; Yin, AY; Zhang, G; Zhou, C | 1 |
| Hashemi Sadraei, N; Patil, PD; Pennell, NA; Shapiro, M | 1 |
| Chang, HL; Chong, IW; Hsu, JF; Lee, YL; Li, CY; Lin, CM; Shen, YT; Wei, PJ; Yang, CJ | 1 |
| Bian, WG; Chen, HT; Chen, P; Shen, Y; Song, S; Zhou, XN | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Blasi, E; Buetow, B; Chunyk, AG; Costa, MJ; Delaria, K; Dorywalska, M; Ho, WH; Holz, C; Kudaravalli, J; Lindquist, K; Liu, SH; Ma, JT; Rajpal, A; Shelton, DL; Stauffer, A; Strop, P; Tran, TT; Zong, Q | 1 |
| Chen, L; Cheng, Y; Han, B; Huang, C; Jiang, G; Li, E; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Zhong, Z; Zhou, C; Zhu, Y | 1 |
| Choi, CM; Ji, W; Kim, S; Kim, WS; Kwon, BS; Lee, JC; Park, JH; Park, S; Park, YR | 1 |
| Lai, ZY; Li, Y; Mu, JB; Xie, J; Xu, J; Yang, MD; Yang, WH; Zhang, GH | 1 |
| Liang, TS; Ma, SL; Yang, CL; Yang, DK; Yang, Y; Zhao, ZJ; Zuo, XX | 1 |
| Cai, X; Chen, W; Gu, X; Guo, M; He, J; He, P; Li, C; Liang, H; Liang, W; Pan, Z; Sun, J; Wang, Z; Xu, C; Yang, H; Yang, X; Yin, W; Zhao, Y | 1 |
| Chen, Y; Cheng, T; Guan, R; Hang, T; Jin, R; Song, M; Sun, X; Wang, Y; Xu, X | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Bie, Z; Li, B; Li, L; Li, X; Li, Y; Wang, D | 1 |
| Aerts, J; Biesma, B; Dingemans, AC; Groen, HJM; Hoekstra, O; Klinkenberg, TJ; Kloosterziel, C; Pieterman, R; Schramel, FMNH; Smit, EF; Smit, HJM; van den Borne, B; van der Heijden, EHFM; van der Noort, V; van Tinteren, H; Verhagen, A | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Hong, D; Hong, W; Kou, JY; Mao, WM; Su, D; Wang, K; Wang, XJ; Xie, FJ; Yu, XM; Zhang, YP | 1 |
| Arnold, S; Baeker, T; Brooks, M; Carloss, H; Croley, J; Kloecker, G; Kvale, E; Leggas, M; Lim, A; Maheshwari, JG; Rinehart, J; Shelton, B; Slone, S; Zaydan, MA | 1 |
| Asami, K; Atagi, S; Fujita, Y; Kawaguchi, T; Minomo, S; Okishio, K; Saitou, R; Takata, S; Tamura, A | 1 |
| Banna, GL; Basile, A; Fraggetta, F; Ippolito, M; Lipari, H; Marletta, F; Nicolosi, M; Saita, S; Terminella, A; Urso, OE; Vaglica, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Ardizzoni, A; Azzoni, C; Baldini, E; Boni, C; Boni, L; Bordi, C; Bordi, P; Bortesi, B; Campanini, N; Fontanini, G; Grossi, F; Naldi, N; Recchia, F; Tiseo, M; Zanelli, F | 1 |
| Chatzaki, E; Constantinidis, TC; Darwiche, K; Domvri, K; Kakolyris, S; Karamanos, NK; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Anile, M; Ciccone, AM; D'Andrilli, A; Ibrahim, M; Maurizi, G; Rendina, EA; Venuta, F | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Abrao, FG; Gross, JL; Naim Younes, R; Rodrigues Pereira, J | 1 |
| Chouaid, C; Pérol, D; Pérol, M | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Lv, M; Ren, JC; Sun, J; Wang, B; Wang, X; Zhang, L; Zhang, T | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Barbera, S; Bianco, R; Cavanna, L; Cinieri, S; Costanzo, R; Daniele, G; De Marinis, F; Di Maio, M; Gallo, C; Gebbia, V; Giordano, P; Gridelli, C; Mancuso, G; Montanino, A; Montesarchio, V; Morabito, A; Nacci, A; Perrone, F; Piccirillo, MC; Rocco, G; Russo, P; Sandomenico, C; Viganò, MG | 1 |
| Ji, M; Li, J; Zhu, LN | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, IS; Kim, MJ; Kim, SH; Lee, GW; Lee, JD; Lee, S; Ling, H; Oh, SY | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Tang, Y; Teng, X; Wang, Y | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| An, G; Chen, W; Wei, P; Yan, D | 1 |
| Fan, KX; Guo, YJ; Huang, A; Wang, B; Zhang, B; Zhang, F | 1 |
| Chen, KZ; Jiang, GC; Li, X; Wang, J; Yang, F | 1 |
| Huang, L; Kim, WY; Rogers, AB; Schwerbrock, NM; Zhang, Y | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Bingham, J; Blasina, A; Cao, J; Fang, DD; Gu, Y; Hostomsky, Z; Jani, JP; Jirout, Z; Kornmann, J; Lira, ME; Los, G; Tsaparikos, K; Vanarsdale, T; Wang, J; Zhu, Z | 1 |
| Shi, X; Yu, XM; Zhang, YP; Zhao, J | 1 |
| Dong, S; Li, WT; Peng, WJ; Ye, XD; Yuan, Z | 1 |
| Dong, X; Du, J; Hao, Y; Wei, Y; Yin, Q; Zhao, X | 2 |
| da Silva, EM; de Castria, TB; Gois, AF; Riera, R | 1 |
| Kolek, V | 1 |
| Bradbury, PA; Coyle, D; Di Maio, M; Evans, WK; Graham, B; Gridelli, C; Hirsh, V; Leighl, NB; Mittmann, N; Perrone, F; Reaume, MN; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Campbell, L; Eakin, RL; Hanna, GG; Hussain, A; Khan, K; McAleese, J; Scullin, P | 1 |
| Chudziak, D; Ciesielka, M; Homa, I; Kalinka-Warzocha, E; Kozioł, P; Krawczyk, P; Kucharczyk, T; Milanowski, J; Mlak, R; Ramlau, R; Wasylecka-Morawiec, M; Wojas-Krawczyk, K | 1 |
| Che, CL; Mei, YF; Shi, YZ; Zhang, HH; Zhang, ZY | 1 |
| Huang, WD; Shen, SY; Zheng, MF | 1 |
| Amoroso, D; Boni, L; Camerini, A; Cecere, FL; Di Costanzo, F; Giuliani, C; Lucchesi, S; Lucherini, E; Martella, F; Mazzoni, F; Meoni, G; Torricelli, F | 1 |
| Chen, M; Zhang, J; Zhou, CC; Zhu, J | 1 |
| Chen, Q; Hu, H; Jiao, D; Song, J; Wu, L; Xu, LQ; Yan, J | 1 |
| Cai, QC; Guan, HH; Lin, ZX; Wu, ZY; Yang, HK; Zhou, L | 1 |
| Jiao, SC; Wu, JJ | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Bonetti, A; Durante, E; Furini, L; Giuliani, J; Greco, F; Mercanti, A; Moratello, G; Piacentini, P; Tognetto, M; Trolese, AR | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Di Sano, C; Ferraro, M; Gjomarkaj, M; Melis, M; Pace, E; Profita, M; Siena, L; Spatafora, M | 1 |
| Chen, JH; Ma, GY; Meng, L; Wang, L; Wang, XW | 1 |
| Gisbert, R; Gómez-Codina, J; Juan, O; Maciá, S; Muñoz, J; Vidal, J | 1 |
| Aljumaily, R; Gay, HA; Parent, T; Russo, S; Walker, PR; Zhang, J | 1 |
| Lee, HY; Lim, KH; Song, SY | 1 |
| Brail, L; Enas, N; Eschbach, C; Hirsh, V; Jänne, PA; Oh, Y; Paz-Ares, L; von Pawel, J | 1 |
| Beer, DG; Bergeron, EJ; Chen, G; Giordano, TJ; Grabauskiene, S; Morgan, MA; Reddy, RM; Thomas, DG | 1 |
| Bianco, R; Bordonaro, R; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Costanzo, R; Di Maio, M; Favaretto, AG; Filipazzi, V; Gallo, C; Gridelli, C; Leo, S; Morabito, A; Perrone, F; Rossi, A; Sandomenico, C | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Li, J; Shi, R; Yu, P | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Boudaya, MS; Brahem, E; Charmiti, F; Kilani, T; Marghli, A; Mestiri, T; Mohamed, J; Ouerghi, S; Smadhi, H; Smati, B | 1 |
| Abdi, E; Button, P; Clarke, S; Clingan, P; Do, H; Dobrovic, A; Gregory, D; Michael, M; Nott, L; Solomon, B; White, SC; Zimet, A | 1 |
| Chen, J; Li, Y; Lou, Y; Wang, LR; Zhang, GB | 1 |
| Ai, B; Cheng, G; Nie, X; Zhang, S | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM | 1 |
| Bootsma, G; Brans, B; Das, M; de Ruysscher, D; Dingemans, AM; Hochstenbag, M; Houben, R; Lambin, P; Reymen, B; van Baardwijk, A; van Belle, A; Wanders, R | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Bottomley, A; Coens, C; Ediebah, DE; Flechtner, H; Gotay, C; Greimel, E; King, MT; Quinten, C; Reeve, BB; Ringash, J; Schmucker von Koch, J; Smit, EF; Taphoorn, MJ; Weis, J; Zikos, E | 1 |
| Archer, V; Burdaeva, O; Delmar, P; Gorbunova, V; Hilton, M; Juhasz, E; Mok, T; Orlov, S; Pallaud, C; Reck, M; Szima, B; Yu, CJ | 1 |
| Hasegawa, Y; Kitamura, C; Kobayashi, K; Miura, D; Sato, N; Suzuki, T | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Ding, YJ; Feng, Y; Wan, HY; Xiang, Y; Zhang, QR; Zhou, M | 1 |
| Guo, YH; Liao, ZJ; Nan, KJ; Xu, R; Yao, JT; Zhao, Z | 1 |
| Li, LQ; Li, Q; Li, YQ; Liang, CY; Liang, R; Liao, SN; Liao, XL; Lin, Y; Liu, ZH; Yuan, CL; Zhang, YM | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Cai, LT; Liu, NN; Qu, QR; Wu, GQ; Xue, XL; Yan, XJ; Zhang, C | 1 |
| Elity, MM; Sad, LM; Younis, SG | 1 |
| Brkic, S; Dedic, S; Jamakosmanovic, S; Osmic, M; Ramic, N; Umihanic, S | 1 |
| Han, ZF; Hong, J; Jiang, Y; Liu, LS; Shen, LP | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Haager, B; Osei-Agyemang, T; Passlick, B; Wiesemann, S | 1 |
| Gao, XD; Ge, LH; Jin, ZY; Liang, JG; Te, MR; Wang, CL | 1 |
| Barraclough, H; Cheng, Y; Chi, H; Lu, S; Lu, Y; Orlando, M; Qin, S; Song, X; Wang, M; Wang, X; Wu, YL; Zhang, X; Zhang, Y; Zhou, C; Zhu, Y | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Huang, J; Lin, Y; Sun, S; Zhang, L; Zhang, Q; Zhu, X | 1 |
| Chen, X; Li, W; Li, X; Liu, L; Ren, S; Zhou, C; Zhou, F | 1 |
| Barlesi, F; Besse, B; Cappuzzo, F; Carcereny, E; Felip, E; Ferry, D; Garcia-Ribas, I; Mazieres, J; Novello, S; Reck, M; Santoro, A; Scagliotti, G; Soria, JC; von Pawel, J; Zalcman, G | 1 |
| Belgum, H; Drees, J; Etchison, R; Federspiel, MJ; Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Raza, A; Russell, SJ; Sadiq, A; Wang, H | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Al Husaini, H; ALHusaini, H; Aparisi, F; Arriola, E; Baize, N; Ballesteros, I; Barneto, I; Berchem, G; Bernabé, R; Blasco, A; Bombaron, P; Bosch-Barrera, J; Botia-Castillo, M; Bover, I; Calvo de Juan, V; Camps, C; Carcereny, E; Catot, S; Chaib, I; Chen, H; Chen, X; Chouaid, C; Cobo, M; Colinet, B; Dansin, E; De Grève, J; de Las Peñas, R; Domine, M; Drozdowskyj, A; Du, J; Felip, E; Fournel, P; Fraboulet, G; Gao, Y; García-Campelo, MR; García-Girón, C; García-Gómez, R; Garcia-Sevila, R; Garde, J; Gasco, A; Germonpre, P; Gervais, R; Gil, J; González-Larriba, JL; Hernando-Polo, S; Hominal, S; Hu, J; Hu, W; Insa, A; Isla, D; Jantus, E; Jiménez, B; Kahlout, S; Karachaliou, N; Kong, W; Lecaer, H; Lena, H; LeTreut, J; Li, L; Li, R; Li, X; Lianes, P; Liu, B; Liu, J; Locher, C; López-López, R; López-Martín, A; Lopez-Vivanco, G; Lu, H; Macias, JA; Majem, M; Marti-Ciriquian, JL; Massuti, B; Mate, JL; Mijangos, E; Molinier, O; Monnet, I; Montoyo, R; Morales-Espinosa, D; Moran, T; Moreno, MA; O'Brate, R; Ocaña, J; Oliviero, G; Pallares, C; Parera, M; Pereira, E; Perez-Cano, M; Pérez-Carrión, R; Porta, R; Provencio, M; Qian, X; Ramirez, JL; Rauh, S; Reguart, N; Ren, W; Robinet, G; Rosell, R; Rosillo, F; Sala, MA; Sanchez, JJ; Sanchez, JM; Sanchez-Rodriguez, B; Sanchez-Ronco, M; Schoot, R; Shao, J; Song, Y; Sullivan, I; Sun, X; Taron, M; Terrasa, J; Thomas, P; Tierno-Garcia, M; Trigo, JM; Valdivia, J; Vergnenegre, A; Viñolas, N; Viteri, S; Wang, L; Wei, J; Wen, L; Wu, Q; Xiao, X; Xu, X; Yan, J; Yang, J; Yang, M; Yang, Y; Yin, J; You, C; Yu, L; Yue, X; Zhang, F; Zhang, J; Zhou, Y; Zhu, L; Zou, Z | 1 |
| Blokzijl, E; Driever, EM; Groen, HJ; Hiltermann, TJ; Kerner, GS; Liesker, JJ; Mertens, MJ; Pieterman, RM; Renkema, TE; van Dullemen, LF; van Putten, JW; Widder, J; Wiegman, EM | 1 |
| Amundsen, T; Grønberg, BH; Helbostad, JL; Hjelde, H; Kaasa, S; Stene, GB; Sørhaug, S | 1 |
| Able, SL; Bowman, L; Brown, J; Cui, ZL; DeLozier, AM; Hess, LM; Natanegara, F; Treat, J; Zhao, L | 1 |
| Qiu, ZQ; Zhao, K | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Hu, N; Liu, Y; Wang, H; Wu, F; Xu, T; Zhang, J; Zheng, Y | 1 |
| Bradley, JD; Curran, WJ; Machtay, M | 1 |
| Guo, Y; Li, E; Ma, K; Shao, G; Sun, H; Wang, X | 1 |
| Alessio, E; Baas, P; Beijnen, JH; Burgers, SA; Leijen, S; Pluim, D; Sava, G; Schellens, JH; Tibben, M; van Werkhoven, E | 1 |
| Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H | 1 |
| Ai, Z; Lu, B; Sun, L; Xu, J; Yan, X | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Adhikari, S; Eisenhaber, F; Feng, M; Kuralmani, V; Li, N; Liem, N; Limviphuvadh, V; Mah, TL; Maurer-Stroh, S; Soo, RA; Sridharan, S; Tong, JC; Yap, XN; Yong, WP | 1 |
| Dong, H; Fu, S; Gao, W; Guan, R; Jia, X; Liu, P; Meng, X; Sun, W; Wang, G; Wu, J; Yu, J; Yu, Y | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Chen, C; Chen, D; Chen, Z; Le, H; Wang, Z; Zhang, B | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Emmanouilidis, Ch; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katsaounis, P; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Nintos, G; Polyzos, A; Stoltidis, D; Vamvakas, L; Vaslamatzis, M; Vetsika, EK | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Branden, E; Hillerdal, G; Kolbeck, K; Koyi, H | 1 |
| Deng, QH; He, JX; He, YW; Yang, XY; Zeng, J; Zhao, ML | 1 |
| Aerts, J; de Castro Carpeño, J; Dyachkova, Y; Girvan, AC; Kraaij, K; Lesniewski-Kmak, K; Moro-Sibilot, D; Nacerddine, K; Schnabel, PA; Smit, E; Smith, KT; Taipale, K; Villatoro, R; Visseren-Grul, C | 1 |
| Ma, GF; Wang, D; Ying, KJ; Zhang, RF | 1 |
| Auquier, P; Barlesi, F; Chouaid, C; Crequit, J; Fabre-Guillevin, E; Le Caer, H; Le Treut, J; Legodec, J; Loundou, A; Pujol, JL; Simeoni, MC; Thomas, PA; Vergnenegre, A | 1 |
| Bastiat, G; Benoit, JP; Cieślak, A; Hureaux, J; Kondo, K; Moal, V; Moysan, E; Rousselet, MC; Wauthoz, N; Zandecki, M | 1 |
| Acker, T; Andreas, S; Fischer, J; Grah, C; Kollmeier, J; Kortsik, C; Müller, E; Penzel, R; Reinmuth, N; Reuss, A; Schenk, M; Schnabel, P; Schröder, M; Serke, M; Thomas, M; Villalobos, M; von Eiff, M; Witt, C; Wolf, M | 1 |
| Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Fu, BH; Fu, ZZ; Gu, T; Meng, W; Sun, XD; Zhang, Z | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Liao, M; Margono, B; Mok, T; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Tsai, J; Wen, W; Wu, L; Wu, YL; Yu, CJ; Zhou, C; Zhu, Y | 1 |
| Choi, HJ; Go, SI; Kang, JH; Kang, MH; Kim, HG; Lee, A; Lee, GW; Lee, US; Lee, WS; Song, HN | 1 |
| Bondarenko, IM; Bycott, P; Cebotaru, CL; Ingrosso, A; Kim, S | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Belderbos, J; De Ruysscher, D; Deasy, JO; Din, S; Dingemans, AM; Houben, R; Lambin, P; Oberije, C; Rimner, A; Uyterlinde, W; van de Heuvel, M | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Sahoo, SK; Vandana, M | 1 |
| Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Xu, J; Yang, H; Yang, L | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Chen, J; He, LJ; Li, Y; Li, YY; Lou, Y; Wang, LR; Wang, Y; Zhang, GB | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Bartolotti, M; Brandes, AA; Cavallo, G; Di Battista, M; Genestreti, G | 1 |
| He, Y; Liu, W; Luo, Y; Su, J; Wu, BP; Wu, W; Yang, S; Yuan, ZJ; Zhao, J; Zhou, WW | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Artal, A; Barneto, I; De Castro, J; Esteban, E; Gascó, P; Gasent, JM; Montalar, J; Muñoz-Langa, J; Sanchez, A; Vidal, S | 1 |
| Chen, C; Fei, K; Hou, L; Jiao, Y; Liu, D; Lu, D; Qian, J; Su, B; Wu, C; Zheng, H | 1 |
| Li, H; Li, K; Wang, H; Zhang, Q; Zhang, Y; Zheng, J | 1 |
| Fan, W; Zeng, C; Zhang, X | 1 |
| Chen, L; Cheng, Y; Fernando, MCL; Han, B; How, SH; Huang, C; Jiang, G; Li, E; Liam, CK; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Xia, F; Zhang, Y; Zhong, Z; Zhou, C; Zhu, Y; Zuo, Y | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Ahn, JS; Ahn, MJ; Ha, SY; Han, J; Jung, SH; Park, K; Sun, J; Sun, JM | 1 |
| Berghmans, T; Meert, AP; Quoix, E | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 2 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Aksoy, A; Aliustaoglu, M; Alkis, N; Aydin, K; Dane, F; Demirci, NS; Ekinci, AS; Gumus, M; Inal, A; Inanc, M; Odabas, H; Sevinc, A; Turkeli, M; Ulas, A; Uysal, M; Yazilitas, D; Yuksel, S | 1 |
| Aass, N; Baracos, VE; Benth, JŠ; Fløtten, Ø; Grønberg, BH; Hjermstad, MJ; Jordhøy, M; Sjøblom, B | 1 |
| Besse, B; Gazzah, A; Remon, J; Soria, JC | 1 |
| Anota, A; Bastien, B; Bonnetain, F; Lacoste, G; Limacher, JM; Mercier, M; Quoix, E; Rotonda, C | 1 |
| De, A; Franklin, MJ; Graff, JR; Jacobson, BA; Jay-Dixon, J; Konicek, BW; Kratzke, RA; Patel, MR; Sadiq, A; Thumma, SC | 1 |
| Go, T; Huang, CL; Liu, D; Nakano, J; Nii, K; Tokunaga, Y; Yokomise, H; Zhang, X | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Bluhme, H; Farr, KP; Grau, C; Kallehauge, JF; Khalil, AA; Kramer, S; Morsing, A; Møller, DS | 1 |
| Yang, S | 1 |
| Tao, ZZ; Xu, B | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Besse, B; Blackhall, F; Brandén, E; de Petris, L; Edsgärd, D; Gréen, H; Hasmats, J; Koyi, H; Kupershmidt, I; Lewensohn, R; Lindgren, A; Lundeberg, J; Peterson, C; Vikingsson, S | 1 |
| Aerts, JG; Dingemans, AM; Goosens, MJ; Haitjema, TJ; Hendriks, LE; Herder, GJ; Krouwels, FH; Masen-Poos, L; Mellema, WW; Pouw, E; Smit, EF; Smit, HJ; Staal-Van den Brekel, AJ; Stigt, JA; Termeer, A; van den Borne, BE; van den Heuvel, MM; van der Wekken, AJ; van Heemst, RC | 1 |
| Badary, O; El Wakeel, L; Elkholy, E; Saad, AS; Sayed, R | 1 |
| Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Castañon, E; Rolfo, C | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Bakkenist, CJ; Conrads, TP; Lau, A; O'Connor, MJ; Schamus, S; Vendetti, FP | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Ciesielka, M; Homa, I; Kozioł, P; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T; Prendecka, M | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Garnock-Jones, KP | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Bakirhan, K; Cheng, H; Perez-Soler, R; Sharma, J | 1 |
| Feng, X; Fu, X; Guo, C; He, W; Hu, X; Pu, K; Wen, S | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Bonomi, P; Brown, J; Chouaki, N; Dediu, M; Gralla, RJ; Losonczy, G; Luft, A; Molinier, O; Obasaju, C; Peterson, P; Ramlau, R; Reck, M; Schumann, C; Socinski, MA; Soldatenkova, V; Szczęsna, A; Thatcher, N | 1 |
| Agelaki, S; Filippa, G; Georgoulias, V; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mala, A; Mavroudis, D; Moutsos, M; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Cheng, S; Coakley, N; Ellis, PM; Gregg, R; Kulkarni, S; Ung, YC; Vella, ET | 1 |
| Abnous, K; Alibolandi, M; Hadizadeh, F; Ramezani, M | 1 |
| Hirsch, FR; Hozak, RR; Kurek, R; Paz-Ares, L; Shahidi, J; Socinski, MA; Soldatenkova, V; Thatcher, N; Varella-Garcia, M | 1 |
| Cuderman, A; Doma, A; Grmek, M; Kern, I; Kovac, V; Rajer, M; Stanic, K; Vrankar, M; Zwitter, M | 1 |
| Anota, A; Bigay-Game, L; Bonnetain, F; Dansin, E; Dauba, J; Debieuvre, D; Fiteni, F; Milleron, B; Molinier, O; Morin, F; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Antonia, S; Borghaei, H; Brahmer, JR; Chen, AC; Chow, LQ; Gerber, DE; Gettinger, S; Goldman, JW; Harbison, CT; Hellmann, MD; Juergens, RA; Laurie, SA; Nathan, FE; Rizvi, NA; Shen, Y; Shepherd, FA | 1 |
| Amitani, H; Inui, T; Kubo, K; Kuchiike, D; Mette, M; Nishikata, T; Uto, Y | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Mok, T; Perez-Moreno, P; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Wu, YL; Yu, CJ | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J | 1 |
| Olaussen, KA; Postel-Vinay, S | 1 |
| Şahin, B; Yalçin Balçik, P | 1 |
| DeCaire, X; Streu, E | 1 |
| Chyczewska, E; Naumnik, B; Naumnik, W; Niklińska, W; Ossolińska, M | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Brown, J; Depenbrock, H; Krause, T; Kropf-Sanchen, C; Mezger, J; Reck, M; Socinski, MA; Soldatenkova, V; Thatcher, N; Thomas, M | 1 |
| Dan, G; Deng, D; Jiang, J; Li, W; Zheng, X; Zheng, Y | 1 |
| Li, L; Li, X; Liu, Y; Miao, L; Ni, R; Wang, J; Wang, X; Zhang, H | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Areepium, N; Kumpiro, S; Sriuranpong, V | 1 |
| Chang, ZF; Chen, QQ; Guo, JR; Lam, CW; Wang, CY; Wong, VK; Zhang, W | 1 |
| Chen, L; Feng, J; Gong, Q; Li, J; Li, L; Li, N; Li, X; Tang, F; Tang, X; Wang, C; Xiao, Z | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| He, J; Li, T; Liu, P; Luo, L; Yang, J; Yu, M | 1 |
| Gajra, A | 1 |
| Abbate, MI; Agustoni, F; Bianchini, G; Bidoli, P; Canova, S; Cicchiello, F; Cortinovis, DL | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Diao, T; Feng, F; Hou, R; Huhe, M; Liu, S; Nan, G; Sun, X; Tang, H; Wang, B; Wang, L; Wu, B; Zhang, Y; Zhang, Z; Zhu, Y | 1 |
| Ahn, MJ; Bello, M; Cho, EK; Depenbrock, H; Orlando, M; Park, K; Puri, T; Soldatenkova, V; Song, EK; Thongprasert, S | 1 |
| Amundsen, T; Grønberg, BH; Hjelde, HH; Kaasa, S; Kristensen, A; Solheim, TS; Sørhaug, S | 1 |
| Barrett, EG; Chougule, MB; Forest, MG; Hill, DB; Hoffmann, PR; Morris, KR; Youngren-Ortiz, SR | 1 |
| Han, J; Li, K; Liang, Y; Tian, B; Wang, L; Wu, Z; Zhang, J | 1 |
| Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Wakelee, H | 1 |
| Chong, PY; Choo, TB; Goh, BC; Lee, HS; Lee, SC; Liu, JJ; Ng, SS; Soo, RA; Soong, R; Tham, LS; Wang, LZ; Yong, WP | 1 |
| Cox, JD; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Kies, M; Komaki, R; Liao, Z; Pisters, KM; Zinner, RG | 1 |
| Nagai, S; Sonobe, M; Takenaka, K; Tanaka, F; Wada, H | 1 |
| Brown, C; Chetiyawardana, AD; Cullen, MH; Draycott, C; El-Modir, A; Hussain, SA; Palmer, DH; Peake, DR; Rea, DW; Riley, P; Swinson, DE; Wills, A | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, L; Yong, WP | 1 |
| Creaven, PJ; Gottlieb, RH; Iyer, RV; Khushalani, NI; Ramnath, N; Rustum, YM; Schwarz, JK; Yu, J | 1 |
| Bandstra, B; Bilynsky, BT; Bondarenko, IN; Eisenfeld, AJ; Ganul, VL; Hotko, YS; Kostinsky, IY; O'Brien, ME; Oldham, FB; Popovich, AY; Sandalic, L; Sandler, AB; Singer, JW; Socinski, MA; Tomova, A | 1 |
| Ko, SK; Lim, JY; Min, SH | 1 |
| Kamiyama, Y; Kodama, T; Kondoh, T; Mori, K | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Alexandre, J; Becht, C; Bekradda, M; Chomy, F; Culine, S; De Cremoux, H; Szyldergemajn, S; Trédaniel, J; Yataghene, Y | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Besenval, M; Bosquee, L; Brain, E; Dansin, E; Dohollou, N; Gervais, R; Quoix, E; Sessa, C; Urban, T; Vansteenkiste, J; Zatloukal, P | 1 |
| Barbera, S; Brancaccio, L; De Maio, E; Gridelli, C; Maione, P; Morabito, A; Perrone, F; Piantedosi, F; Piazza, E; Renda, F; Sannicolo, M; Signoriello, G | 1 |
| Lin, CS; Tsai, CM; Wang, LS; Wei, YH | 1 |
| Andriani, F; Bajetta, E; Bidoli, P; Cortinovis, DL; Fabbri, A; Livio, A; Marcomini, B; Mariani, L; Perrone, F; Pilotti, S; Roz, L; Sozzi, G | 1 |
| Hall, B; Li, LY; Liao, ML; Wan, HY; Wang, L; West, T; Yu, SY; Zhu, YZ | 1 |
| Brooks, KJ; Coleman, EJ; Vitetta, ES | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Choi, H; Choi, JH; Han, JH; Hwang, SC; Jeong, SH; Jung, YM; Kang, SY; Kim, JH; Lee, HW; Lim, HY; Oh, YJ; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Chohnabayashi, N; Horinouchi, H; Nishimura, N; Ono, H; Sugiura, R; Uchiyama, N; Ueda, H | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Tsuchiya, T; Utsugi, M; Yanagitani, N | 1 |
| Alard, S; Berghmans, T; Giner, V; Holbrechts, S; Koumakis, G; Leclercq, N; Lecomte, J; Meert, AP; Paesmans, M; Richez, M; Roelandts, M; Sculier, JP; Van Houtte, P | 1 |
| Azim, H; Azim, HA; Elattar, I; Ganti, AK; Loberiza, FR; Mok, T | 1 |
| Anevlavis, S; Argiana, E; Bouros, D; Froudarakis, ME; Kouliatis, G; Marselos, M; Nikolaidou, M; Pappas, P; Pataka, A; Pozova, S | 1 |
| Antonia, S; Bepler, G; Cantor, A; Chiappori, A; Haura, E; Li, X; Obasaju, C; Robinson, LA; Sharma, A; Simon, G; Sommers, KE; Tanvetyanon, T; Williams, C | 1 |
| Ardman, B; Fidias, P; Heist, RS; Huberman, M; Lynch, TJ; Sequist, LV; Temel, JS | 1 |
| Bandiera, A; Carretta, A; Ciriaco, P; Ferla, L; Melloni, G; Puglisi, A; Sayed, I; Zannini, P | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bird, B; Janku, F | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Levien, TL; Reynolds, JK | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Babineaux, S; Buesching, D; Earle, C; Faries, D; Lang, K; Marciniak, MD; Morissette, N; Stokes, M; Thompson, D; Treat, J | 1 |
| Boukovinas, I; Georgoulias, V; Koutsopoulos, A; Mavroudis, D; Mendez, P; Papadaki, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Souglakos, J; Staphopoulos, E; Taron, M; Trypaki, M | 1 |
| Bosch-Barrera, J; Ferrer, M; García-Foncillas, J; Gil-Bazo, I; López-Picazo, JM; Montero, A; Yuste, JR | 1 |
| Boersma, L; Bootsma, G; Borger, J; De Ruysscher, D; Dehing, C; Dekker, A; Dingemans, AM; Geraedts, W; Hochstenbag, M; Lambin, P; Ollers, M; Pitz, C; Simons, J; Wanders, R; Yu, S | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Arnold, A; Crabb, SJ; Ellis, PM; Goss, G; Laurie, SA; Leighl, NB; Patsios, D; Powers, J; Sauerbrei, E; Seymour, L; Shepherd, FA | 1 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Alomar, A; Corella, F; Dalmau, J; García-Navarro, X; Roé, E | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Choy, H; Curran, W; Demas, WF; Ettinger, DS; Jain, AK; Moughan, J; Whipple, G | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Altavilla, G; Danesi, R; Giovannetti, E; Rosell, R | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, HJ; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Anbarasu, A; Bhide, A; Gurumurthy, M; Hocking, M; Koh, P; Satodia, P; Singh, R; Wood, LE | 1 |
| Alonso, G; Alvarez, E; Amenedo, M; Fernández, I; Fírvida, JL; Huidobro, G; Lázaro, M; Mel, JR; Rubio, JC; Vázquez, F; Vázquez, S | 1 |
| Chu, Z; Gao, G; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Choi, JH; Choi, YW; Han, JH; Hwang, SC; Jeong, SH; Jung, JH; Kang, SY; Kim, JH; Lee, HW; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Belt, RJ; Chen, R; Obasaju, C; Perry, MC; Wakelee, HA; West, HL | 1 |
| Fukui, T; Hatooka, S; Ishiguro, F; Kobayashi, R; Mitsudomi, T; Mori, S; Ogawa, S; Okuda, K; Shinoda, M | 1 |
| Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
| Ando, M; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Semba, H; Shibata, T; Takada, Y; Takeda, K; Tamura, T; Yokota, S | 1 |
| Blakely, LJ; Epperson, A; Henry, D; Keaton, M; Schnell, F; Schwartzberg, L; Walker, MS | 1 |
| Gao, HJ; Liu, XQ; Tang, CH; Yang, SF; Zhu, B | 1 |
| Ansari, RH; Detterbeck, FC; Edelman, MJ; Gralla, RJ; Jahan, TM; Luketich, JD; Monberg, M; Moore, DT; Obasaju, CK; Peng, G; Rivera, MP; Socinski, MA | 1 |
| Archer, V; Gorbounova, V; Hirsh, V; Leighl, N; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; von Pawel, J; Zatloukal, P | 2 |
| Bussom, S; Cheng, YC; Lam, W | 1 |
| Blatter, J; Fossella, F; Hanna, N; Peterson, P; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Adamo, V; Carreca, I; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A; Santini, D; Vincenzi, B | 1 |
| Bayer, GK; Graham, DL; Kolesar, JM; Lee, JW; Mazurczak, M; Schiller, JH; Tate, JM; Thomas, SP; Traynor, AM | 1 |
| Caraglia, M; Correale, P; Francini, G; Gotti, G; Macrì, P; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tindara Miano, S | 1 |
| Belderbos, J; Borst, GR; Burgers, S; Lebesque, J; Sonke, JJ | 1 |
| Altug, S; Chu, DT; Cok, G; Damyanov, D; Hall, B; Hsu, HK; Kim, SW; Patil, S; Roubec, J; West, T | 1 |
| Aasebø, U; Bremnes, RM; Helbekkmo, N; Strøm, HH; Sundstrøm, SH; Von Plessen, C | 1 |
| Antonuzzo, A; Arcabasso, G; D'Incecco, A; Falcone, A; Mazzoni, E; Menconi, G; Tibaldi, C | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Crinò, L; De Marinis, F; Falcone, A; Grassivaro, N; Nardi, M; Novello, S; Rinaldi, M; Russo, F; Scagliotti, GV; Tibaldi, C; Tinazzi, A; Tonato, M | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Ardizzoni, A; Bartolotti, M; Gelsomino, F; Tiseo, M | 1 |
| Bollina, R; Carrozza, F; Cascone, T; Ciardiello, F; Di Maio, M; Gallo, C; Gebbia, V; Gridelli, C; Maione, P; Mattioli, R; Mencoboni, M; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Rossi, A; Valerio, MR; Valmadre, G; Verusio, C; Viganò, MG | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Choong, NW; Connor, TB; George, B; Wirostko, WJ | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Barneto, I; Blanco, R; Catot, S; Chaib, I; Cobo, M; de Las Peñas, R; Diz, P; Domine, M; Ibeas, R; Isla, D; Jimenez, U; Lopez-Vivanco, G; Macias, JA; Mendez, P; Moran, T; Oramas, J; Perez-Roca, L; Provencio, M; Reguart, N; Rosell, R; Sala, MA; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Davies, AM; Gandara, DR; Gautschi, O; Jablons, DM; Mack, PC; Rosell, R | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Aasebø, U; Amundsen, T; Bremnes, RM; Brunsvig, PF; Fløtten, O; Grønberg, BH; Hjelde, HH; Kaasa, S; Stornes, F; Sundstrøm, S; Tollåli, T; von Plessen, C; Wammer, F | 1 |
| Ece, F; Hanta, I; Hasturk, S; Hatabay, N; Karatasli, M | 1 |
| Chu, Z; Mao, L; Ren, H | 1 |
| Chang, JJ; Chi, RM; Frethem, CD; Kirstein, MN; Kratzke, RA; Le, CT; Marker, PH; Williams, BW | 1 |
| Gans, SJ; Goksel, T; Martins, R; Park, K; Patil, S; Peterson, P; Rolski, J; Scagliotti, GV; Visseren-Grul, C | 1 |
| Fong, KW; Hee, SW; Leong, SS; Lim, WT; Tan, EH; Toh, CK; Yap, SP | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Arrieta, O; Astorga-Ramos, AM; de la Garza, J; Gallardo-Rincón, D; Martínez-Barrera, L; Michel, RM; Villarreal-Garza, C | 1 |
| Patel, SR; Shord, SS | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Kovac, V; Smrdel, U; Vrankar, M; Zadnik, V; Zwitter, M | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Blackstock, AW; Lally, B; Urbanic, JJ | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Funai, K; Itaya, T; Mochizuki, T; Momiki, S; Nakamura, T; Neyatani, H; Sasaki, K; Suzuki, K; Takahashi, T; Takamochi, K; Toyoda, F; Yong-Il, K | 1 |
| de Marinis, F; Gridelli, C; Maione, P; Ricciardi, S; Rossi, A | 1 |
| Coffey, MC; Mussio, JK; Nagashima, K; Parchment, RE; Sei, S; Shoemaker, RH; Tomaszewski, JE; Yang, QE | 1 |
| Choi, EK; Kang, YS; Kim, IY; Kim, JS; Lee, DS; Oh, YK; Park, HJ; Son, HJ | 1 |
| Angel, J; Athanasiou, A; Karanikas, C; Kosmas, C; Lampaki, S; Mylonakis, N; Politis, N; Rapti, A; Ziras, N | 1 |
| Dragnev, K; Dudek, AZ; Gupta, V; Isaksson, R; Kratzke, RA; Larson, T; Lesniewski-Kmak, K; Maddaus, MA | 1 |
| Mendiola, C; Vaz, MA | 1 |
| Belderbos, JS; Burgers, SA; Kappers, I; Klomp, HM; van Sandick, JW; van Zandwijk, N | 1 |
| Holm, B; Mellemgaard, A; Skov, BG; Skov, T | 1 |
| Guan, Y; He, J; Jiang, M; Shao, W; Tucker, S; Wang, D; Wu, Y; Xu, X; Yang, H; Ying, W; Zhong, B; Zhong, N | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Catania, C; De Braud, F; De Pas, TM; Noberasco, C; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Fidias, P; Heist, RS; Lynch, TJ; Muzikansky, A; Ostler, P; Sequist, LV | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, DC; Lam, WK; Wong, MK | 1 |
| Alberola, V; Camps, C; Carcereny, E; Cobo, M; de Aguirre, I; Domine, M; Isla, D; Lopez-Vivanco, G; Massuti, B; Mendez, P; Moran, T; Okamoto, T; Provencio, M; Ramirez, JL; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Wei, J | 1 |
| Cohen, MH; Justice, R; Pazdur, R | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Baulieux, J; Bossard, N; de la Roche, E; Gamondes, JP; Geriniere, L; Guibert, B; Mulsant, P; Remontet, L; Souquet, PJ; Thibout, Y; Tiffet, O; Tronc, F | 1 |
| Gilligan, D; Gower, N; Hackshaw, A; Jitlal, M; Lee, SM; Ottensmeier, C; Price, A; Rudd, R; Spiro, S; Woll, PJ | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Arimoto, T; Hiramatsu, A; Hosogi, S; Iwasaki, Y; Kohno, Y; Koyama, Y; Marunaka, Y; Nakanishi, M; Tamiya, N; Ueda, M | 1 |
| Draux, F; Dumas, P; Gobinet, C; Jeannesson, P; Manfait, M; Pijanka, J; Sandt, C; Sockalingum, GD; Sule-Suso, J | 1 |
| Matsuzawa, H; Suemitsu, R; Takeo, S; Yamaguchi, M | 1 |
| Manegold, C; Martins, RG; Parikh, P; Scagliotti, GV; Simms, L; Sugarman, KP; Syrigos, KN; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
| Abdel Karim, N; Flora, D; Gupta, A; Issa, M; Jazieh, AR; Knapp, M; Komrokji, R; Patil, S | 1 |
| Ansari, R; Belani, CP; Catalano, RB; Comis, RL; Edelman, MJ; Gillenwater, HH; Gonin, R; Marinucci, DM; Obasaju, CK; Rowland, KM; Socinski, MA; Treat, JA | 1 |
| Ngeow, J; Toh, CK | 1 |
| Cellini, F; Cesario, A; Ciresa, M; D'Angelillo, RM; Fiore, M; Granone, P; Greco, C; Mineo, TC; Paleari, L; Pompeo, E; Ramella, S; Trodella, L | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Asmar, L; Bepler, G; Boehm, KA; Boulware, D; Bromund, J; Caton, JR; Demarco, LC; Li, X; Monberg, MJ; O'Rourke, MA; Obasaju, C; Peng, G; Reynolds, C; Schell, MJ; Shaw Wright, G; Zheng, Z | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Chau, WK; Chung, CL; Hsieh, CC; Hsu, CH; Tai, CJ; Wang, FJ | 1 |
| Boselli, S; Catania, C; Danesi, R; de Braud, F; De Pas, T; Giovannetti, E; Manzotti, M; Minocci, D; Noberasco, C; Pelosi, G; Radice, D; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Gao, F; Leong, SS; Lim, WT; Ngeow, J; Poon, D; Tan, EH; Toh, CK | 1 |
| Araújo, A; Catarino, R; Coelho, A; Gomes, M; Medeiros, R; Nogueira, A | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Liu, B; Qu, Y; Xiao, W; Yang, Y | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, AG; Simou, E | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C | 1 |
| Abdel Wahab, M; Dorgham, Y; Hamouda, W; Yosry, A | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y | 1 |
| Liu, LS; Shi, ZM; Tian, JH; Wang, L; Zhou, ZY | 1 |
| Caffo, O; Cassetta, MI; Fallani, S; Galligioni, E; Marangon, E; Mini, E; Murgia, V; Nobili, S; Novelli, A; Sala, F; Zucchetti, M | 1 |
| Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S | 1 |
| Lee, JS; Orlando, M; Park, K; Scagliotti, G; Simms, L; Yang, CH | 1 |
| Eguchi, K; Ichinose, Y; Masuda, N; Ogura, T; Okamoto, H; Seki, N; Seto, T; Shibuya, M; Shinkai, T; Takiguchi, Y; Wasada, I; Watanabe, K; Yamanaka, T | 1 |
| Dong, X; English, JC; Evans, K; Flint, J; Gout, PW; Guan, J; Lam, S; Lam, WL; Laskin, J; Ling, V; Macaulay, C; Murray, N; Ng, RT; Wang, Y; Yee, J | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT | 1 |
| Lin, L; Liu, XQ; Song, ST; Wang, WX | 1 |
| Boezen, HM; de Vries, EG; Groen, HJ; Maring, JG; Maurer, JM; Slijfer, M; Uges, DR; Wachters, FM | 1 |
| Chen, ZH; Cheng, H; Dong, S; Guo, AL; Huang, Y; Wang, Z; Wu, YL; Xie, Z; Yan, HH; Zhang, XC | 1 |
| Ashley, S; Hubner, R; Myerson, J; O'Brien, ME; Popat, S; Puglisi, M; Sheri, A; Trani, L; Young, K | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 1 |
| de Vries, EG; Groen, HJ; Maring, JG; Maurer, M; Uges, DR; Wachters, FM | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Gu, CP; Hong, D; Li, T; Lou, GY; Zhang, YP | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, A | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Ansari, RH; Belani, CP; Catalano, RB; Chen, R; Comis, RL; Edelman, MJ; Gonin, R; Marinucci, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Barton, JH; Burris, HA; Greco, FA; Griner, P; Hainsworth, JD; Patton, JF; Simons, L; Spigel, DR; Zubkus, JD | 1 |
| Bergman, AM; Hoebe, EK; Leon, LG; Loves, WJ; Peters, GJ; Sigmond, J | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Inhorn, RC; Lane, CM; Reeves, J; Rubinsak, J; Spigel, DR; Thompson, DS; Vazquez, ER; Webb, C | 1 |
| Cappuzzo, F; Toschi, L | 1 |
| Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Chaudhary, RT; Kleynberg, RL; Sofi, AA | 1 |
| Amundsen, T; Bremnes, RM; Fløtten, O; Grønberg, BH; Hjelde, HH; Jordhøy, M; Kaasa, S; Plessen, Cv; Sundstrøm, S | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Fajkic, A; Mekic-Abazovic, A; Music, M; Zerem, E | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Aerts, JG; Hoogsteden, HC; Legrand, C; Schmitz, PI; Surmont, V; Tan, KY; Tournoy, K; van Klaveren, RJ; van Meerbeeck, JP; Vernhout, RM | 1 |
| Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Ma, SL; Wu, FQ; Yu, HF | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| André, N; Ciccolini, J; Dahan, L; Mercier, C; Ouafik, L | 1 |
| Bandera, M; Dominioni, L; Imperatori, A; La Salvia, D; Nardecchia, E; Rotolo, N; Spanevello, A; Toungoussova, O | 1 |
| Hasse, J; Henke, M; Kaden, M; Momm, F; Schumacher, M; Tannock, I | 1 |
| Ansari, RH; Catalano, RB; Chen, R; Comis, RL; Liles, DK; Marinucci, DM; Monberg, MJ; Obasaju, CK; Ribeiro, MJ; Socinski, MA; Treat, J | 1 |
| Frings, V; Maassen van den Brink, KI; Melissant, CF; Phernambucq, ECJ; Postmus, PE; Senan, S; Smit, EF; Spoelstra, FOB; van de Ven, PM; Verbakel, WFAR | 1 |
| Ashley, S; Brunetto, AT; Carden, CP; Faria, AL; Myerson, J; O'Brien, ME; Popat, S | 1 |
| Adjei, AA; Dy, GK; Endo, C; Mandrekar, SJ; Molina, JR; Salavaggione, OE; Schild, SE; Ziegler, KL | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Kim, YH; Mishima, M; Yoshizawa, A | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Gou, Y; Guo, H; Jiang, L; Tian, J; Yang, K; Yang, Q; Zhang, L; Zhang, R | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pennucci, MC; Pezzuolo, D; Tartarini, R | 1 |
| Chen, H; Li, C; Pan, Y; Sun, Y; Wang, Q; Yang, S | 1 |
| Hasegawa, Y; Imaizumi, K; Kondo, M; Shimokata, K; Shindo, J; Suzuki, R; Taniguchi, H; Usami, N; Yamamoto, M; Yokoi, K | 1 |
| Baay, M; Lambrechts, HA; Lardon, F; Meijnders, P; Pattyn, GG; Pauwels, B; Vermorken, JB; Wouters, A | 1 |
| de Marinis, F; Giuliani, G; Grossi, F; Walzer, S | 1 |
| Bischoff, HG; Heigener, DF; Nuijten, M; Walzer, S | 1 |
| Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Mueller, E; Schmidt, E; Stanisic, S; Vergnenègre, A; Walzer, S | 1 |
| Aultman, R; Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Nuijten, M; Siebert, U; Vergnenègre, A; Walzer, S | 1 |
| Douillard, JY; Eckardt, J; Liepa, AM; Novello, S; O'Brien, M; Paz-Ares, L; Pimentel, FL; Simms, L; Visseren-Grul, C; von Pawel, J | 1 |
| Ebina, A; Imai, T; Kishimoto, K; Nakamura, Y; Sato, N | 1 |
| Chiu, YF; Kuo, YH; Lin, YW; Su, YC; Tsai, MS | 1 |
| Li, XD; Shen, H; Shu, YQ; Wang, RS; Wu, CP; Yin, YM | 1 |
| Bafaloukos, D; Bakogiannis, C; Boukovinas, J; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Kalofonos, HP; Katirtzoglou, N; Kosmidis, PA; Lambaki, S; Pectasides, D; Pentheroudakis, G; Samantas, E; Skarlos, D; Syrigos, KN | 1 |
| Clément-Duchêne, C; Colevas, AD; Ganjoo, K; Krupitskaya, Y; Kumar, A; Lavori, P; McMillan, A; Padda, S; Pedro-Salcedo, MS; Wakelee, HA; Zhao, G; Zhou, L | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Amarantidis, K; Chamalidou, E; Chatzaki, E; Chelis, L; Kakolyris, S; Karakitsos, P; Mikroulis, D; Neanidis, K; Prassopoulos, P; Xenidis, N | 1 |
| Leighl, NB; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; Zatloukal, P | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Fujita, S; Fukuhara, A; Hata, A; Hatachi, Y; Kaji, R; Katakami, N; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Fan, XW; Shan, L; Yang, SF; Zhang, GQ | 1 |
| Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Balzelloni, ML; Banna, GL; Barbieri, F; Barletta, E; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bria, E; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Collovà, E; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Di Maio, M; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Follador, A; Garetto, L; Gebbia, V; Genestreti, G; Gentile, AL; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Menis, J; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Novello, S; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, MR; Verderame, F; Zanelli, F; Zanon, E | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Ikeda, R; Jiang, Z; Kolesar, JM; Lau, E; Sachidanandam, K; Vermeulen, LC; Yamada, K | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Jiang, J; Li, L; Lin, Q; Tian, J; Wang, Q; Wang, X | 1 |
| Wang, XY; Zhao, YL | 1 |
| Cai, X; Chen, J; Li, Q; Mei, K; Yu, J; Zhao, X; Zhou, C | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Baracos, VE; Chu, QS; Mazurak, VC; Mourtzakis, M; Murphy, RA; Reiman, T | 1 |
| Angeli, I; Calamai, G; Catania, C; Danesi, R; De Braud, F; De Pas, TM; Giovannetti, E; Milani, A; Noberasco, C; Pelosi, G; Radice, D; Russo, F; Spitaleri, G; Toffalorio, F | 1 |
| Chen, J; Li, J; Li, MW; Shen Tu, JZ; Wang, LR; Wang, Y; Xu, N; Zhang, GB | 1 |
| Baay, M; Ides, J; Lambrechts, HA; Lardon, F; Meijnders, P; Pattyn, GG; Pauwels, B; Peeters, M; Vermorken, JB; Wouters, A | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalykaki, A; Karampeazis, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Vamvakas, L; Vardakis, N | 1 |
| Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X | 1 |
| Fernández Domínguez, J; García Rodríguez, R; Mateos Marcos, V; Valle Pereda, M | 1 |
| Au, JSK; Benner, RJ; Blasinska-Morawiec, M; Ingrosso, A; Jassem, J; Krzakowski, M; Manegold, C; Meech, SJ; Readett, D; Serwatowski, P; Szczesna, A; Tan, EH; Thatcher, N; van Zandwijk, N; Zatloukal, P | 1 |
| Blackstock, AW; Bogart, JA; Crawford, JC; Gu, L; Morano, K; Salama, JK; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Brichkova, OY; Davidov, MI; Karaseva, VV; Lazarev, AF; Marenich, AF; Orlov, SV; Pavlushkov, EV; Polotzky, BE; Semenchenya, VA; Skryabina, LS | 1 |
| Gao, Z; Gu, A; Han, B; Shen, J; Zhong, H | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Burylo, A; deJong, D; Huitema, AD; Joerger, M; Schellens, JH | 1 |
| Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Chen, Y; Liu, B; Qian, X | 1 |
| Che, L; DI, LJ; Fang, J; Jiang, HF; Ren, J; Song, GH; Yu, J; Zhu, YL | 1 |
| Liu, T; Zhang, JQ; Zhang, L | 1 |
| Chang, GC; Chang, JW; Chua, DT; Hsia, TC; Manegold, C; Mok, TS; Moore, N; Sirisinha, T; Sriuranpong, V; Thitiya, S; Thongprasert, S; Tsai, CM; Tsang, K | 1 |
| Ahn, MJ; Chang, JW; Kang, JH; Kim, HT; Kim, JH; Kim, SW; Thongprasert, S; Tsang, K; Walzer, S; Wright, E | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Doodeman, VD; Huitema, AD; Jansen, RS; Joerger, M; Rosing, H; Schellens, JH; Smits, PH; Vainchtein, LD | 1 |
| Adamo, V; Alabiso, O; Ardizzoni, A; Barbera, S; Barni, S; Buscarino, C; Caprioli, A; Crinò, L; De Marinis, F; Filippelli, G; Gebbia, V; Gridelli, C; Lorusso, V; Maione, P; Marangolo, M; Morena, R; Pela, R; Piazza, E; Venturino, P; Zilembo, N | 1 |
| Bennouna, J; Favrel, S; Lemarie, E; Pinel, MC; Pouget, JC; Senellart, H; Tourani, JM; Tournoux-Facon, C | 1 |
| Bang, YJ; Bergethon, K; Camidge, DR; Christensen, J; Clark, JW; Dy, J; Iafrate, AJ; Kim, DW; Kwak, EL; Maki, RG; Ou, SH; Salgia, R; Siwak-Tapp, C; Solomon, BJ; Tan, W; Wilner, KD | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| Aakre, JA; Aubry, MC; Croghan, GA; Cunningham, JM; Johnson, C; Li, Y; Molina, J; Pankratz, VS; Sun, Z; Wampfler, JA; Wang, L; Wu, D; Yang, P | 1 |
| Cho, JH; Kim, CS; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES; Yi, HG | 1 |
| He, J; Yang, H; Zhao, M | 1 |
| Ardizzoni, A; Bartolotti, M; Cappuzzo, F; D'Incecco, A; Giovannetti, E; Honeywell, R; Leon, LG; Loosekoot, N; Peters, GJ; Tibaldi, C; Tiseo, M | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Bertetto, O; Dall'agata, M; Fumagalli, L; Galliano, M; Lissoni, P; Lopez, M; Maglie, M; Naglieri, E; Porta, C; Recchia, F; Ridolfi, L; Ridolfi, R; Santo, A; Testore, F | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Hou, M; Li, Z; Wang, H; Wang, Z | 1 |
| Aerts, HJ; Bussink, J; De Ruysscher, D; Emans, D; Folgering, AM; Lambin, P; Oyen, WJ; van Elmpt, W; Velders, M | 1 |
| Boidron-Celle, M; Diot, P; el Houfia, A; Gagnadoux, F; Giraudeau, B; Grimbert, D; Hureaux, J; le Pape, A; Lemarie, E; Pichon, E; Prunier, C; Valat, C; Vecellio, L | 1 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Cetto, GL; Cingarlini, S; Frizziero, M; Genestreti, G; Giovannini, N; Maglie, M; Molino, AM; Piciucchi, S; Sanna, S; Santo, A | 1 |
| Kamei, H; Katoh, T; Kiura, K; Shiote, Y; Suwaki, T; Takigawa, N; Umemura, S; Yamane, H; Yano, T | 1 |
| Reckamp, KL | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Hanna, N; Langer, C; Monberg, M; Ortuzar, W; Peng, G; Pennella, E; Scagliotti, G | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Choi, DH; Choi, Y; Jeon, YK; Kim, CW; Kim, MK; Kim, YH; Woo, JK | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Chen, L; Dong, J; Du, Y; Gong, W; Jin, H; Li, L; Lv, Y; Sun, J; Wei, X; Wu, J; Zhang, X | 1 |
| Ball, D; Burmeister, BH; Burmeister, E; Cox, S; Forouzesh, B; Horwood, K; Lehman, M; Michael, M; Sasso, G; Wirth, A | 1 |
| Milleron, B; Quoix, E; Westeel, V; Zalcman, G | 1 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Horai, T; Ikeda, N; Imamura, F; Inoue, A; Kimura, Y; Nishino, K; Nishio, M; Noro, R; Ohsaki, Y; Tsuboi, M; Uchida, J | 1 |
| Gao, Y; Lv, Y; Xie, X; Yu, F; Yu, P; Zhang, Q; Zhang, S; Zheng, Y | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Acres, B; Bastien, B; Bizouarne, N; Bonnefoy, JY; Braun, D; Breton, JL; Buyse, M; Chenard, MP; Debieuvre, D; Koralewski, P; Lacoste, G; Lena, H; Limacher, JM; Madroszyk, A; Papai, Z; Quoix, E; Ramlau, R; Riviere, A; Stoelben, E; Tavernaro, A; Westeel, V | 1 |
| Baas, P; Bard, MP; Beijnen, JH; Burgers, SA; Doodeman, VD; Haitjema, TJ; Huitema, AD; Joerger, M; Schellens, JH; Smit, EF; Smits, PH; Vincent, A | 1 |
| Brekken, RA; Gazdar, AF; Girard, L; Greer, RM; Harran, P; Larsen, JE; Minna, JD; Peyton, M; Wang, L; Wang, X; Xie, Y | 1 |
| Baldelli, E; Chiari, R; Crinò, L; Flacco, A; Floriani, I; Garavaglia, D; Ludovini, V; Meacci, M; Minotti, V; Pistola, L; Siggillino, A; Tofanetti, FR; Tonato, M | 1 |
| Chougule, MB; Jackson, T; Patel, A; Sachdeva, P; Singh, M | 1 |
| Aragno, M; Canuto, RA; Catalano, MG; Fadda, M; Finocchiaro, C; Fortunati, N; Maggiora, M; Monge, T; Muzio, G; Oraldi, M; Pugliese, M; Schena, M; Scigliano, M; Segre, O; Tinivella, M; Tiozzo, E | 1 |
| Monberg, MJ; Obasaju, CK; Peng, G; Scagliotti, GV; Socinski, MA; Treat, J | 1 |
| Bartucci, M; Biffoni, M; Dattilo, R; De Maria, R; Duranti, E; Eramo, A; Lotti, F; Martinelli, S; Maugeri-Saccà, M; Navarra, S; Patrizii, M; Pilozzi, E; Rinaldo, C; Romania, P; Signore, M; Svensson, S; Zeuner, A | 1 |
| Chen, F; Liu, Y; Sun, Y; Wu, X | 1 |
| Adachi, M; Hirose, T; Ishida, K; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Facciolo, F; Hetzel, M; Leschinger, M; Maiorino, L; Orlowski, TM; Pastorino, U; Scagliotti, GV; Spaggiari, L; Torri, V; Vansteenkiste, JF; Visseren-Grul, C | 1 |
| Abraham, R; Broad, A; Burns, I; Clarke, S; Diiulio, J; Galettis, P; Links, M; Milner, A; Mitchell, PL; Rosenthal, MA | 1 |
| Abo, RP; Batzler, A; Eckloff, BW; Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Moon, I; Pelleymounter, L; Schaid, DJ; Sun, Z; Wang, L; Wieben, ED; Yang, P | 1 |
| Jiang, G; Li, J; Li, X; Li, Y; Liu, J; Wang, J; Yang, F; Zhao, H | 1 |
| Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Lee, YJ; Min, YJ; Noh, YJ; Oh, S; Park, CR; Park, JH; Ra, SW; Seo, KW | 1 |
| Cormier, Y; Gitlitz, B; Gleave, ME; Hao, D; Laskin, JJ; Lee, C; Murray, N; Nemunaitis, J; Nicholas, G; Nugent, F; Pressnail, B; Sanborn, R; Stephenson, J; Ung, Y; Vincent, M | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Fan, Y; Huang, Z; Lin, N; Luo, L; Miao, L; Yu, H | 1 |
| Ardizzoni, A; Bagnulo, A; Baldini, E; Barone, C; Boni, C; Boni, L; Cafferata, MA; Caroti, C; Di Costanzo, F; Germano, D; Grossi, F; Labianca, R; Marini, G; Matano, E; Mencoboni, M; Pennucci, C; Prochilo, T; Recchia, F; Tiseo, M; Zanelli, F | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Du, Z; Shi, M; Xu, X; Yu, Y | 1 |
| Chen, J; Li, J; Li, MW; Shentu, JZ; Wang, LR; Wang, Y; Xu, N; Zhang, GB | 1 |
| Aoki, T; Fukuoka, M; Hirashima, T; Ikeda, N; Ishiguro, T; Iwamoto, Y; Kawaguchi, T; Kotani, Y; Kurata, T; Nakagawa, K; Sawa, T; Tsuboi, M | 1 |
| Gao, Q; Wang, FY; Yu, H | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Fu, L; Gao, Y; Hong, D; Hong, W; Hu, L; Kou, JY; Su, D; Xie, FJ; Zhang, YP; Zhao, P | 1 |
| Kamiyama, Y; Kasai, H; Kodama, T; Mori, K | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Chang, YC; Chen, CM; Chih-Hsin Yang, J; Hsu, HH; Hu, FC; Ting-Fang Shih, T; Tseng, WY; Yang, PC; Yu, CJ | 1 |
| Chang, GC; Chen, YM; Cheng, YK; Liao, WY; Shih, JY; Yang, JC; Yu, CJ | 1 |
| Li, Z; Lu, S; Ren, Z; Yu, Y; Zhang, L; Zhao, J | 1 |
| Guo, Z; Li, J | 1 |
| Li, W; Liu, H; Qu, X; Sun, C; Yue, B; Zhao, C | 1 |
| Comans, EF; Hartemink, KJ; Paul, MA; Phernambucq, EC; Postmus, PE; Senan, S; Smit, EF | 1 |
| Erridge, S; Faivre-Finn, C; Gilligan, D; Hatton, M; Keerie, C; Mohammed, N; Price, A; Russell, S; Skailes, G; Snee, M; Yellowlees, A | 1 |
| Berchier, MC; Berghmans, T; Bosschaerts, T; Giner, V; Lafitte, JJ; Leclercq, N; Lewin, D; Meert, AP; Paesmans, M; Scherpereel, A; Sculier, JP | 1 |
| Chida, K; Inui, N; Karayama, M; Kuroishi, S; Kusagaya, H; Masuda, M; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Aasebø, U; Amundsen, T; Bremnes, R; Fløtten, Ø; Grønberg, BH; Hornslien, K; Rolke, H; Sundstrøm, S; von Plessen, C; Wentzel-Larsen, T | 1 |
| Chen, J; He, J; Jiang, L; Li, B; Sun, G; Wang, L; Xiu, Q; Yu, H; Zhao, L | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Amoroso, D; Camerini, A; Cappuzzo, F; D'Incecco, A; Fabbri, A; Tibaldi, C; Vasile, E | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| De Pas, T; Giovannetti, E; Peters, GJ; Toffalorio, F | 1 |
| Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 2 |
| He, J; Li, H; Lu, J; Ma, P; Qin, Y; Wang, J; Wei, L; Xu, J; Zhang, X | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Cao, N; Li, Z; Ma, B; Mi, D; Tian, J; Yang, K | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Alken, S; Breathnach, OS; El-Helali, A; Greene, J; Grogan, L; Korpanty, G; Smyth, L | 1 |
| Chen, G; Lu, S; Yu, Y; Zhang, L; Zhao, Q | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Cho, JH; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES | 1 |
| Santoni-Rugiu, E; Sorensen, JB; Vilmar, AC | 1 |
| Chen, S; Cheng, YL; Gu, B; Li, ST; Ni, YJ | 1 |
| Ding, XX; Hu, JW; Qiu, MT; Tian, HY; Xu, L; Yin, R | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R | 1 |
| Chang, J; Fang, J; Hu, Z; Huang, C; Huang, Y; Li, B; Li, K; Liang, H; Liu, W; Liu, X; Liu, Y; Lu, Y; Wang, M; Wang, S; Wang, Y; Wang, Z; Wu, G; Xu, N; Yu, S; Zhang, L; Zhang, Y; Zhou, J | 1 |
| Bekaii-Saab, T; Bertino, EM; Diasio, RB; Fernandez, S; Karim, NA; Otterson, GA; Villalona-Calero, MA | 1 |
| Lecca, P; Morpurgo, D | 1 |
| Chen, SP; Fu, MY; Jiang, CP; Liu, F; Wang, BQ; Wu, BH; Yang, M | 1 |
| Cao, Q; Dudek, AZ; H Thaw, SS; Kumar, P; Larson, T; Pawloski, P | 1 |
| Baird, AM; Gray, SG; Kilmartin, L; Leonard, J; Naicker, KM; O'Byrne, KJ | 1 |
| Hwang, YI; Jang, SH; Jung, KS; Kim, DG; Kim, JH; Kim, SY; Park, S | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH | 1 |
| Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Minami, S; Nakatani, T; Namba, Y; Ogata, Y; Okafuji, K; Osaki, T; Otsuka, T; Shiroyama, T; Tachibana, I; Uchida, J; Yamamoto, S | 1 |
| Chen, DY; Zhao, WY | 1 |
| Ishigatsubo, Y; Kaneko, T; Klinman, DM; Sato, T; Shimosato, T; Takahashi, R | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; D'Amico, M; Fedele, P; Marino, A; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Batra, S; Sharma, N; Vaid, AK; Wadhwa, J | 1 |
| Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER | 1 |
| Goyal, A; Singh, N | 1 |
| Alberola, V; Brabender, J; Camps, C; Cardenal, F; Danenberg, KD; Danenberg, PV; Domine, M; Gandara, D; Gumerlock, PH; Lord, RV; Rosell, R; Sánchez, JJ; Sánchez, JM; Tarón, M | 1 |
| Caness, P; Pensa, F; Pronzato, P; Sinaccio, G; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Alexopoulos, CG; Berghmans, T; Efremidis, A; Florin, MC; Klastersky, J; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Recloux, P; Sculier, JP; Thiriaux, J | 1 |
| Blumenschein, G; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Jung, MS; Khuri, FR; Kies, MS; Kurie, JM; Lee, JJ; Lee, JS; Liu, DD; Lu, C; Lu, R; Munden, RF; Papadimitrakopoulou, VA; Pisters, KM; Shin, DM; Zinner, R | 1 |
| Cottrell, W; Dranitsaris, G; Evans, WK | 1 |
| Cesario, A; Corbo, GM; d'Angelillo, RM; Galetta, D; Granone, P; Macis, G; Mangiacotti, MG; Margaritora, S; Porziella, V; Ramella, S; Trodella, L; Valente, S | 1 |
| Cynowska, B; Damps, I; Jassem, E; Mierzejewska, E; Słomiński, JM; Wolf, H | 1 |
| Delbaldo, C; Faivre, S; Le Chevalier, T; Monnerat, C | 1 |
| Green, MR | 1 |
| Colantuoni, G; Gridelli, C; Maione, P; Rossi, A | 1 |
| Casado, E; De Castro, J; Feliu, J; González Barón, M; Ordoñez, A | 1 |
| Alloisio, M; Antonelli, G; Cavina, R; Dambrosio, M; Latteri, F; Morenghi, E; Ravasi, G; Sala, A; Santoro, A; Soto Parra, H | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Loves, WJ; Peters, GJ; van Bree, C | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Armand, JP; Faivre, S; Kayitalire, L; Le Chevalier, T; Lhommé, C; Lokiec, F; Monnerat, C; Novello, S; Pautier, P; Raymond, E; Ruffié, P; Taieb, J | 1 |
| Buesa, JM; Carrasco, J; Corral, N; Esteban, E; Estrada, E; Fra, J; Lacave, AJ; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Bunn, PA | 5 |
| Bacoyiannis, C; Boukovinas, J; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nicolaides, C; Papakostas, P; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Barnes, BC; Brierre, JE; Buller, EJ; Cole, JL; Felicia Fontenot, M; Lormand, NA; Mills, G; Rainey, JM; Rinaldi, DA; Yadlapati, S | 1 |
| Barton, JH; Burris, HA; Butts, JA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Scott, C; Thompson, DS; Webb, C | 1 |
| Adachi, S; Fung, MC; Ishiguro, H; Sakata, T | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Joppert, MG; Rocha Lima, CM | 1 |
| Berger, J; Dahlmann, N; Dierlamm, T; Fiedler, W; Hossfeld, DK; Knuffmann, C; Köhler, A; Kugler, C; Laack, E; Niestroy, A; Peters, A; Vohwinkel, G | 1 |
| Crawford, J; Green, MR; Herndon, JE; Leopold, KA; Miller, AA; Perry, MC; Vokes, EE | 1 |
| Curran, MP; Plosker, GL | 1 |
| Duan, EY; Liu, AH; Wang, XS; Wu, YX; Zhou, Y | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 2 |
| Fuxius, S; Mansouri, K; Mross, K; Unger, C | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Calandri, C; Crinò, L | 1 |
| Novello, S; Scagliotti, GV | 2 |
| Szczepura, A | 1 |
| Petruzelka, L; Zatloukal, P | 1 |
| Gridelli, C | 1 |
| Harper, P; Marx, G | 1 |
| Bagnes, C; Chacón, RD; Morero, J; Orlando, M; Rojas, O; Rosenberg, M; Silva, C; Van Kooten, M; Vicente, H; Vilanova, M | 1 |
| Gerinière, L; Souquet, PJ | 2 |
| Depierre, A; Jacoulet, P; Westeel, V | 2 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| Mornex, F | 1 |
| Ash-Bernal, R; Browner, I; Erlich, R | 1 |
| Carpagnano, F; Crucitta, E; De Lena, M; Guida, M; Lorusso, V; Mancarella, S; Panza, N; Sambiasi, D; Silvestris, N | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 2 |
| Chen, CW; Chen, HH; Chen, TY; Hsiue, TR; Huang, WT; Lai, WW; Su, WC; Tsao, CJ; Wang, NS | 1 |
| Aramendia, JM; Aristu, JJ; Bosch, A; Brugarolas, A; Calvo, E; Claver, A; Cortes, J; Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Rodriguez, J; Salgado, E | 1 |
| Terao, I | 1 |
| Manegold, C | 4 |
| Crinò, L | 1 |
| Pirker, R | 1 |
| Choma, D; Jacot, W; Khial, F; Pujol, JL; Quantin, X | 1 |
| Thatcher, N | 1 |
| Bonnaud, F; Sabria-Trias, J; Sioniac, M | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S | 1 |
| Adachi, M; Hirose, T; Horichi, N; Ohmori, T; Ohnishi, T; Shirai, T; Sohma, S; Yamaoka, T | 1 |
| Arcangeli, V; Fochessati, F; Panzini, I; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Hirai, I; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Morère, JF | 2 |
| Fournel, P | 2 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Zaffaroni, N; Zilembo, N | 1 |
| Alonso, V; Antón, A; Artal-Cortés, A; Ceballos, C; Corral, M; Herrero, A; Martínez-Trufero, J; Maurel, J; Puértolas, T | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Shepherd, FA | 3 |
| Senzer, N | 1 |
| Borsellino, N; Caruso, M; Colucci, G; Durini, E; Galetta, D; Gebbia, N; Gebbia, V; Loizzi, M; Pandolfo, G; Pezzella, G; Rinaldi, M; Tirrito, ML; Valdesi, M; Valenza, R; Varvara, F; Verderame, F | 1 |
| Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ | 1 |
| Castro, M | 1 |
| Hiroi, M; Hojyo, T; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Eda, H; Endoh, M; Hattori, K; Horii, I; Ishikawa, T; Ishitsuka, H; Kawashima, A; Kohchi, Y; Miwa, M; Oikawa, N; Shimma, N; Suda, H; Tanimura, H; Ura, M | 1 |
| Bunn, PA; Lilenbaum, R | 1 |
| Barbera, S; Bertetto, O; Castiglione, F; Cigolari, S; Clerici, M; Favaretto, A; Ferraù, F; Frontini, L; Galetta, D; Gallo, C; Gasparini, G; Gebbia, V; Gridelli, C; Iaffaioli, RV; Migliorino, MR; Novello, S; Perrone, F; Piantedosi, F; Piazza, E; Robbiati, SF; Rosetti, F; Rossi, A; Sacco, C | 1 |
| Kalofonos, HP; Kosmas, C; Mylonakis, N; Tsavaris, N | 1 |
| Bunn, PA; Simon, GR | 1 |
| Albrecht, P; Elmer, A; Kortsik, C | 1 |
| Chen, MC; Chen, YM; Perng, RP; Tsai, CM | 1 |
| He, YJ; Liu, DG; Su, YS; Teng, XY; Zhou, NN; Zhou, ZM | 1 |
| Bosquée, L; D'Odemont, JP; Dams, N; Delobbe, A; Deman, R; Deschepper, K; Dooms, C; Galdermans, D; Nackaerts, K; Siemons, L; Van den Brande, P; Van Kerckhoven, W; Vandebroek, J; Vandeurzen, K; Vansteenkiste, J | 1 |
| Amenedo, M; Barón, FJ; Caeiro, M; Casal, J; Castellanos, J; Cueva-Banuelos, JF; Estévez, SV; Fírvida, JL; García Mata, J; Gómez, A; González, A; Grande, C; Huidobro, G; Lázaro, M; León, L; Rodríguez, MR; Romero, C | 1 |
| Chen, MC; Chen, YM; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Ayoub, J; Charpentier, D; Desjardins, P; Hirsh, V; Langleben, A; Ofiara, L; Pintos, J; Small, D; Whittom, R | 1 |
| Faucette, SR; Gillenwater, HH; Hawke, RL; Lindley, C; Pescatore, SL; Shord, SS; Socinski, MA | 1 |
| Hosoda, C; Ishikura, K; Izawa, M; Kawasaki, Y; Kikkawa, N; Koshohbu, T; Nakatani, S; Shimizu, E | 1 |
| Bosquée, L; D'Orio, V; Mommens, V | 1 |
| Goh, BC; Lee, HS; Lee, SC; Lehnert, M; Lim, HL; Millward, MJ; Soo, RA; Tok, LT; Wang, LZ | 1 |
| Bolaño, M; Casado, E; Castro, J; Checa, T; Feliu, J; González-Barón, M; Madroñal, C; Martín, G; Rodríguez, A; Rodríguez-Jaráiz, A | 1 |
| Bepler, G; Boni, C; Cooc, J; Crinò, L; Danenberg, KD; De Marinis, F; Di Costanzo, F; Gozzelino, F; Lord, RV; Marangolo, M; Novello, S; Rinaldi, M; Rosell, R; Salonga, D; Sánchez, JJ; Scagliotti, G; Stephens, C; Taron, M; Tonato, M | 1 |
| Battelli, T; Bonsignori, M; Buzzi, F; Catanzani, S; De Signoribus, G; Di Lullo, L; Lippe, P; Massacesi, C; Mattioli, R; Mazzanti, P; Morale, D; Pilone, A; Rocchi, MB; Rossi, G; Sturba, F; Trivisonne, R; Tuveri, G | 1 |
| Aitini, E; Barbieri, R; Cacciani, GC; Camisa, R; Capra, R; Cascinu, S; Franciosi, V; Vasini, G | 1 |
| Bartolini, S; Betti, M; Cappuzzo, F; Crinò, L; Darwish, S; De Angelis, V; De Marinis, F; Gregorc, V; Maestri, A; Mazzoni, F; Nelli, F; Novello, S; Rita Migliorino, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Barbera, S; Bezjak, A; Cigolari, S; Fava, S; Findlay, B; Frontini, L; Gallo, C; Gasparini, G; Gebbia, V; Gridelli, C; Hirsh, V; Ianniello, GP; Illiano, A; Manzione, L; Myers, R; Perrone, F; Piantedosi, F; Robbiati, SF; Seymour, L; Shepherd, FA; Veltri, E | 1 |
| Araki, J; Nishio, K; Oda, T; Watanabe, M | 1 |
| Gregor, A; Groen, HJ; Little, FA; Price, A; van der Leest, AH; van Putten, JW | 1 |
| Alberola, V; Felip, E; Massuti, B; Rosell, R; Taron, M | 1 |
| Antimi, M; Barduagni, M; Ceribelli, A; Cognetti, F; Cortesi, E; De Marinis, F; Fabi, A; Gamucci, T; Giannarelli, D; Gridelli, C; Maione, P; Migliorino, MR | 1 |
| Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N | 1 |
| Dueñas Garcia, R; Fernandez Flores, E; Fernandez Morales, M; Jaen Morago, A; Lozano Barriuso, A; Medina Magan, B; Mohedano Mohedano, N; Moreno Moreno, MA; Porras Quintela, I; Sánchez Rovira, P | 1 |
| Harper, P | 1 |
| Alberola, V; Bepler, G; Camps, C; Crino, L; Danenberg, K; De Marinis, F; Peñas, R; Provencio, M; Rosell, R; Sanchez, JJ; Scagliotti, G; Taron, M | 1 |
| Fojtů, H; Grygárková, I; Havel, L; Horenková, E; Kolek, V; Kůta, M; Nováková, L; Pesek, M; Petruzelka, L; Průsa, P; Roubec, J; Sixtová, D; Skácel, T; Skricková, J; Zatloukal, P; Zemanová, M | 1 |
| Bolt, K; Lammers, JW; Maas, KW; Schramel, FM; van der Lee, I; Zanen, P | 1 |
| Bosse, U; Froeschle, P; Granetzny, A; Klinke, F; Koch, O; Striehn, E; Vogt, U; Wagner, W | 1 |
| Alberola, V; Artal, A; Azagra, P; Bover, I; Camps, C; Cardenal, F; Carrato, A; de las Peñas, R; Diz, P; Felip, E; González-Larriba, JL; Isla, D; Jiménez, U; López-Vivanco, G; Morales, S; Provencio, M; Rosell, R; Ruiz-Casado, A; Sanchez, JJ; Vadell, C | 1 |
| Le Chevalier, T | 3 |
| Adamo, V; Aiello, RA; Aitini, E; Altavilla, G; Angelini, V; Angiolillo, M; Anselmo, A; Ardizzoia, A; Aschelter, A; Azzarello, G; Barbera, S; Barletta, E; Barni, S; Bartolucci, R; Barzelloni, ML; Battiloro, C; Bearz, A; Belli, M; Bellia, V; Belloni, P; Belometti, MO; Bertetto, O; Bilancia, D; Bollina, R; Borsellino, N; Brancacio, L; Bretti, S; Bumma, C; Cabiddu, M; Caffo, O; Calandriello, A; Calcagno, A; Candido, P; Caprio, MG; Capuano, MA; Carrozza, F; Castiglione, F; Cazzaniga, M; Celano, A; Cigolari, S; Cioffi, A; Ciuffreda, L; Clerici, M; Colantuoni, G; Colucci, G; Corradini, GM; Cortesi, E; Crispino, C; Curcio, C; D'Aprile, M; D'Auria, G; Darwish, S; De Maio, E; De Marinis, F; Di Costanzo, F; Di Maio, M; Dinota, A; Esani, G; Esposito, M; Failla, G; Fava, S; Favaretto, A; Febbraro, A; Ferrario, S; Ferraù, F; Filipazzi, V; Foa, P; Frontini, L; Gaion, F; Galetta, D; Galligioni, E; Gallo, C; Gambaro, A; Gasparini, G; Gasperoni, S; Gattuso, D; Gebbia, N; Gebbia, V; Germano, D; Giotta, F; Gridelli, C; Grimi, E; Guardasole, V; Guidetti, G; Hopps, MR; Iaffaioli, RV; Ianniello, GP; Illiano, A; Isa, L; Labianca, R; Lamberti, A; Locatelli, MC; Luporini, G; Maione, P; Maiorino, L; Malaponte, E; Manzione, L; Martelli, O; Mattioli, R; Michetti, G; Migliorino, MR; Monfardini, S; Morabito, A; Nettis, G; Nisticò, C; Novello, S; Ostellino, O; Palazzolo, G; Parello, G; Pari, F; Pavia, G; Pedicini, T; Perrone, F; Piantedosi, FV; Piazza, E; Pistillucci, G; Pontillo, V; Porcile, G; Quadri, A; Raina, A; Renda, F; Robbiati, SF; Romano, F; Romito, S; Rosati, G; Rosetti, F; Rossi, A; Rossi, N; Sacco, C; Sannicolò, M; Santoro, A; Santoro, M; Scagliotti, G; Scalone, S; Scimone, A; Selvaggi, G; Sibau, A; Signoriello, G; Sollitto, F; Sorio, R; Spatafora, M; Stefani, M; Testa, A; Tinessa, V; Tonato, M; Tufano, G; Valerio, MR; Vasta, M; Veltri, E; Vinante, O; Volpintesta, A; Zollo, C; Zonato, S | 1 |
| Ferenczi, E; Gergely-Farnos, E; Kovács, G; Magyar, P; Ostoros, G; Strausz, J; Szondy, K | 1 |
| Lénárt, T; Sárosi, V | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Baas, P; Beijnen, JH; Crul, M; Maliepaard, M; Pluim, D; Schellens, JH; Schoemaker, NE; Schot, M; Sparidans, RW; Underberg, RW; Van Zandwijk, N | 1 |
| Boezen, HM; de Leede, GP; de Vries, EG; Eppinga, P; Erjavec, Z; Groen, HJ; Kramer, H; Strijbos, JH; Van Putten, JW; Wachters, FM | 1 |
| Cantor, R; Dabrow, MB; Francesco, MR; Gilman, PB; Meyer, TJ; Rose, L | 1 |
| Brancaccio, L; Cortesi, E; Crispino, C; De Marinis, F; Gridelli, C; Martelli, O; Migliorino, MR; Nelli, F; Portalone, L; Treggiari, S | 1 |
| Dowlati, A; Levitan, N | 1 |
| Biesma, B; Debruyne, C; Gaafar, R; Giaccone, G; Legrand, C; Lianes, P; Manegold, C; Neymark, N; Schramel, F; Smit, EF; Smit, H; van Meerbeeck, JP | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Boni, C; Zanelli, F | 1 |
| Emoto, T; Kawamura, T; Matsumoto, T; Matsunaga, N; Miura, G; Tanaka, N | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Spiridonidis, CH | 1 |
| Inoue, T; Kato, T; Kobashi, Y; Maeda, Y; Maniwa, K; Minakuchi, M; Noma, S; Sakuramoto, M; Taguchi, Y; Tanaka, E | 1 |
| Barceló, R; Ferreiro, J; Fuente, N; López-Vivanco, G; Mañé, JM; Muñoz, A; Pérez-Hoyos, T; Rubio, I; Viteri, A | 1 |
| Boiron, C; Fouques Duparc, V; Jagot, JL; Lazzerini, C; Mathieu, M; Virally, J | 1 |
| Albert, A; Bosch, C; Camps, C; Giner, V; Gómez, J; Gómez-Aldaraví, L; Llorca, C; Maestu, I; Oltra, A; Torregrosa, MD | 1 |
| Andruccetti, M; Bartolini, S; Benedetti, G; Calandri, C; Cappuzzo, F; Cortesi, E; Crinò, L; De Marinis, F; Maestri, A; Martelli, O; Migliorino, MR; Nelli, F; Rastelli, F | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Berardi, R; Carle, F; Cellerino, R; Lippe, P; Menichetti, ET; Nacciarriti, D; Piga, A; Porfiri, E; Scartozzi, M; Silva, RR; Tummarello, D | 1 |
| Chen, YM; Lee, CS; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Cable, CT; Mott, FE; Sharma, N | 1 |
| Camps, C; López-Vivanco, G; Rosell, R; Taron, M | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Battermann, JJ; El Sharouni, SY; Kal, HB | 1 |
| Addington-Hall, JM; Anderson, H; Keane, K; McKendrik, J; Peake, MD; Thatcher, N | 1 |
| Ardizzoni, A; Barton, C; Butts, C; Gatzemeier, U; Ghahramani, P; Groth, G; Hirsh, V; Shepherd, F; Van Zandwijk, N | 1 |
| Di, LJ; Gao, YJ; Li, L; Li, R; Liu, JW; Liu, SJ; Sun, H; Wang, J; Xu, GW; Yang, L; Zhang, MH | 1 |
| Gao, GQ; Mei, QD; Wang, LP | 1 |
| Ariyoshi, Y; Katakami, N; Kodama, K; Nakano, T; Negoro, S; Nogami, T; Okamoto, N; Sugiura, T; Takada, Y; Yamamoto, H | 1 |
| Aristides, M; Bhalla, S; Kielhorn, A; Lees, M; Maniadakis, N; Schiller, J; Tilden, D | 1 |
| Comella, G; Comella, P; De Cataldis, G; De Rosa, V; Fiore, F; Frasci, G; Lapenta, L; Licenziato, M; Maiorino, L | 1 |
| Choi, BG; Han, JY; Hong, EK; Hong, YS; Jin, JY; Kang, JH; Kim, KW; Lee, KS; Park, JN; Park, SY | 1 |
| Arminio, D; Barbera, S; Colosimo, M; De Gregorio, P; De Sarro, GB; Gallelli, L; Maselli, R; Nardi, M; Pelaia, G; Pirritano, D; Prantera, T; Raffaele, M | 1 |
| Anderson, N; Coco, F; Lokich, J | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Toffolatti, L; Zilembo, N | 1 |
| Barlési, F; Doddoli, C; Gimenez, C; Kleisbauer, JP; Villani, P | 1 |
| Boyer, M; Clarke, S; Fife, K; Hong, A; Rivory, L; Stevens, G; Zhang, M | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Billiart, I; Bourgeois, H; Chabrun, V; Chieze, S; Daban, A; Ferrand, V; Germain, T; Lemerre, D; Meurice, JC; Tourani, JM | 1 |
| Berthaud, P; Faivre, S; Henriksson, R; Le Chevalier, T; Monnerat, C; Novello, S; Raymond, E | 1 |
| Alberola, V; Artal, A; Bepler, G; Camps, C; Danenberg, KD; Diz, P; Isla, D; Provencio, M; Rosell, R; Sanchez, JJ; Taron, M | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Fossella, FV; Fritsche, HA; Glisson, BS; Herbst, RS; Kies, MS; Lee, PM; Mass, RD; Massarelli, E; Ordonez, NG; Pisters, KM; Ro, JY; Sabloff, B; Smith, TL; Tran, HT; Yang, Y; Zinner, RG | 1 |
| Dizdarević, Z; Lomigorić, J; Mehić, B; Zutić, H | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Yoh, K | 1 |
| Israel, V; Jeffers, S; Raghavan, D; Snyder, T; Tagawa, ST | 1 |
| Buyukcelik, A; Utkan, G; Yalcin, B | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| Pérol, D; Pérol, M | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Satoh, T; Tamura, K; Yamamoto, N | 1 |
| Ferson, PF; Friberg, D; Gooding, WE; Kassem, B; Keenan, R; Landreneau, RJ; Levitt, ML; Lindberg, CA; Miketic, LM; Ponas, RS; Sabatine, JM; Tarasoff, P; Trenn, MR; Whiteside, TL; Yousem, SA | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Davidson, JD; Flagella, M; Geeganage, S; Gelbert, LM; Ma, L; Slapak, CA | 1 |
| Agustí, C; Casas, F; Gascón, P; Gimferrer, JM; Martin-Richard, M; Molina, R; Reguart, N; Sanchez-Reyes, A; Viñolas, N | 1 |
| Benk, J; Burk, M; Burkholder, I; Dalhoff, K; Dickgreber, N; Dierlamm, T; Dürk, H; Edler, L; Engel-Riedel, W; Gieseler, F; Graeven, U; Hossfeld, DK; Knuth, A; Kortsik, C; Laack, E; Lorenz, C; Müller, T; Welte, T | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Alberola, V; Almenar, D; Artal, A; Barcelo, R; Bover, I; Camps, C; Cobo, M; de las Peñas, R; Diz, P; Garcia-Gomez, R; Gonzalez-Larria, JL; Insa, A; Isla, D; Massuti, B; Muñoz, MA; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Sarries, C; Taron, M; Terrasa, J | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Taron, M | 1 |
| Alloisio, A; Bruzzi, P; Costa, R; Maineri, P; Ratto, GB; Vassallo, G | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Argiris, A; Kies, MS; LaCombe, M; Liptay, M; Marymont, M; Masters, G; Sundaresan, S | 1 |
| Langer, CJ | 2 |
| Ikehara, M; Noda, K; Oshita, F; Saitoh, H; Suzuki, R; Yamada, K | 1 |
| Buzzi, F; Carnicelli, P; Cioffi, R; Comella, P; Filippelli, G; Frasci, G; Guida, M; Maiorino, L; Mancarella, S; Massidda, B; Panza, N | 1 |
| Cheng, ZW; Zhang, L | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Hatayama, O; Hayasaka, M; Inou, H; Koizumi, T; Kubo, K; Sasabayashi, M; Tsushima, K; Yamamoto, H; Yoshiike, F | 1 |
| Chen, JH; Lan, SM; Luo, J; Peng, ZM; Wang, WB; Wang, XH | 1 |
| Buccheri, G; Ferrigno, D | 2 |
| Barón, MG; Belón, J; Casado, E; De Castro, J; Dorta, J; Feliu, J; Gallurt, PM; Lizón, J; Lorenzo, A; Madroñal, C; Morales, S | 1 |
| Bozec, L; Brahmer, J; Bunn, PA; Ettinger, DS; Kelly, K; Le Chevalier, T; Liepa, AM; Monnerat, C; Nakamura, T; Novello, S; Obasaju, CK | 1 |
| Bunn, P | 1 |
| Natale, RB | 4 |
| Choy, H | 2 |
| Onn, A; Thatcher, N; Tsuboi, M | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Airoldi, M; Cagliero, E; Cattel, L; Goffredo, F; Passera, R; Stella, B | 1 |
| Belt, R; Dow, E; Figueroa, JA; Geary, R; George, S; Holmlund, J; Leonardo, J; McCachren, S; Miller, GL; Modiano, M; Oliver, JW; Otterson, GA; Ritch, P; Valdivieso, M; Villalona-Calero, MA | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Achiwa, H; Maeda, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Albain, KS; Doroshow, JH; Edelman, MJ; Frankel, P; Gandara, DR; Gandour-Edwards, R; Gumerlock, PH; Israel, V; Lara, PN; Lau, DH; Law, LY; Longmate, J; Mack, PC; Reddy, GP | 1 |
| Lilenbaum, RC | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Hermant, P; Jouveshomme, S; Patte, D | 1 |
| Buyukcelik, A; Demirkazik, A; Utkan, G; Yalcin, B | 1 |
| Reddy, KG | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Guan, ZZ; Li, N; Pan, ZK; Xu, F; Zhang, L; Zhang, Y | 1 |
| Li, LY; Liang, HJ; Liao, ML; Liu, JW; Wan, HY; Wang, L; Xu, N | 1 |
| Catalano, G; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Jereczek-Fossa, B; Orecchia, R; Spaggiari, L; Veronesi, G | 1 |
| Aguiar, D; Aguiar, J; Bohn, U | 1 |
| Gatzemeier, U; Groth, G; Nimmermann, C; Reck, M; von Pawel, J | 1 |
| Chen, CS; Chidiac, T; Lane, SR; Lilenbaum, RC; Schwarzenberger, PO; Thant, M; Versola, M | 1 |
| Aristides, M; Brown, A; Crino, L; Danson, S; Fitzgerald, P; Gridelli, C; Le Chevalier, T; Manegold, C; Natale, R; Pujol, JL; Rosell, R; Rudd, RM; Scagliotti, G; Schiller, JH; Stahel, R; Thatcher, N; Thomas, P; van Meerbeeck, JP; van Zandwijk, N; Vansteenkiste, J | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Artioli, F; Di Fabio, F; Farris, A; Giaquinta, S; Guaraldi, M; Mantovani, L; Marino, A; Martoni, A; Melotti, B; Palomba, G; Petralia, A; Picece, V; Preti, P; Sperandi, F | 1 |
| Eisen, TG; Gower, NH; Gregory, WM; Harper, PG; Hatton, M; James, LE; Johnson, PW; Lee, SM; Littler, JA; Martin, WM; Qian, W; Rankin, EM; Rudd, RM; Spiro, SG | 1 |
| Cardaci, V; Cesario, A; Galetta, D; Granone, P; Margaritora, S; Onorati, D; Piraino, A; Porziella, V; Vita, L | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Amsterdam, A; Dantes, A; Hirsh, L; Land-Bracha, A; Merimsky, O; Suh, BS | 1 |
| Alberola, V; Besse, B; Isla, D; Massuti, B; Moran, T; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Colantonio, I; Di Costanzo, G; Dongiovanni, V; Fea, E; Garrone, O; Gasco, M; Granetto, C; Heouaine, A; Merlano, M; Numico, G; Occelli, M; Silvestris, N | 1 |
| Akita, H | 1 |
| Nishimoto, H; Ohara, T; Shimada, K | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Normanno, N | 1 |
| Asmar, L; Ghaddar, H; Joppert, MG; Marsland, TA; Neubauer, MA; Reynolds, CH; Whitaker, T | 1 |
| Belani, CP; Eckardt, J | 1 |
| Barachini, S; Basolo, F; Danesi, R; Del Tacca, M; Deri, M; Giovannetti, E; Mey, V | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 3 |
| Breton, JL; Depierre, A; Ducoloné, A; Germa, C; Lemarié, E; Mennecier, B; Moro-Sibilot, D; Neidhardt, AC; Quoix, E | 1 |
| Gillenwater, HH; Hensing, TA; Qaqish, BF; Socinski, MA; Stinchcombe, TE; Tyann, M | 1 |
| Anderson, H; Ashcroft, L; Baka, S; Burt, P; Dowd, I; Lind, M; Lorigan, P; Smith, D; Stout, R; Thatcher, N | 1 |
| Dumontet, C; Sève, P | 1 |
| Boehle, AS; Boenicke, L; Dohrmann, P; Kalthoff, H; Kurdow, R; Schniewind, B; Zoefelt, S | 1 |
| Agelidou, A; Anagnostopoulou, O; Androulakis, N; Ardavanis, A; Chatzidaki, D; Christou, A; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mixalopoulou, P; Polyzos, A; Samaras, N; Samonis, G; Syrigos, K; Toubis, M; Tsiafaki, X; Ziotopoulos, P | 1 |
| Braun, D; Breton, JL; Castéra, D; Clary, C; Debieuvre, D; Depierre, A; Gervais, R; Janicot, H; Kessler, R; Lemarié, E; Milleron, B; Morère, JF; Moro-Sibilot, D; Pujol, JL; Quantin, X; Rebattu, P; Souquet, PJ; Spaeth, D | 1 |
| Funazaki, T; Nagasaki, N; Naitoh, N; Shiba, M; Watanabe, S | 1 |
| Criswell, T; Diasio, R; Kindwall-Keller, T; Neki, A; Nuovo, G; Otterson, GA; Soong, R; Villalona-Calero, MA; Young, D | 1 |
| Horai, T; Matsuda, M; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Taguch, F | 1 |
| Bernardini, I; Chioni, A; Conte, PF; Fabbri, A; Falcone, A; Ferrari, K; Galli, L; Grosso, AM; Innocenti, F; Orlandini, C; Pegna, AL; Ricci, S; Russo, F; Tibaldi, C; Tognarini, L | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Marini, L; Mey, V; Nannizzi, S; Pasqualetti, G | 1 |
| Cai, J; Huang, MZ; Liu, J; Shentu, JZ; Wang, LR; Xu, N | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Ronco, MS; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Fukuoka, M; Furukawa, M; Hirashima, T; Kamoi, H; Kobayashi, M; Kudoh, S; Matsui, K; Mukohara, T; Nakagawa, K; Negoro, S; Nitta, T; Ogata, Y; Shiraishi, S; Takada, M; Takeda, K; Yamauchi, S; Yana, T; Yoshimura, N | 1 |
| Chen, YM; Perng, RP; Tsai, CM | 1 |
| Canon, JL; John, W; Lahn, M; Mali, P; Peterson, P; Pirker, R; Riska, H; Vansteenkiste, J | 1 |
| Buck, M; Byrne, MJ; Cameron, F; De Melker, Y; Dewar, J; Joseph, D; Lund, H; Newman, M; Phillips, M; Powell, A; Spry, N; Van Hazel, G | 1 |
| Crinò, L; De Marinis, F; Foggi, P; Kielhorn, A; Maestri, A; Migliorino, AM; Novello, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Stynes, G; Tilden, D; Tonato, M | 1 |
| Barlési, F; Pujol, JL | 1 |
| Han, JY; Hong, EK; Lee, DH; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Cass, C; Dumontet, C; Isaac, S; Mackey, JR; Pérol, M; Sève, P; Souquet, PJ; Trédan, O | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Desjardins, P; Fox, S; Hirsh, V; Kreisman, H; Latreille, J; Ofiara, L; Palayew, MD; Pintos, J; Whittom, R | 1 |
| Hughes, DA | 1 |
| Barbieri, F; Bartolini, S; Cappuzzo, F; Castaldini, L; Ceribelli, A; Crinò, L; Crucitta, E; De Marinis, F; Franciosi, V; Lorusso, V; Marini, L; Maur, M; Novello, S; Scagliotti, GV | 1 |
| Ueoka, H | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Abacioglu, U; Caglar, H; Sengoz, M; Turhal, NS; Yumuk, PF | 1 |
| Barceló, R; López-Vivanco, G; Muñoz, A | 1 |
| Dranitsaris, G; Evans, WK; Milliken, D; Zanke, B | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Chak, K; Chan, AT; Lam, KC; Lee, C; Mok, TS; Wong, H; Yeo, W; Yim, AP; Zee, B; Zhang, L | 1 |
| Abratt, R; Bertetto, O; Burillon, JP; Gatzemeier, U; Hui, R; Krzakowski, M; Macha, HN; Mattson, K; Parlier, Y; Pawel, JV; Pouget, JC; Reiterer, P; Szczesna, A; Tan, EH; Wernli, M | 1 |
| Agelidou, A; Agelidou, M; Chainis, K; Georgoulias, V; Kalykaki, A; Nikolakopoulos, I; Rapti, A; Stergiou, I; Tzanakis, N; Varthalitis, J | 1 |
| Cho, KH; Han, JY; Kim, HY; Lee, DH; Lee, JS; Pyo, HR; Yoon, SJ | 1 |
| Esteban-Gonzalez, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Arnaud, I; Blandin, S; Geriniere, L; Guibert, B; Mulsant, P; Perrot, E; Roy, P; Souquet, PJ | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Ando, S; Iida, T; Kimura, H; Nakajima, T; Suzuki, M | 1 |
| Cao, CW; Gao, Y; Guo, J; Shi, ZQ; Zhu, CL | 1 |
| Buesa, JM; Corral, N; de Sande, JL; Esteban, E; Estrada, E; Fernández, JL; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Baumann, KC; Burmeister, BH; Dauth, M; Fielding, DI; Ramsay, JR; Walpole, ET | 1 |
| Dixon, B; Erridge, SC; Mohammed, N; Price, A | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Akkoclu, A; Cakir, E; Cikrikicioglu, S; Firat, H; Goksel, T; Gorguner, M; Guzelant, A; Hatipoglu, ON; Itil, O; Kiyik, M; Ozturk, C; Sanal, S; Soyer, S; Tabakoglu, E; Tasbakan, S; Tutar, U; Yilmaz, U | 1 |
| Adjei, AA; Fitch, TR; Hillman, SL; Jett, JR; Ma, CX; Mandrekar, SJ; Nair, S; Nikcevich, DA; Obasaju, C; Rowland, KM; Schild, SE; Thomas, S; Windschitl, HE | 1 |
| Boor, PJ; Coscio, AM; Das, GC; Goodwin, TJ; Logrono, R; Popov, VL; Vertrees, RA; Zwischenberger, JB | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Baas, P; Beijnen, JH; Crul, M; Pluim, D; Rademaker-Lakhai, JM; Schellens, JH; Sparidans, RW; van Zandwijk, N | 1 |
| Edelman, MJ | 2 |
| Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
| Araki, J; Ichinose, Y; Inoue, Y; Itoh, K; Iwamoto, N; Semba, H; Seto, T; Tamanoi, M; Tanaka, F; Yamamoto, H | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Athanasiadis, A; Georgoulias, V; Kalbakis, K; Mavroudis, D; Nikolakopoulos, J; Polyzos, A; Rapti, A; Samonis, G; Syrigos, K; Tselepatiotis, E | 1 |
| Kuramoto, K; Terao, I | 1 |
| Adamo, V; Altavilla, G; Angelini, V; Angiolillo, M; Annamaria, A; Ardizzoia, A; Azzarello, G; Barbera, S; Barletta, E; Barni, S; Barzelloni, ML; Bearz, A; Belli, M; Belloni, P; Bertetto, O; Bilancia, D; Bollina, R; Bordonaro, R; Borsellino, N; Brancaccio, L; Cabiddu, M; Caffo, O; Calandriello, A; Calcagno, A; Candido, P; Capuano, MA; Carrozza, F; Caruso, M; Castiglione, F; Cazzaniga, M; Celano, A; Chiodini, P; Cigolari, S; Cioffi, A; Ciuffreda, L; Clerici, M; Colantuoni, G; Colucci, G; Corradini, GM; Cortesi, E; Curcio, C; D'Aprile, M; D'Auria, G; Darwish, S; De Feo, G; De Maio, E; De Marinis, F; Di Costanzo, F; Di Maio, M; Di Negro, GB; Esani, G; Failla, G; Fava, S; Favaretto, A; Felletti, R; Ferraù, F; Foa, P; Frontini, L; Gaion, F; Galetta, D; Galligioni, E; Gallo, C; Gambaro, A; Gasparini, G; Gasperoni, S; Gattuso, D; Gebbia, N; Gebbia, V; Germano, D; Giotta, F; Gridelli, C; Guardasole, V; Hopps, MR; Iaffaioli, RV; Ianniello, GP; Illiano, A; Isa, L; Labianca, R; Lamberti, A; Locatelli, MC; Lopez, M; Luporini, G; Maione, P; Maiorino, L; Malaponte, E; Manzione, L; Martelli, O; Mattioli, R; Migliorino, MR; Monfardini, S; Morabito, A; Nettis, G; Novello, S; Ostellino, O; Palazzolo, G; Parello, G; Pavia, G; Perrone, F; Piantedosi, F; Piazza, E; Pontillo, V; Porcile, G; Quadri, A; Raucci, CA; Renda, F; Repetto, L; Rinaldi, M; Robbiati, SF; Romano, F; Romito, S; Rosetti, F; Rossi, A; Rossi, N; Sacco, C; Sannicolò, M; Scagliotti, G; Schiavon, S; Scimone, A; Selvaggi, G; Sibau, A; Sigoriello, G; Sollitto, F; Spatafora, M; Spazzapan, S; Stefani, M; Tartamella, F; Testa, A; Tinessa, V; Tirelli, U; Tonato, M; Tonini, G; Valerio, MR; Veltri, E; Vinante, O | 1 |
| Barceló, R; Fuente, N; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I; Viteri, A | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Kocijancic, I; Kovac, V; Segedin, B; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Hada, M; Horiuchi, T | 1 |
| An, CH; Bang, SM; Cho, EK; Jeong, SH; Kyung, SY; Lee, JH; Lee, SP; Lim, YH; Park, JW; Park, SH; Shin, DB | 1 |
| De Petris, L; Friesland, S; Lax, I; Sirzén, F | 1 |
| Scagliotti, GV | 2 |
| Govindan, R | 1 |
| Leow, CH; Liam, CK | 1 |
| Barata, F | 1 |
| Lianes, P; Neymark, N; Smit, EF; van Meerbeeck, JP | 1 |
| Bordonaro, R; Castorina, S; Giannitto, GC; Giuffrida, D; La Venia, G; Marletta, F; Pappalardo, A; Potenza, E; Russo, A; Saita, S; Vincenzi, B | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Choy, H; Vokes, E | 1 |
| Bepler, G | 2 |
| Natale, R | 1 |
| Cullen, M | 1 |
| Treat, J | 1 |
| Dufmats, M; Gawande, SR; Hillerdal, G; Kölbeck, K; Lamberg, K; Sederholm, C; Westberg, R | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Park, CG | 1 |
| Blumenschein, G; Fossella, FV; Herbst, RS; Needle, M; Robert, F; Saleh, MN; Tseng, J | 1 |
| Lokich, J | 1 |
| Davis, JJ; Dong, F; Fang, B; Guo, W; Lin, A; Teraishi, F; Zhang, L | 1 |
| Aguiar, J; Barón, MG; Chacón, JI; Colmenarejo, A; de Carpeño, JC; Feliu, J; García, MJ; Madroñal, C; Ordóñez, A; Sánchez, JJ | 1 |
| Berard, H; Bombaron, P; Fournel, P; Gouva, S; Kleisbauer, JP; Le Caer, H; Léna, H; Perol, M; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Bloss, LP; Curiel, RE; Monberg, MJ; Obasaju, CK; Ye, Z | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Alberola, V; Camps, C; Catot, S; de Las Peñas, R; Massuti, B; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M | 1 |
| Ambrosino, N; Bernardini, I; Chella, A; Falcone, A; Malventi, M; Russo, F; Tempestini, F; Tibaldi, C; Toma, G; Vasile, E | 1 |
| Alberola, V; Botia, M; Camps, C; Cecere, F; Cobo, M; de las Peñas, R; Garcia-Carbonero, R; Garcia-Gomez, R; Isla, D; Massuti, B; Mendez, P; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Santarpia, M; Taron, M | 1 |
| Baricević, D; Cucević, B; Jakopović, M; Redzepi, G; Samarzija, M; Samija, M | 1 |
| Ahn, YM; Cho, EH; Cho, KH; Choi, IS; Choi, JW; Kim, BS; Nam, SH; Roh, YH; Song, YB | 1 |
| Giannarelli, D; Moscetti, L; Nelli, F; Padalino, D; Pollera, CF; Sperduti, I | 1 |
| Amal, K; Fethi, el M; Habib, G; Imen, A; Ines, Z; Sameh, el F | 1 |
| Cardaci, V; Cesario, A; Corbo, GM; D'Angelillo, RM; Galetta, D; Gambacorta, MA; Granone, P; Macis, G; Margaritora, S; Mulè, A; Piraino, A; Porziella, V; Ramella, S; Russo, P; Sterzi, S; Trodella, L; Valente, S | 1 |
| Rudd, R; Saha, A | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Braun, D; Breton, JL; Debieuvre, D; Depierre, A; Germa, C; Jacoulet, P; Kayitalire, L; Milleron, B; Quoix, E; Westeel, V | 1 |
| Chew, L; Foo, KF; Leong, SS; Poon, D; Tan, EH; Wee, J | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Dooms, CA; Lievens, YN; Vansteenkiste, JF | 1 |
| Baas, P; Beijnen, JH; Crul, M; Rademaker-Lakhai, JM; Schellens, JH; Simis, YJ; van Zandwijk, N; Zuur, L | 1 |
| Cho, EK; Heo, DS; Jung, KH; Kim, JH; Kim, SY; Kim, YH; Lim, HY; Park, BJ; Park, K; Ryoo, BY; Suh, CW | 1 |
| Bitran, JD; Edelman, MJ; Irwin, D; John, WJ; Lilenbaum, R; Makalinao, A; Peterson, P; Ritch, P; Rudin, CM | 1 |
| Asadpour, B; Buell, U; Coenen, HH; Demirel, C; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Pinkawa, M; Piroth, M; Reinartz, P; Stanzel, S; Zimny, M | 1 |
| Carbone, C; Codecà, C; Ferrari, D; Foa, P; Fumagalli, L; Gilardi, L; Marussi, D; Oldani, S; Tartaro, T; Zannier, F | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Smit, EF; Van der Born, K; Van der Vijgh, WJ; Van Groeningen, CJ | 1 |
| Canti, G; Chiaviello, A; Crescenzi, E; Palumbo, G; Reddi, E; Veneziani, BM | 1 |
| Chang, GC; Douillard, JY; Gandara, DR; John, WJ; Koralewski, P; Lahn, M; Manegold, C; Obasaju, CK; Paz-Ares, L; Peterson, PM; Reyes, JM; Smit, EF | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
| Belani, CP | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noda, M; Ohmori, T; Ohnishi, T; Okuda, K; Ozawa, T; Shirai, T | 1 |
| Brodowicz, T; Ciuleanu, T; Cucevic, B; Ghilezan, N; Grgic, M; Gyurkovits, K; Jassem, J; Krzakowski, M; Oskina, N; Ramlau, R; Saip, P; Soldatenkova, V; Szilasi, M; Tzekova, V; Ulsperger, E; Wagnerova, M; Wenczl, M; Wiltschke, C; Zielinski, C; Zwitter, M | 1 |
| Chai, XS; Deng, H; Liu, WS; Long, SQ; Luo, HY; Wang, B; Wu, WY; Xue, XG; Zhang, HB | 1 |
| Chellappan, S; Dasgupta, P; Decook, C; Haura, E; Joshi, B; Kinkade, R | 1 |
| Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Yoon, SJ; Yoon, SM | 1 |
| Gridelli, C; Rossi, A | 1 |
| Bao, HY; Chen, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Fukuchi, Y; Ito, J; Kajiyama, Y; Miura, K; Miyamoto, H; Nagashima, O; Sato, K; Shimanuki, Y; Suzuki, T; Tajima, K; Takahashi, K; Uekusa, T | 1 |
| Alter, MD; Avdulov, S; Bitterman, PB; Frizelle, SP; Jacobson, BA; Kratzke, MG; Kratzke, RA; Mohorn, RP; Peterson, MS; Polunovsky, VA; Whitson, BA; Zhang, Y | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Barbieri, F; Bartolini, S; Cappuzzo, F; Crinò, L; De Marinis, F; Marini, L; Maur, M; Novello, S; Papi, M; Pasquini, E; Scagliotti, GV; Selvaggi, G | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Beale, P; Boyer, M; Goh, BC; Lee, HS; Lee, SC; Liang, S; Lim, HL; Millward, M; Soo, RA; Tham, LS; Wang, LZ; Yong, WP | 1 |
| Asadpour, B; Breuer, C; Buell, U; Eble, MJ; Fischedik, K; Gagel, B; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Skobel, E; Stanzel, S; Zimny, M | 1 |
| Giaccone, G; Voortman, J | 1 |
| Alloisio, M; Brambilla, G; Campagnoli, E; Cavina, R; Latteri, F; Morenghi, E; Parra, HS; Santoro, A; Torri, W | 1 |
| Ardizzoni, A; Barbieri, F; Benedetti, G; Berardi, R; Camisa, R; Campanini, N; Cascinu, S; Crinò, L; Franciosi, V; Rindi, G; Rossi, G; Santinelli, A; Scartozzi, M; Silva, RR | 1 |
| Krazkowski, M | 1 |
| Battiloro, C; Caponigro, F; Danilo, R; Formato, R; Iaffaioli, RV; Illiano, A; Tortoriello, A | 1 |
| Bonomi, P; Chen, R; Christiansen, NP; McCleod, M; Mintzer, DM; Monberg, MJ; Obasaju, CK; Treat, J; Ye, Z | 1 |
| Al Refai, M; Brunelli, A; Marasco, R; Sabbatini, A; Salati, M; Xiume', F | 1 |
| Girard, N; Mornex, F | 3 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Kunitoh, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Carrato Mena, A; Gallego Plazas, J; Guillén Ponce, C; Maciá Escalante, S; Martínez Ortiz, MJ; Rodríguez Lescure, A | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Fukuoka, M; Kashii, T; Kato, T; Matsui, K; Nakagawa, K; Nakanishi, Y; Negoro, S; Sugiura, T; Takada, M; Takada, Y; Uejima, H; Yamamoto, N | 1 |
| Camps, C; Cobo, M; Isla, D; Massuti, B; Rosell, R | 1 |
| Adjei, AA | 2 |
| Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L | 1 |
| Bearz, A; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Colombrino, E; Fantoni, U; Iop, A; Palamidese, A; Sacco, C; Scalone, S | 1 |
| Cellini, F; Cesario, A; Ciresa, M; D'Angelillo, RM; Granone, P; Ramella, S; Trodella, L | 1 |
| Cauchi, C; Gridelli, C; Rinaldi, M | 1 |
| Ambroggi, M; Bologna, A; Boni, C; Zanelli, F | 1 |
| Favaretto, AG | 1 |
| Le Chevalier, T; Monnerat, C | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Agrawal, S; Kandimalla, ER; Rayburn, ER; Wang, H; Wang, W; Zhang, R | 1 |
| Azzoni, P; Cetto, GL; Genestreti, G; Manno, P; Micciolo, R; Molino, A; Pattaro, C; Santo, A; Sava, T; Terzi, A | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Ahn, JS; Jung, JY; Kim, HJ; Kim, JH; Kwon, JH; Lee, DH; Lee, JA; Lee, KS; Park, YL; Shin, HC; Song, HH; Zang, DY | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Miyazaki, M; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Takano, Y; Ueda, R | 1 |
| Adoun, M; Blanc, P; Bourgeois, H; Deletage, C; Ferru, A; Genet, D; Meurice, JC; Paitel, JF; Planchard, D; Tourani, JM | 1 |
| Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Brahmer, J; Ettinger, D; Juergens, R | 1 |
| Mountzios, G; Soria, JC | 1 |
| Li, L; Liu, L; Wang, XW; Yu, XJ; Zhang, WD; Zhang, X | 1 |
| Guo, YL; Lian, HY; Luo, H; Qiu, F; Xiong, JP; Zhang, L; Zhong, LX | 1 |
| Bepler, G; Cantor, A; Gautam, A; Kusmartseva, I; Sharma, A; Sharma, S; Simon, G | 1 |
| Griep, C; Lelie, B; Pinson, PJ; Sanders, WH | 1 |
| Calogero, R; Cambieri, A; Ceppi, P; Danenberg, KD; Danenberg, PV; Novello, S; Papotti, M; Rapa, I; Saviozzi, S; Scagliotti, GV; Selvaggi, G; Volante, M | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Bonassi, S; Cellini, F; Cesario, A; Ciresa, M; Corbo, GM; Cortesi, E; D'Angelillo, RM; De Marinis, F; Granone, P; Margaritora, S; Migliorino, MR; Nelli, F; Porziella, V; Ramella, S; Russo, P; Trodella, L; Valente, S | 1 |
| Blankenburg, T; Chemaissani, A; Guetz, S; Laier-Groeneveld, G; Reck, M; Schneider, CP; Schuette, W; Virchow, JC; von Weikersthal, LF | 1 |
| Boselli, S; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Milani, A; Noberasco, C; Orlando, L; Putzu, C; Sabrina, B; Spaggiari, L | 1 |
| Amarantidis, K; Georgoulias, V; Kakolyris, S; Kalykaki, A; Papakotoulas, P; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, J; Ziras, N | 1 |
| Beinert, T; Binder, D; Grah, C; Schäper, C; Schweisfurth, H; Siebert, G; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Chun, JH; Han, JY; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Buesa, JM; Capellan, M; Corral, N; de Sande, JL; Esteban, E; Estrada, E; Fernandez, JL; Fernández, Y; Fra, J; Jimenez, P; Lacave, AJ; Luque, M; Mareque, B; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Barceló, R; Díaz-Aguirregoitia, J; Fernández, R; López-Vivanco, G; Mañé, JM; Muñoz, A; Saiz, M | 1 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Ameshima, S; Chiba, Y; Demura, Y; Ishizaki, T; Miyamori, I; Nakanishi, M; Umeda, Y | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Dranitsaris, G; Gascon, P; Lau, C; Ludwig, H; Van Belle, S; Verma, S; Vincent, M | 1 |
| Cai, J; Huang, M; Liu, J; Wang, L; Wu, X; Xu, N | 1 |
| Arcara, C; Badalamenti, G; Caraceni, A; Cicero, G; Fulfaro, F; Gebbia, N; Intrivici, C | 1 |
| Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y | 1 |
| Chan, M; Feller, E; Gold, R; Mega, A; Squire, S | 1 |
| Alberola, V; De las Peñas, R; Gupta, J; Ramírez, JL; Salazar, MF; Sánchez, JM; Sanchez-Ronco, M; Taron, M | 1 |
| Fischer, JR; Lahm, H; Manegold, C; Ohnmacht, U; Rieger, N; Stoffregen, C; Zemaitis, M | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Avallone, A; Barbato, E; Comella, P; Condemi, G; De Cataldis, G; Franco, L; Gambardella, A; Massidda, B; Putzu, C | 1 |
| Araya, T; Fujimura, M; Hara, J; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Nishi, K; Nobata, K; Oribe, Y; Shibata, K; Shirasaki, H; Sone, T; Yoshimi, Y | 1 |
| Adelstein, D; Davis, M; Kalmadi, S; McNeill, G; Mekhail, T; Peereboom, D | 1 |
| Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Scott-von-Römer, K | 1 |
| Astoul, P; Auquier, P; Barlési, F; Barrau, K; Doddoli, C; Morange, S; Thirion, X; Thomas, P | 1 |
| Beddy, P; Connolly, RM; Doherty, CP; O'Byrne, K | 1 |
| Anile, M; Coloni, GF; De Giacomo, T; Diso, D; Ibrahim, M; Liparulo, V; Rolla, M; Venuta, F | 1 |
| Esquerdo, G; Gómez-Aldaraví, L; Maestu, I; Muñoz, J; Romero, R; Torregrosa, MD; Yubero, A | 1 |
| De Grève, J; De Mey, J; Fontaine, C; Meysman, M; Neyns, B; Schallier, D; Steene, JV | 1 |
| Altug, S; Chu, DT; Damyanov, D; Kim, SW; Krishnamurthy, S; Kuo, HP; Ozacar, R; Reece, WH; Salajka, F; Wang, L | 1 |
| Barbera, S; Barone, C; Bruzzi, P; Buosi, R; Crinò, L; Dongiovanni, V; Fioretti, M; Garetto, L; Masotti, A; Mazzanti, P; Michetti, G; Novello, S; Scagliotti, GV; Selvaggi, G; Spatafora, M | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Baggstrom, MQ; Govindan, R; Subramanian, J; Velcheti, V | 1 |
| Mandrekar, SJ; Sargent, DJ | 1 |
| Argiris, AE; Beck, JT; Bloss, LP; Curiel, RE; Hahn, EA; Masters, GA; Monberg, MJ; Obasaju, CK; Rausch, PG; Ye, Z | 1 |
| Abratt, RP; Boyer, M; Brnabic, AJ; Han, JY; Kim, SW; Lee, JS; Lehnert, M; Mok, T; Reece, WH; Tsai, CM | 1 |
| Ahuja, HG; Hensing, TA; Hoang, T; Kim, K; Larson, M; McGovern, J; Merchant, J; Oettel, KR; Sanchez, FA; Schiller, JH; Traynor, AM | 1 |
| Erridge, S; Jackson, S; Law, A; Rae, P | 1 |
| Blackstock, AW; Butler, J; Case, LD; Fletcher-Steede, J; Hinson, W; Ho, C; Miller, AA | 1 |
| Bessho, A; Isobe, H; Katakami, N; Niitani, H; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Aerts, JG; Hoogsteden, HC; Senan, S; Surmont, V; Tan, KY; van Klaveren, RJ; van Meerbeeck, JP; van Wijhe, G; Verhoeven, GT; Vernhout, R | 1 |
| Kovac, V; Smrdel, U; Strojan, P; Zwitter, M | 1 |
| Dowlati, A; Johnson, D; Langer, C; Li, S; Madajewicz, S; Masters, GA; Schiller, J | 1 |
| Aravantinos, G; Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Nicolaides, C; Pectasides, D; Syrigos, K | 1 |
| Blackstock, AW; Capellari, J; Knight, SN; Lovato, J; Miller, AA; Miller, MS; Mosley, L; Petty, WJ; Tucker, R | 1 |
| Caffo, O; Favaretto, A; Gregorc, V; Gridelli, C; Kaukel, E; Manegold, C; Martoni, A; Migliorino, MR; Müller, TR; Muñoz, M; Peterson, P; Reck, M; Rossi, A; Russo, F; Schmittel, A | 1 |
| Foo, KF; Ho, J; Leong, SS; Lim, WT; Lin, X; Poon, D; Tan, EH; Tan, SB; Tay, MH; Toh, CK | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Huang, YJ; Huang, YS; Liao, RQ; Wu, YL; Xie, SX; Yang, JJ | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Ariganello, O; Belli, R; Cipri, A; Condò, S; de Marinis, F; De Santis, S; Di Molfetta, M; Migliorino, MR; Tedesco, B; Treggiari, S | 1 |
| Arslan, U; Boyaci, B; Okyay, K; Sen, N; Tavil, Y | 1 |
| Basson, BR; Ciuleanu, T; Firoiu, E; Grigorescu, A; Muresan, DR; Teodorescu, G | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Hermann, TW; Negro-Vilar, A; Ng, SC; Tooker, P; Yen, WC | 1 |
| Barbera, S; Carozza, F; Ceribelli, A; Ciardiello, F; Cognetti, F; Daniele, B; Di Maio, M; Favaretto, A; Galetta, D; Gallo, C; Gamucci, T; Gebbia, V; Gridelli, C; Maione, P; Morabito, A; Perrone, F; Rosetti, F; Rossi, A; Testa, A | 1 |
| Huang, MZ; Liu, J; Wang, LR; Xu, N | 1 |
| Huang, MZ; Wang, LR; Wu, XH; Xu, N; Zhang, GB | 1 |
| Belzer, K; Gadgeel, S; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Kucuk, O; Venkatramanamoorthy, R; Wozniak, AJ | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Branscheid, D; Droemann, D; Goldmann, T; Lang, DS; Martin, C; Ressmeyer, AR; Schultz, H; Vollmer, E; Zabel, P | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Blajman, CR; Del Giglio, A; Fein, L; Hall, BJ; Orlando, M; Pereira, JR; Richardet, E; Schwartsmann, G; van Kooten, M; West, TM | 1 |
| Aasebø, U; Bailey, A; Bremnes, RM; Brunsvig, PF; Garpestad, OK; Helbekkmo, N; Hjelde, HH; Sundstrøm, SH; von Plessen, C | 1 |
| Asadpour, B; Breuer, C; Eble, MJ; Gagel, B; Kaiser, HJ; Krohn, T; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Stanzel, S | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Fisher, JE; Kirstein, MN; Kratzke, RA; Le, CT; Marker, PH; Wieman, KM; Williams, BW; Yee, D | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Achiwa, H; Eimoto, T; Muramatsu, H; Oguri, T; Ozasa, H; Sato, S; Shimizu, S; Ueda, R; Yamazaki, H | 1 |
| Chouaid, C; Fournel, P; Gimenez, C; Jullian, H; LeCaer, H; Letreut, J; Paillotin, D; Perol, M; Thomas, P; Vergnenegre, A | 1 |
| Aydiner, A; Cakan, A; Cikrikcioglu, S; Dilege, S; Goksel, T; Gurses, A; Kiyik, M; Kosar, F; Turna, A; Yazar, A | 1 |
| Akasaka, H; Hara, Y; Hashimoto, H; Hayashi, K; Inokuchi, M; Kasahara, K; Miyamoto, K; Nakamura, M; Nishigami, J; Nishimura, G; Shimizu, M; Suga, Y; Yonejima, M | 1 |
| Kim, CH; Kim, HS; Kim, JH; Kim, KJ; Lee, KY; Sung, CW | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O; Vaslamatzis, MM | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Huang, MZ; Wang, LR; Zhang, GB | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kotsakis, A; Mavroudis, D; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Buesa, JM; Capelan, M; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Jiménez, P; Jiménez-Lacave, A; Llorente, B; Luque, M; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Ann Houston, G; Anthony Greco, F; Bearden, JD; Farley, C; Gandhi, J; Hainsworth, JD; Shipley, DL; Spigel, DR | 1 |
| Besse, B; Vignot, S | 1 |
| Seto, T | 1 |
| Ho, CC; Huang, HY; Huang, PH; Kuo, SH; Yang, CH; Yang, PC | 1 |
| Chan, AT; Goh, BC; Lam, KC; Leong, SS; Ma, B; Mo, F; Mok, T; Soo, R; Tan, EH; Wang, LZ; Zee, B | 1 |
| Charpidou, A; Dannos, I; Dilana, K; Dionellis, G; Georgatou, N; Karapanagiotou, E; Rigopoulou, A; Roussos, C; Syrigos, KN | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Cucherat, M; Douillard, JY; Fossella, F; Georgoulias, V; Kubota, K; Kudoh, S; Laporte, S; Monnier, A; Pujol, JL; Rubio, JE | 1 |
| Aoki, H; Iijima, H; Imai, H; Inoue, T; Ishida, E; Ishihara, S; Iwasaki, Y; Kawashima, O; Kobayashi, G; Mori, M; Saito, R; Sato, K; Tomizawa, Y; Watanabe, S; Yamada, H; Yatomi, M | 1 |
| Miletzki, A | 1 |
| Burris, HA; Gandhi, JG; Gray, JR; Greco, FA; Hainsworth, JD; Kuzur, ME; Pati, A; Shipley, D; Spigel, DR; Thompson, DS; Webb, CD; Yardley, DA | 1 |
| Bearz, A; Carrozza, F; Favaretto, A; Filipazzi, V; Gallo, C; Gridelli, C; Iaffaioli, RV; Illiano, A; Lorusso, V; Maione, P; Manzione, L; Morabito, A; Perrone, F; Piantedosi, FV; Robbiati, SF | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Caffo, O; D'Incalci, M; Galligioni, E; Marangon, E; Sala, F; Zucchetti, M | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Raj Pandey, K | 1 |
| Camsari, T; Cavdar, C; Cokmert, S; Oztop, I; Secil, M; Toprak, O | 1 |
| Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jeong, AK; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Min, YJ; Noh, YJ; Park, CR; Park, JH; Seo, KW; Shin, JK; Shin, SJ | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Hsu, CH; Lin, CC; Lin, ZZ; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Feng, M; Gong, WY; Ma, XT; Qiu, F; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX | 1 |
| Blackhall, F; Califano, R; Nagel, S; Thatcher, N | 1 |
| Ceribelli, A; Cognetti, F; Fariello, AM; Gamucci, T; Giampaolo, MA; Mansueto, G; Narducci, F; Pino, MS; Sperduti, I; Trapasso, T | 1 |
| Li, GZ; Wang, RL; Zhang, SH; Zhang, Z | 1 |
| Alam, Y; Bodkin, D; Butts, CA; Ellis, PM; Ellison, D; Englund, CW; Graze, P; Kaplan, E; Kreisman, H; Maher, J; McNulty, W; Middleman, EL; Pautret, V; Ross, HJ; Shepherd, FA; Weber, MR | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Davies, AM; Gandara, DR; Sangha, R | 1 |
| Bedor, M; Brahmer, J; Bridges, BB; Doyle, LA; Edelman, MJ; Hausner, PF; Smith, R; Thomas, L | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Di Marsico, R; Fabbri, A; Falcone, A; Innocenti, F; Lo Dico, M; Tartarelli, G; Tibaldi, C; Vasile, E | 1 |
| Drömann, D; Goldmann, T; Lang, DS; Marwitz, S; Radtke, J; Schultz, H; Vollmer, E | 1 |
| Begum, M; Bepler, G; Simon, GR | 1 |
| Belani, C; Ramalingam, S | 1 |
| Klein, F | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Fukushima, M; Hamada, C; Hosoe, S; Kawahara, M; Matsui, S; Tada, H | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, LZ | 1 |
| Aysan, T; Cok, G; Göksel, T; Soyer, S | 1 |
| An, CH; Cho, EK; Hong, J; Jeong, SH; Kim, Y; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Antonuzzo, A; Danesi, R; Del Tacca, M; Di Marsico, R; Falcone, A; Giovannetti, E; Laan, AC; Mey, V; Nannizzi, S; Orlandini, C; Peters, GJ; Ricciardi, S; Tibaldi, C; Vasile, E | 1 |
| Kameda, A; Minami, K; Miyahara, E; Noso, Y; Suzuki, T; Tsutani, Y | 1 |
| Alemany, R; Amat, JC; Besalduch, J; Galmés, A; Ginés, J; Gutiérrez, A; Martín, J; Navarro, M; Ros, T; Sampol, A; Saus, C; Serra, JM; Serra-Moisés, L; Vögler, O | 1 |
| Banerjee, TK; Bromund, JL; Chen, R; Dowell, JE; Dudek, AZ; Larson, T; McCleod, MJ; Monberg, MJ; Obasaju, CK; Pandya, KJ; Schneider, DJ | 1 |
| Chereddy, S; Dudek, AZ; Maddaus, M; Nguyen, S; Wagner, JE | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Dunlop, D; Graham, J; McLaren, V; Paul, J | 1 |
| Aasebø, U; Bremnes, RM; Brunsvig, PF; Helbekkmo, N; Sundstrøm, SH; von Plessen, C | 1 |
| Algara, M; Bastus, R; Blanco, R; Bover, I; Domenech, M; Gay, M; Mesía, C; Montesinos, J; Nogué, M; Solé, J; Terrassa, J; Vadell, C | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Davila, E; Lilenbaum, R; Raez, L; Seigel, L; Tseng, J | 1 |
| Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE | 1 |
| Cheng, AL; Hsu, C; Hu, FC; Huang, TC; Kuo, SH; Lin, CC; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Cho, HJ; Jeong, JY; Ju, JY; Kim, KS; Kim, MR; Kim, SO; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Oh, IJ | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Song, JE | 1 |
| Cerny, T; D'Addario, G; Demmer, R; Früh, M; Gillessen, S | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Hasegawa, Y; Hida, T; Horio, Y; Osada, H; Sekido, Y; Shimizu, J; Shimokata, K; Takahashi, T; Yatabe, Y | 1 |
| Cloud, G; Davidson, S; deShazo, M; Kuo, KL; Leggas, M; Li, M; Rinehart, J; Robert, F; Wang, H; Zhang, R | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Biesma, B; de Marinis, F; Digumarti, R; Gandara, D; Gatzemeier, U; Goksel, T; Lee, JS; Manegold, C; Mellemgaard, A; Parikh, P; Park, K; Patil, S; Rolski, J; Scagliotti, GV; Serwatowski, P; Simms, L; Sugarman, KP; Vansteenkiste, J; von Pawel, J; Zukin, M | 1 |
| Sørensen, JB | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Anderson, H; Dombernowsky, P; Lund, B; Petersen, PM; Ryberg, M; Thatcher, N | 1 |
| Kaye, SB | 1 |
| Abratt, RP; Bezwoda, WR; Falkson, G; Goedhals, L; Hacking, D; Rugg, TA | 1 |
| Anderson, H; Bach, F; Hansen, HH; Lund, B; Thatcher, N; Walling, J | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Burkes, RL; Shepherd, FA | 1 |
| Burkes, R; Cormier, Y; Crump, M; Feld, R; Schulz, M; Shepherd, FA; Strack, T | 1 |
| Chen, YM; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Chang, KT; Chen, JY; Chen, MH; Chen, YM; Perng, RP; Tsai, CM | 1 |
| Burkes, RL; Cortes-Funes, H; Cottier, B; Gatzemeier, U; Gottfried, M; Groen, HJ; Le Chevalier, T; Mattson, K; Rosso, R; Shepherd, FA; Tonato, M; Voi, M; Weynants, P | 1 |
| Anderson, H; Hansen, H; Thatcher, N; Walling, J | 1 |
| Burkes, R; Cormier, Y; Crump, M; Feld, R; Shepherd, FA; Strack, T | 1 |
| Copley-Merriman, C; Corral, J; Dorr, FA; King, K; McDonald, RC; Voi, M; Whiteside, R | 1 |
| Abratt, RP | 1 |
| Cameron, C; Dabouis, G; Dunlop, DJ; Guerin, JC; Kleisbauer, JP; Perol, M; Sanson, C; Steward, WP; Talbot, DC; Thomas, P | 1 |
| Anderson, H; Betticher, DC; Ranson, M; Thatcher, N | 1 |
| Andersen, S; Blatter, J; Bosanquet, N; Copley-Merriman, K; Drings, P; Johnson, N; Koch, P; van Schaik, J | 1 |
| Giaccone, G; van Zandwijk, N | 1 |
| Anderson, H; Lund, B; Martin, C; Thatcher, N | 1 |
| Kurita, Y; Nakai, Y; Niitani, H; Taguchi, T; Yokoyama, A; Yoneda, S | 1 |
| Dabouis, G; Dunlop, DJ; Lacroix, H; Steward, WP; Talbot, D | 1 |
| Burkes, RL; Cormier, Y; Crump, M; Feld, R; Schulz, M; Shepherd, FA; Strack, T | 1 |
| Allerheiligen, S; Carmichael, J; Walling, J | 1 |
| Bosanquet, N; Copley-Merriman, C; Drings, PA; Johnson, N; Martin, C; Sacristan, JA | 1 |
| Evans, WK | 2 |
| Brandt, A; Palmer, AJ | 1 |
| Alvord, WG; Gazdar, AF; Gray-Goodrich, M; Koo, HM; McWilliams, MJ; Mikheev, A; Monks, A; Oie, HK; Paull, KD; Rubinstein, LV; Vande Woude, GF; Zarbl, H | 1 |
| Guchelaar, HJ | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Taguchi, T; Takada, Y | 1 |
| Von Hoff, DD | 1 |
| Adamo, V; Altavilla, G; Clerici, M; Crinò, L; Cruciani, G; De Marinis, F; Dogliotti, L; Figoli, F; Incoronato, P; Marangolo, M; Mosconi, AM; Oliva, C; Paccagnella, A; Pucci, F; Salvati, F; Santucci, A; Scagliotti, G; Sorbolini, S; Tonato, M; Trippetti, M | 1 |
| Calayag-Jung, M; Fossella, FV; Glisson, B; Hong, WK; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Rivera, E; Shin, DM; Tarassoff, P | 1 |
| Martin, C; Pollera, CF | 1 |
| Abratt, RP; Bezwoda, WR; Goedhals, L; Hacking, DJ | 2 |
| Chen, YM; Lin, WC; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J; Yang, KY | 1 |
| Pollera, CF | 1 |
| Anderson, H; Hopwood, P; Thatcher, N | 1 |
| Crinò, L; Mosconi, AM; Tonato, M | 2 |
| Tsukagoshi, S | 1 |
| Allerheiligen, SR; Pearce, HL; Storniolo, AM | 1 |
| Kanzawa, F; Saijo, N | 1 |
| Hansen, HH; Sørensen, JB | 1 |
| Fukuoka, M; Kurita, Y; Niitani, H; Takada, M; Yokoyama, A | 1 |
| Gottfried, M; Le Chevalier, T | 1 |
| Abratt, RP; Anderson, H; Anglin, G; Gatzemeier, U; Iglesias, J; Shepherd, FA | 1 |
| Pedersen, AG | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Anderson, H; Bradley, B; Jayson, G; Ranson, M; Thatcher, N | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, P; ten Bokkel Huinink, W; van Walree, N; von Pawel, J; Wagenius, G | 1 |
| Einhorn, LH | 1 |
| Burkes, R; Cormier, Y; Evans, WK; Feld, R; Goss, G; Klimo, P; Shepherd, FA; Taylor, M | 1 |
| Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ | 2 |
| Gregor, A | 1 |
| Burkes, RL; Cortes-Funes, H; Cottier, B; Gatzemeier, U; Gottfried, M; Groen, HJ; Le Chevalier, T; Mattson, K; Ponzio, A; Rosso, R; Shepherd, F; Tonato, M; Voi, M; Weynants, P | 1 |
| Fukuoka, M; Furuse, K; Kudoh, S; Kurita, Y; Niitani, H; Ohnoshi, T; Saijoh, N | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel-Huinink, W; van Pawel, J; van Walree, N; Wagenius, G | 1 |
| Goa, KL; Noble, S | 1 |
| Kurita, Y; Nakai, Y; Niitani, H; Yokoyama, A; Yoneda, S | 1 |
| Abratt, R; Cortes-Funes, H; Lund, B; Martin, C | 1 |
| Halme, M; Jekunen, A; Mattson, K; Tamminen, K | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Merambeliotakis, N; Papadakis, E; Vardakis, N | 1 |
| Aigner, K; Baumgartner, G; Forstner, B; Huber, H; Hubner, M; Krajnik, G; Krejcy, K; Kummer, F; Malayeri, R; Pirker, R; Ulsperger, E; Zöchbauer, S | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Furuse, K | 2 |
| Ardizzoni, A; Martin, C; Rosso, R | 1 |
| Masuda, N | 1 |
| Botti, G; Caputi, V; Comella, G; Comella, P; Frasci, G; Gravina, A; Natale, M; Nicolella, GP; Pacilio, C; Panza, N | 1 |
| Breiteneder, S; Brodowicz, T; Wiltschke, C; Zielinski, CC | 1 |
| Boyer, MJ | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Takada, M; Takada, Y | 1 |
| Dormann, AJ; Grünewald, T; Huchzermeyer, H; Wigginghaus, B | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Veerman, G | 1 |
| Kroep, JR; Merriman, RL; Peters, GJ; Pinedo, HM; Schultz, RM; Tanzer, LR; van Moorsel, CJ; Veerman, G; Voorn, DA; Worzalla, JF | 1 |
| Adjei, AA; Rajkumar, SV | 1 |
| Bunn, PA; Kelly, K | 1 |
| Gietema, JA; Groen, HJ; Meijer, S; Smit, EF | 1 |
| Calzas, J; Castellano, D; Cortés-Funes, H; Gómez, H; Gómez-Martín, C; Guerra, JA; Hidalgo, M; Lianes, P; Paz-Ares, L | 1 |
| Dobbie, M; Herrmann, R; Hofer, S; Oberholzer, M | 1 |
| Rigas, JR | 2 |
| Loddenkemper, R; Schönfeld, N; Serke, M | 1 |
| Steward, WP | 1 |
| Calandri, C; Crinò, L; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Noseda, M; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Abratt, RP; Crinò, L; Green, MR; Nguyen, B; Peters, GJ; Sandler, A; Shepherd, FA; Steward, WP | 1 |
| Rosell, R; Sandler, A; Tonato, M | 1 |
| Dombernowsky, P; Giaccone, G; Sandler, A; Schwartsmann, G | 1 |
| Calvert, P; Langer, CJ; Ozols, RF | 1 |
| Gregor, A; Turrisi, AT; Vokes, EE | 1 |
| Carney, DN | 1 |
| Fernberg, JO; Tennvall, GR | 1 |
| Androulakis, N; Dimopoulou, I; Georgopoulou, T; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Souglakos, J; Tzannes, S; Vardakis, N | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Steward, WP; Thomas, A | 1 |
| Daenen, M; Demedts, M; Nackaerts, K; Van Bleyenbergh, P; Vandevelde, A; Vansteenkiste, J | 1 |
| Guechev, A; Loves, WJ; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Antón, A; Artal, A; Barneto, I; Díaz-Fernández, N; González Larriba, JL; Masutti, B; Montalar, J; Rosell, R; Vadell, C | 1 |
| Greil, R; Huber, H; Krajnik, G; Kummer, F; Malayeri, R; Marhold, F; Mohn-Staudner, A; Pirker, R; Wein, W; Zöchbauer-Müller, S | 1 |
| Chovan, L; Janko, C; Jassem, J; Kanitz, E; Krejcy, K; Krzakowski, M; Magyar, P; Pawlicki, M; Pesek, M; Petruzelka, L; Zatloukal, P | 1 |
| Bergman, B; Dombernowsky, P; Hansen, HH; Krarup, M; Nielsen, AL; Sørensen, JB | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Caponigro, F; Costagliola, G; De Marino, V; Dimitri, P; Facchini, G; Ferrante, G; Ferraro, A; Gentile, M; Gravina, A; Iaffaioli, RV; Illiano, A; Marzano, N; Tortoriello, A | 1 |
| Cascinu, S; Cellerino, R; Cetto, GL; Giuliodori, L; Lippe, P; Mari, D; Monterubbianesi, MC; Pasini, F; Porfiri, E; Rossi, D; Santo, A; Silva, RR; Tummarello, D | 1 |
| Apostolopoulos, N; Giannios, J; Ginopoulos, P; Karana, A; Karvelas, F; Mastorakou, A; Mastronikolis, NS; Rathossis, S; Siabi, V | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Meluch, AA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Johnson, D; Tonato, M | 1 |
| Calvert, P; Edelman, MJ; Gandara, DR; Langer, CJ; Ozols, RF | 1 |
| Giaccone, G | 2 |
| Barton-Burke, M | 1 |
| Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N | 1 |
| Liepa, AM; Minshall, ME | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Ettinger, DS; Sandler, A | 1 |
| Taguchi, T; Tsukagoshi, S | 1 |
| Asai, G; Fukuoka, M | 1 |
| Hara, N; Kurita, Y; Matsui, K; Nakai, Y; Niitani, H; Ohhashi, Y; Yokoyama, A | 1 |
| Yokoyama, A | 2 |
| van Oosterom, AT | 1 |
| Biesma, B; Postmus, PE; Smit, EF | 1 |
| Rizvi, NA | 1 |
| Alberola, V; Antón, A; Artal, A; Barneto, I; Cardenal, F; Carrato, A; García, M; González-Larriba, JL; Lianes, P; Lomas, M; López-Cabrerizo, MP; Massuti, B; Montalar, J; Nguyen, B; Rosell, R; Vadell, C | 1 |
| Carmichael, J | 1 |
| Beinert, T; Binder, D; Fleischhacker, M; Mergenthaler, HG; Oehm, C; Possinger, K; Priem, F; Schweigert, M; Sezer, O; Siebert, G; Stuschke, M; Werner, TG; Ziemer, S | 1 |
| Eady, A; Evans, WK; Gagliardi, A; Kocha, W; Newman, TE | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Ferreira, CG; Giaccone, G; Peters, GJ; Pinedo, HM; Tolis, C | 1 |
| Peters, GJ; Pinedo, HM; Postmus, PE; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Barón, MG; Castro, J; De la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Girón, CG; López Gómez, L; Madroñal, C; Martínez, B | 1 |
| Adamo, V; Barni, S; Bianco, R; Ceribelli, A; Crinò, L; Cruciani, G; De Marinis, F; Di Costanzo, F; Ferrara, G; Gozzelino, F; Gridelli, C; Marangolo, M; Masotti, A; Portalone, L; Ravaioli, A; Ricci, S; Rinaldi, M; Sassi, M; Scagliotti, GV; Tonato, M | 1 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Comella, G; Frasci, G; Pacilio, G; Panza, N | 1 |
| Cazap, E; Cinat, G; Comba, AZ; Nievas, OR; Orlando, M; Sena, S; Traine, G; Van Kooten, M; Vicente, H | 1 |
| Calandri, C; Crinò, L; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Noseda, M; Novello, S; Rinaldi, M; Rossi, A; Scagliotti, G; Selvaggi, G; Tonato, M | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Rosing, H; Smit, EF; van Groeningen, CJ; van Moorsel, CJ; Voorn, DA | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, PL; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel Huinink, WW; von Pawel, J; Wagenius, G; Walree, NV | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Halme, M; Isokangas, OP; Joensuu, H; Knuuttila, A; Lindström, I; Mäntylä, M; Mattson, K; Nikkanen, V; Viren, M | 1 |
| Aapro, MS; Gwyther, SJ; Hatty, SR; Postmus, PE; Smith, IE | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Kelly, K | 1 |
| Cartei, G; Iop, A; Pella, N; Sacco, C; Sibau, A; Tabaro, G | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Bahadori, HR; Eckardt, JR; Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Herbst, RS; Lilenbaum, R | 1 |
| Einhorn, LH; Ng, EW; Robinson, L; Sandler, AB | 1 |
| Cormier, Y; Denham, C; Einhorn, LH; Gatzemeier, U; Gregor, A; Manegold, C; Mattson, K; Nemunaitis, J; Nguyen, B; Niyikiza, C; Palmer, MC; Sandler, AB; von Pawel, J | 1 |
| Brunetti, C; Carpagnano, F; Cinieri, S; Cisternino, ML; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Napoli, G; Orlando, S; Palazzo, S; Panza, N | 1 |
| Barreras, L; Cano, R; Davila, E; Krill, E; Lewis, M; Lilenbaum, R; Lutzky, J; Schwartz, M; Siegel, L | 1 |
| Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Camps, C; Herrero, CC; Jaime, AB; Martínez, EN | 1 |
| De Filippis, S; Guerriero, G; Pompili, P; Rea, S; Recchia, F; Rosselli, M | 1 |
| Algeri, R; Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Conte, PF; Fioretto, ML; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| Giaccone, G; Golding, RP; Laan, D; Pinedo, HM; Postmus, PE; Smit, EF; Splinter, T; van Meerbeeck, JP; van Tinteren, H | 1 |
| Ettinger, DS | 2 |
| Dimitriadis, K; Dimopoulos, A; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Alberola, V; Antón, A; Cardenal, F; Carrato, A; Kennedy-Martin, T; Lomas, M; Massuti, B; Minshall, M; Rosell, R; Sacristán, JA | 1 |
| Fabregat-Mayol, X; Gallén-Castillo, M; Nogué-Aliguer, M; Saigí-Grau, E; Vadell-Nadal, C | 1 |
| Brierre, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Litchy, S | 1 |
| Bilancia, D; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; Di Nota, A; Di Rienzo, G; Filippelli, G; Frasci, G; Lamberti, A; Lorusso, V; Maiorino, L; Manzione, L; Micillo, E; Natale, M; Nicolella, G; Panza, N | 1 |
| Asna, N; Greif, Y; Inbar, M; Mann, A; Merimsky, O; Paz, J; Schwartz, Y; Wigler, N | 1 |
| Banach, MJ; Williams, GA | 1 |
| Fukuoka, M | 1 |
| Blatter, J; Krejcy, K; Manegold, C; Zatloukal, P | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Chen, YM; Liu, TW; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J; Yang, KY | 1 |
| Berghmans, T; Efremidis, A; Klastersky, J; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J | 1 |
| Belli, M; Bianco, A; Bilancia, D; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Frasci, G; Iannelli, A; Lorusso, V; Massidda, B; Nicolella, G; Panza, N; Piantedosi, F | 1 |
| Curran, D; Debruyne, C; Festen, J; Gans, S; Giaccone, G; Kramer, GW; Schlosser, NJ; Schramel, F; Smit, EF; Termeer, A; Van Zandwijk, N | 1 |
| Banzi, MC; Bisagni, G; Boni, C; De Pas, T; Franciosi, V; Moretti, G; Pajetta, V; Pazzola, A; Rondini, E; Sassi, M; Savoldi, L; Vignoli, R; Zadro, A | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Chan, AT; Johnson, P; Leung, SF; Leung, TW; Mok, TS; Nguyen, B; Yang, WT; Yeo, W; Yim, A; Zee, B | 1 |
| Belometti, MO; Beretta, GD; Gritti, G; Labianca, R; Michetti, G; Poletti, P; Quadri, A | 1 |
| Anderson, H; Bond, MG; Burt, PA; Carmichael, J; Connolly, CK; Cottier, B; Falk, SJ; Hopwood, P; Maughan, TS; McIllmurray, MB; Milroy, R; Nicholson, M; Stephens, RJ; Thatcher, N | 1 |
| Bajetta, E; Bidoli, P; Chiara Stani, S; De Candis, D; Mariani, L; Pozzi, P; Procopio, G; Zilembo, N | 1 |
| Castiglione, F; Cigolari, S; Farris, A; Felletti, R; Frontini, L; Gallo, C; Gasparini, G; Gridelli, C; Gulisano, M; Ianniello, GP; Locatelli, MC; Perrone, F; Piazza, E; Robbiati, SF | 1 |
| Czerniak, PM; Devenny, JJ; Gravallese, EM; Kerr, JS; Longtine, J; Slee, AM; Wexler, EJ; Wong, MK | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Edelman, MJ; Gandara, DR; Lara, PN; Lau, DH | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 2 |
| Comella, P | 3 |
| Kosmidis, P | 1 |
| Sandler, A | 1 |
| Giaccone, G; Groeningen, CJ; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Tolis, C; Voorn, DA | 1 |
| Catania, C; Cinieri, S; Curigliano, G; Danesi, R; de Braud, F; De Pas, T; del Tacca, M; Fogli, S; Goldhirsch, A; Marrocco, E; Milani, A; Rocca, A; Sbanotto, A; Sessa, C; Zampino, G | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Baldwin, AS; Broad, RM; Jones, DR; Madrid, LV; Mayo, MW | 1 |
| Deutsch, J; Greil, R; Huber, H; Krajnik, G; Malayeri, R; Marhold, F; Mohn-Staudner, A; Pirker, R; Preiss, P; Schäfer-Prokop, C; Schmeikal, S; Thaler, J; Wein, W | 1 |
| Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Franco Conte, P; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| Barceló, R; Fernández, R; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Abratt, R; Anglin, G; Crino, L; Green, M; Iglesias, J; Sandler, A; Shepherd, FA; Steward, W | 1 |
| Cox, G; Jeyapalan, K; Muller, S; O'Byrne, KJ; Sharma, RA; Shields, F; Steward, WP; Thomas, AL | 1 |
| Bartolucci, R; Calandri, C; Cipri, A; Crinò, L; Darwish, S; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Novello, S; Porrozzi, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Centoni, PE; Ceretelli, S; Liumbruno, G; Sodini, ML | 1 |
| Ranson, MR; Thatcher, N; White, S | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Bonsignore, G; Bucchieri, F; Gjomarkaj, M; Melis, M; Pace, E; Profita, M; Siena, L; Vignola, AM | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Coeman, DC; Demedts, MG; Nackaerts, KL; Vansteenkiste, JF; Verbeken, EK | 1 |
| Brindley, CJ; Devlin, AJ; Friberg, LE; Karlsson, MO | 1 |
| Chang, JW; Chen, SC; Lee, CH; Lin, MC; Tsao, TC; Wang, SW | 1 |
| Ferreira, CG; Giaccone, G; Kruyt, FA; Peters, GJ; Span, SW | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Lilenbaum, R | 1 |
| Vokes, EE | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Benk, J; Chemaissani, A; Dalhoff, K; Dürk, H; Edler, L; Hossfeld, DK; Laack, E; Lorenz, C; Mende, T; Müller, T; Niestroy, A; Scholtze, J; Walter, T | 1 |
| Awwad, E; Cacayorin, ED; Dunphy, F; Nassif, AS; Perman, W; Russell, MT | 1 |
| Johnson, DH | 1 |
| Calandri, C; Crinò, L; Maestri, A; Marrocolo, F | 1 |
| Choy, H; Curran, WJ | 1 |
| Rixe, O; Seigneur, J; Spano, JP | 1 |
| Bianco, V; Di Girolamo, B; Florio, G; Gemma, D; Girolami, M; Marchei, P; Pignatelli, E; Speranza, I; Vietri, F | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Gajra, A; Graziano, SL; Kirshner, J; Mehdi, SA; Newman, N | 1 |
| Bancalari, L; Canessa, P; Fiasella, L; Maggiani, R; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Huber, H; Malayeri, R | 1 |
| Bandala, E; Espinosa, M; Maldonado, V; Meléndez-Zajgla, J | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Barón, F; Candamio, S; Cueva, J; Curiel, T; Graña, B; León, L; López, R; Vázquez, F | 1 |
| Farrugia, D; Lewis, R | 1 |
| Mattson, K | 1 |
| Edelman, MJ; Gandara, DR; Lara, P; Lau, DH; Lauder, IJ; Tracy, D | 1 |
| Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D | 1 |
| Chewaskulyong, B; Pothirat, C; Thongprasert, S | 1 |
| Murren, JR | 1 |
| Casado, V; Castillo, M; Dómine, M; Estévez, LG; León, A; Lobo, F; Martin, JI; Rubio, G | 1 |
| Barroso, A; Conde, S; Guimarães, T; Parente, B; Seada, J | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Inoue, A; Saijo, N | 1 |
| Rixe, O | 1 |
| Ayoub, J; Cormier, Y; Hirsh, V; Iglésias, JL; Langleben, A; Pintos, J | 1 |
| Van Zandwijk, N | 1 |
| Cappuzzo, F; Crino, L | 2 |
| Accurso, V; Agostara, B; Carroccio, R; De Bella, MT; Di Vita, G; Faillú, G; Ferraù, F; Gebbia, V; Leonardi, V; Licata, G; Palmeri, S; Sciortino, G; Spatafora, M; Vaglica, M; Valenza, R; Vitello, S | 1 |
| Edelman, MJ; Mullins, B; Quam, H | 1 |
| Gatzemeier, U | 1 |
| Greif, J; Inbar, M; Mann, A; Marmor, S; Merimsky, O; Schwartz, Y; Staroselsky, A; Wigler, N | 1 |
| Cufer, T; Wein, W; Zwitter, M | 1 |
| Baron, A; Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Soriano, AF; Varella-Garcia, M; Zeng, C | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Dams, NL; Devogelaere, RC; Humblet, YP; Marien, SA; Nackaerts, KL; Valcke, YJ; Vandebroek, JE; Vansteenkiste, JF; Verresen, DA; Weynants, P | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Conte, PF; Neumaier, C; Prochilo, T; Rosso, R; Tibaldi, C | 1 |
| Monzo, M; Rosell, R; Taron, M | 1 |
| Blackstock, AW; Case, LD; Fletcher-Steede, J; Lesser, GJ; Miller, A; Russo, SM; Tucker, RW; White, DR | 1 |
| Calabrò, F; Cartei, G; Cetto, GL; Maiorino, A; Maluta, S; Molino, A; Oletti, MV; Panza, N; Pari, F; Pasini, F; Pedersini, R; Santo, A; Sibau, A; Terzi, A | 1 |
| Crinò, L; Rinaldi, M | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Van Putten, JW | 1 |
| Belli, M; Bianco, A; Comella, G; Comella, P; De Lena, M; DeCataldis, G; Frasci, G; Iannelli, N; Lorusso, V; Mascia, V; Massidda, B; Nicolella, G; Panza, N | 1 |
| Caffo, O | 1 |
| le Chevalier, T; Novello, S | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Jassem, J; Krawczyk, K; Krzakowski, M; Lis, J; Miracki, K; Mozejko-Pastewka, B; Ramlau, R; Roszkowski, K; Szczesna, A; Słomiński, JM | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Artioli, F; Bandieri, E; Di Fabio, F; Guaraldi, M; Lelli, G; Martoni, A; Palomba, G; Piana, E; Preti, P; Ramini, R; Robustelli Della Cuna, G | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Cellini, N; Cesario, A; Corbo, GM; D'Angelillo, RM; Galetta, D; Granone, P; Gualano, G; Macis, G; Margaritora, S; Ramella, S; Trodella, L; Turriziani, A; Valente, S | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Pas, T; Del Tacca, M; Fogli, S; Giovannetti, G | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Pas, T; Franceschelli, L; Spaggiari, L | 1 |
| Broad, RM; Comeau, LD; Jones, DR; Mayo, MW; Parsons, SJ | 1 |
| Fujita, Y; Kunikane, H; Kurita, Y; Nakai, Y; Niitani, H; Noda, K; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Hossfeld, DK; Knuffmann, C; Laack, E; Mende, T | 1 |
| Ammaturo, MV; Ariganello, O; Belli, R; Cipri, A; De Marinis, F; Di Molfetta, M; Diana, F; Facciolo, F; Martelli, O; Migliorino, MR; Nelli, F | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Chang, CJ; Chen, YM; Cheng, AL; Chiang, SC; Hsu, C; Huang, MH; Lee, YC; Liu, MY; Luh, KT; Lui, LT; Perng, RP; Tsai, CM; Wang, LS; Yang, CH; Yang, PC; Yen, SH | 1 |
| D'Aiuto, M; De Braud, F; Leo, F; Leon, ME; Pastorino, U; Pelosi, G; Solli, PG; Spaggiari, L; Veronesi, G | 1 |
| Gentile, A; Masotti, A; Morandini, G; Zannini, G | 1 |
| Alberola, V; Barnadas, A; Manzano, JL; Monzó, M; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Kato, Y; Saijo, N | 1 |
| Matranga, CB; Shapiro, GI | 1 |
| Bando, K; Hasegawa, Y; Hatachi, Y; Murayama, T; Nakata, M; Ohyama, S; Taniguchi, M; Ueda, T | 1 |
| Dickgreber, N; Dürk, H; Edler, L; Graeven, U; Hossfeld, DK; Jasiewicz, Y; Kneba, M; Laack, E; Mende, T; Müller, T; Scholtze, J; Welte, T | 1 |
| Mavroudis, D | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N | 1 |
| Schramel, FM; Seldenrijk, CA; Slee, PH; van Beek, FT; Voorburg, AM | 1 |
| Ferri-Dessens, RM; Gouva, S; Kleisbauer, JP; Léna, H; Robinet, G; Thomas, P; Vernejoux, JM | 1 |
| Aristides, M; Botwood, N; Lees, M; Maniadakis, N; McKendrick, J; Stephenson, D | 1 |
| Buesa, JM; Carrasco, J; Corral, N; Esteban, E; Estrada, E; Fra, J; Lacave, AJ; Palacio, I; Puerta, J; Sala, M; Valle, M; Vieitez, JM | 1 |
| Bernardo, A; Bernardo, G; Brunetti, G; Cuzzoni, Q; Jedrychowska, I; Palumbo, R; Pozzi, U; Strada, MR | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Prochilo, T; Tibaldi, C | 1 |
| Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Varella-Garcia, M | 1 |
| Corlan, E; Draghici, IN; Grigorescu, AC; Gutulescu, N; Nitipir, C | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Cortés-Funes, H | 1 |
| Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH | 1 |
| Sederholm, C | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Fukuoka, M; Matsui, K | 1 |
270 review(s) available for deoxycytidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Recent Development of Prodrugs of Gemcitabine.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prodrugs | 2022 |
Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Gemcitabine; Humans; Lung Neoplasms | 2022 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic; Vinorelbine | 2018 |
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2018 |
Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Records; Middle Aged; Neoplasm Staging; Risk Factors; Thrombocytopenia; Treatment Outcome | 2018 |
Necitumumab for the treatment of advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms | 2019 |
Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.
Topics: Administration, Inhalation; Adsorption; Aerosols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Lung; Lung Neoplasms; Particle Size; Platinum Compounds; Small Cell Lung Carcinoma; Taxoids | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Systematic Reviews as Topic | 2014 |
Maintenance therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2015 |
RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
Necitumumab: First Global Approval.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms | 2016 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Geriatric Assessment; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pemetrexed; Programmed Cell Death 1 Receptor; Taxoids; Vinblastine; Vinorelbine | 2016 |
Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate | 2016 |
The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Taxoids | 2016 |
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; Pemetrexed; Poly-ADP-Ribose Binding Proteins; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Gemcitabine; Humans; Injections; Lung Neoplasms; Randomized Controlled Trials as Topic | 2017 |
The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Platinum Compounds; Survival Analysis; Treatment Outcome | 2016 |
Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Sex Factors; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2009 |
Quality-of-life assessment in phase III clinical trials of gemcitabine in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Patient Compliance; Quality of Life | 2008 |
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Monitoring; Gemcitabine; Humans; Pharmacogenetics; Prognosis | 2009 |
A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Bibliographic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum; Vinblastine; Vinorelbine | 2009 |
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2009 |
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease Management; Gemcitabine; Glutamates; Guanine; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Palliative Care; Pemetrexed; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Genes, BRCA1; Humans; Lung Neoplasms; Pharmacogenetics; Prognosis; Taxoids | 2008 |
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Small Cell Lung Carcinoma | 2009 |
The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2010 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Impact of biomarkers on non-small cell lung cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Taxoids; Tubulin; Tumor Suppressor Proteins | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
[A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Treatment Outcome | 2010 |
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms | 2011 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Odds Ratio; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Time Factors; Tumor Suppressor Proteins | 2012 |
Chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Biological; Neutropenia; Platinum Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Topics: Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
[Thermo-chemotherapy of GP or TP for advanced non-small cell lung cancer: a systematic review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Paclitaxel; Safety; Taxoids | 2012 |
Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Gemcitabine; Health Policy; Humans; Lung Neoplasms; Policy Making; Quality of Life; Survival; Vinblastine; Vinorelbine | 2002 |
[New drugs in bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Chemotherapy of non-small cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Risk Factors; Vinblastine; Vinorelbine | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Palliative Care; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2002 |
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Injections, Intravenous; Liver Diseases; Lung Neoplasms; Vinblastine; Vinorelbine | 2002 |
Gemzar platinum combinations: phase III trials in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival | 2002 |
Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Quality of Life; Survival | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Combined gemcitabine and radiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasms; Neoplasms, Experimental; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Tumor Cells, Cultured | 2002 |
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Chemotherapy for advanced non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
Pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2002 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
Genetic testing for chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Genetic Testing; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Biosynthesis; Repressor Proteins; RNA, Messenger; Survival Analysis; Taxoids; Transcription Factors; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2003 |
Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Randomized Controlled Trials as Topic | 2003 |
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Polymorphism, Genetic; Ribonucleotide Reductases; Survival Rate | 2003 |
The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Thymidylate Synthase | 2003 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
An autopsy case of acute pulmonary toxicity associated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Respiratory Distress Syndrome | 2003 |
Influence of genetic markers on survival in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Helicases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Polymorphism, Genetic; Proteins; Ribonucleotide Reductases; Survival Rate; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2003 |
Gemcitabine-induced severe pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Disease Progression; Drug Interactions; Dyspnea; Gemcitabine; Humans; Lung; Lung Diseases; Lung Neoplasms; Radiography, Thoracic; Risk Factors | 2004 |
State-of-the-art chemotherapy for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Treatment Outcome | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
[The role of meta-analysis in assessing the treatment of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic | 2004 |
Gemcitabine (Gemzar) in non-small cell lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer.
Topics: Aged; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Heart Atria; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Ribonucleotide Reductases; Thymidylate Synthase | 2004 |
Carboplatin/gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2004 |
Chemoradiation in NSCLC: focus on the role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2004 |
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Pharmacogenetics; Thymidylate Synthase | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[First-line non-small-cell lung cancer: role of gemcitabine].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2006 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Chemotherapy of advanced non-small cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Pharmacogenomics and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Genes, BRCA1; Humans; Lung Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2006 |
Clinical studies of pemetrexed and gemcitabine combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Neoplasms; Pancreatic Neoplasms; Pemetrexed | 2006 |
Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Routes; Gemcitabine; Humans; Italy; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic | 2006 |
Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiation-Sensitizing Agents | 2006 |
First line chemotherapy in advanced or metastatic NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Metastasis | 2006 |
Non-small-cell lung cancer: which platinum for gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Platinum Compounds; Survival Analysis | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Pemetrexed | 2006 |
Usefulness of predictive tests for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases | 2006 |
Methylation patterns and chemosensitivity in NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Role of induction chemotherapy in resectable N2 non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine and radiotherapy for the future].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine and non small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic | 2007 |
[Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vindesine; Vinorelbine | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Survival Rate | 2007 |
Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Survival Analysis; Taxoids; Tumor Suppressor Proteins | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Current chemotherapy of advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Quality of Life; Survival Rate | 1995 |
Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; North America; South Africa | 1995 |
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 1995 |
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Kidney Diseases; Lung Neoplasms; Neoplasms; Thrombocytopenia | 1996 |
Single-agent activity of gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Economic value of gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms | 1996 |
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Etoposide; Gemcitabine; Health Care Costs; Humans; Ifosfamide; Insurance, Health, Reimbursement; Italy; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases; Vinblastine; Vinorelbine | 1996 |
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1997 |
Combination therapy with gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1997 |
[Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytidine Monophosphate; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation | 1997 |
Preclinical, pharmacologic, and phase I studies of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Drug Evaluation, Preclinical; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Ribonucleotide Reductases; Safety | 1997 |
Overview of current and future chemotherapeutic agents in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 1997 |
Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Survival Rate | 1997 |
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases; Treatment Outcome | 1997 |
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 1997 |
Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dyspnea; Edema; Fever; Gemcitabine; Heart; Humans; Kidney; Liver; Lung Neoplasms; Middle Aged; Nausea; Vomiting | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Middle Aged; Vinblastine; Vinorelbine | 1998 |
The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 1998 |
Gemcitabine and paclitaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Gemcitabine and carboplatin in combination: phase I and phase II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
Gemcitabine and radiation therapy for non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Evaluation Studies as Topic; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Hemolytic-uremic syndrome caused by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 1998 |
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1999 |
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 1999 |
Gemcitabine plus taxane combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1999 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Gemcitabine: a pharmacologic and clinical overview.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Nursing Care; Oncology Nursing; Pancreatic Neoplasms | 1999 |
Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Europe; Gemcitabine; Humans; Lung Neoplasms; Models, Econometric; United States | 1998 |
Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Analysis; Treatment Outcome | 1999 |
[Clinical development in gemcitabine and its clinical pharmacological profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
[Gemcitabine hydrochloride is a new anti-cancer agent which will be available in the patients with non-small cell lung cancer (NSCLC) in Japan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neutropenia; Patient Selection; Thrombocytopenia; Treatment Outcome | 1999 |
Cisplatin and gemcitabine in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Analysis; Vinblastine; Vinorelbine | 1999 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine in non-small cell lung cancer (NSCLC).
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
[Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Etoposide; Forecasting; Gemcitabine; Lung Neoplasms; Pancreatic Neoplasms | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Preoperative Care; Randomized Controlled Trials as Topic; Remission Induction; Tomography, Emission-Computed | 2000 |
Combination chemoradiotherapy with gemcitabine: potential applications.
Topics: Agranulocytosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Thrombocytopenia | 2000 |
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Randomized Controlled Trials as Topic; Thrombocytopenia | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
The role of new agents in advanced non-small-cell lung carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2000 |
Management of elderly patients with lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Decision Making; Deoxycytidine; Gemcitabine; Geriatrics; Humans; Lung Neoplasms; Prognosis; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2000 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and nonplatinum combinations in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Treatment Outcome | 2001 |
Gemcitabine for the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Treatment Outcome | 2001 |
Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2001 |
Optimizing chemoradiation in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
[Gemcitabine + Cisplatin combinations in advanced non-small cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
[Chemotherapy of non-small cell lung cancer: non-cisplatin based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
[Therapeutic strategies in neoadjuvant therapy of non-small cell lung cancer: benefits of gemcitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Survival Rate | 2001 |
[Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2001 |
ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Determinants of response and resistance to cytotoxics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Damage; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Loss of Heterozygosity; Lung Neoplasms; Predictive Value of Tests; Signal Transduction | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Gemcitabine in non-small cell lung cancer.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Radiotherapy, Adjuvant | 2002 |
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Protective Agents; Vinblastine; Vinorelbine | 2002 |
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Drug Evaluation, Preclinical; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Ribonucleotide Reductases; Trastuzumab; Tumor Cells, Cultured | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
New treatment approaches for lung cancer and impact on survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Neoplasms; Paclitaxel; Survival Rate | 2002 |
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Pleural Neoplasms; Thymidylate Synthase; Vitamin B 12 | 2002 |
Gemcitabine and pemetrexed (Alimta) in thoracic cancers: present and future perspectives. Introduction and current controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2002 |
Gemcitabine induction chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Randomized Controlled Trials as Topic | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
[New antitumor antimetabolites--gemcitabine and DMDC].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male | 1992 |
776 trial(s) available for deoxycytidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Tegafur; Uracil | 2021 |
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2019 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Frail Elderly; Gemcitabine; Germany; Humans; Immunotherapy; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic; Vinorelbine | 2020 |
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2020 |
[Prevention effect of transcutaneous electrical acupoint stimulation for chemotherapy-related myelosuppression in non-small cell lung cancer].
Topics: Acupuncture Points; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Transcutaneous Electric Nerve Stimulation | 2020 |
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Period; Ribonucleoside Diphosphate Reductase; Treatment Outcome | 2020 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis | 2020 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival; Survival Rate | 2021 |
Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Theoretical; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2017 |
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Smokers | 2017 |
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Deoxycytidine; Diarrhea; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Lethargy; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Protein Kinase Inhibitors; Thrombocytopenia; Vomiting | 2017 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Estrogen Receptor alpha; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies | 2018 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Progression-Free Survival | 2018 |
Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Genotype; Genotyping Techniques; Humans; Lung Neoplasms; Male; Polymorphism, Single Nucleotide; Precision Medicine; Singapore; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2018 |
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Quality of Life; Treatment Outcome | 2018 |
An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cross-Over Studies; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2019 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nadroparin; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Pneumonectomy; Positron-Emission Tomography | 2019 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Serum Albumin; Survival Rate; Treatment Outcome | 2013 |
Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil; Vinblastine; Vinorelbine | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Ifosfamide; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Vinblastine; Vinorelbine | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
[Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Chronotherapy; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Flow Cytometry; Gemcitabine; Glutamates; Guanine; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Pemetrexed; Taxoids | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
[Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Neutropenia; Pemetrexed; Quality of Life; Survival Rate; Thrombocytopenia; Vomiting | 2013 |
Intra-arterial infusion chemotherapy for advanced non-small-cell lung cancer: preliminary experience on the safety, efficacy, and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2014 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Taxoids | 2014 |
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Thorax | 2014 |
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Leukotriene B4; Lung Neoplasms; Male; Middle Aged | 2014 |
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Pemetrexed; Prognosis; Prospective Studies; Quality of Life; Research Design; Survival Rate | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA-Binding Proteins; Female; Folate Receptor 1; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Peptide Synthases; Prognosis; Retrospective Studies; Survival Rate; Thymidylate Synthase; Tissue Array Analysis; Transcription Factors | 2013 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2015 |
First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Precision Medicine; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Neuropilins; Paclitaxel; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2013 |
Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Treatment Outcome | 2014 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2014 |
[Effect of integrated Chinese medical treatment (as maintenance therapy) on the survival time of patients with advanced non-small-cell lung cancer: a clinical study].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Taxoids | 2014 |
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Risk Factors; Treatment Outcome | 2014 |
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2014 |
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; China; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Male; Middle Aged; Nuclear Proteins; Taxoids; Treatment Outcome; White People | 2014 |
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Treatment Outcome; Vinblastine | 2014 |
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pilot Projects; Radiography; Sarcopenia; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Nausea; Organoplatinum Compounds; Ribonucleoside Diphosphate Reductase; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vault Ribonucleoprotein Particles; Vomiting | 2014 |
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dimethyl Sulfoxide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Ruthenium; Ruthenium Compounds; Treatment Outcome | 2015 |
Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-s
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Pemetrexed and gemcitabine versus carboplatin and gemcitabine in non-small cell lung cancer: a randomized noninferiority phase II study in one center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2015 |
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Drug Administration Schedule; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Precision Medicine; Predictive Value of Tests; Prospective Studies; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins | 2015 |
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Quality of Life; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome | 2015 |
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2015 |
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution | 2015 |
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2015 |
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, erbB-1; Humans; Intercalating Agents; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum Compounds; Treatment Outcome | 2015 |
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pemetrexed; Predictive Value of Tests; Thymidylate Synthase; Treatment Outcome | 2015 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Sectional Studies; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Muscle, Skeletal; Neoplasm Staging; Vinblastine; Vinorelbine | 2015 |
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
Topics: Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Quality of Life; Treatment Outcome | 2015 |
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Nausea; Neoplasm Staging; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome | 2015 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate | 2016 |
A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2016 |
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with st
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2016 |
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Decision Making; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Vinblastine; Vinorelbine | 2016 |
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Pemetrexed; Proto-Oncogene Proteins p21(ras); Survival Rate | 2016 |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Treatment Outcome | 2016 |
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2017 |
Measurement of health-related quality of life during chemotherapy - the importance of timing.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Time Factors; Vinblastine; Vinorelbine | 2017 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Treatment Outcome | 2009 |
A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2008 |
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasms; Time Factors | 2008 |
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2008 |
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Rate | 2008 |
[Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Vinblastine; Vinorelbine | 2009 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2008 |
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male | 2008 |
Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2008 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Vinblastine; Vinorelbine | 2009 |
Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy | 2008 |
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2008 |
A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Time Factors; Treatment Outcome; United States | 2009 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2009 |
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Demography; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Treatment Outcome | 2009 |
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Probability; Respiratory Function Tests; Risk Assessment; Survival Analysis | 2009 |
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2009 |
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Taxoids | 2009 |
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Pyridines; Survival Analysis; Thiosemicarbazones; Time Factors; Treatment Outcome | 2010 |
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Recombinant Proteins; Taxoids; Treatment Outcome | 2009 |
Chemotherapy and quality of life in NSCLC PS 2 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pneumonectomy | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2009 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome; Young Adult | 2010 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Topics: Adult; Aged; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Dosage Calculations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Histone Chaperones; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Pharmacogenetics; RNA, Messenger; RNA, Neoplasm; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life | 2009 |
Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Practice Guidelines as Topic; Prognosis; Risk Assessment; Survival Analysis | 2009 |
A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vinblastine; Vinorelbine | 2010 |
A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2009 |
Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Patient Compliance; Pneumonectomy; Prospective Studies; Thrombocytopenia | 2010 |
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2010 |
Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Prognosis; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Sulfonamides; Toluene; Treatment Outcome | 2009 |
Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed | 2009 |
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Nicotinic; Survival Analysis; Taxoids | 2010 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Thalidomide; Treatment Outcome | 2009 |
Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Neutropenia; Survival Rate | 2009 |
Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Patient Compliance; Treatment Outcome | 2010 |
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thalidomide; Time Factors; Treatment Outcome | 2009 |
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2009 |
Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; Female; Gemcitabine; Genetic Variation; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Rad51 Recombinase; Smoking; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nomograms; Radiotherapy, Adjuvant; Suramin; Taxoids; Treatment Outcome | 2010 |
A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Health Surveys; Humans; Lung Neoplasms; Middle Aged; Phytotherapy; Pilot Projects; Plants, Medicinal; Quality of Life; Surveys and Questionnaires; Vinblastine; Vinorelbine; Young Adult | 2010 |
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2010 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Placebos; Prognosis; Survival Rate | 2010 |
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2010 |
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infections; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Staging; Silicates; Survival Analysis; Titanium | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Prospective Studies; Thalidomide; Vomiting | 2009 |
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Female; Floxuridine; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Single Nucleotide | 2010 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2010 |
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Young Adult | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed | 2010 |
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Tennessee; Treatment Outcome | 2010 |
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged | 2010 |
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; Young Adult | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Young Adult | 2010 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis | 2010 |
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; White People | 2010 |
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Genotype; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Reduced Folate Carrier Protein; Survival Rate | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2010 |
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Health Resources; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome | 2010 |
[A phase II study of gemcitabine and carboplatin bi-weekly combination chemotherapy for complete resected non-small-cell lung cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2010 |
The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Quality of Life; Radio Waves; Remission Induction | 2011 |
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2010 |
Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Vinblastine; Vinorelbine | 2010 |
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Efficacy and safety of chemotherapy combined with interstitial (125)I seed implantation brachytherapy in unresectable stage IIIa/IIIb non-small cell lung cancer].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diarrhea; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
[Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Recombinant Proteins | 2012 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2011 |
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib | 2011 |
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Proportional Hazards Models | 2012 |
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Concurrent versus sequential systemic chemotherapy and whole brain radiation therapy for brain matastases in non-small-cell lung cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging | 2011 |
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Analysis; Treatment Outcome | 2011 |
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Survival Analysis | 2011 |
Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Maintenance Chemotherapy; Male; Medication Adherence; Middle Aged; Neoplasm Staging | 2011 |
[A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organoplatinum Compounds; Treatment Outcome | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Dyspnea; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2011 |
The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Radiosurgery; Radiotherapy Dosage; Radiotherapy, Image-Guided; Tomography, X-Ray Computed | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Interleukin-2; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neoplasm Staging; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vaccines, Synthetic; Vaccinia virus | 2011 |
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Germ Cells; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Treatment Outcome | 2012 |
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Interleukin-6; Lung Neoplasms; Male; Oxidative Stress; Patient Dropouts; Weight Gain | 2012 |
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Vinblastine; Vinorelbine | 2012 |
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2012 |
Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2012 |
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotides, Antisense; Survival Rate; Thionucleotides; Treatment Outcome | 2012 |
[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2012 |
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vinorelbine | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Regression Analysis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Young Adult | 2012 |
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Treatment Outcome | 2012 |
[A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 2011 |
A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Treatment Outcome | 2012 |
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Costs and Cost Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Neoadjuvant Therapy; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2012 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Quality of Life; Vinblastine; Vinorelbine | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids; Treatment Outcome | 2012 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Isosorbide Dinitrate; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced non-small cell lung cancer: a multi-center retrospective study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2013 |
[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2012 |
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids | 2013 |
High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Topics: Actins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Collagen Type IV; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; RNA, Messenger; Treatment Outcome | 2013 |
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2014 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung can
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2013 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2013 |
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome | 2002 |
A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2002 |
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Belgium; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Reference Values; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiotherapy Dosage; Treatment Outcome | 2002 |
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Reference Values; Survival Analysis; Treatment Outcome | 2002 |
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2002 |
Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival; Vinblastine; Vinorelbine | 2002 |
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Greece; Health Care Costs; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Survival Rate | 2002 |
A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan | 2002 |
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Health Status; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Staging; Prognosis; Survival; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vinblastine; Vinorelbine | 2002 |
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2002 |
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Assessment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intralesional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pleural Effusion, Malignant; Pleurodesis; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2003 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Survival Rate; Treatment Outcome | 2003 |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2003 |
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia | 2003 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Surveys and Questionnaires; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Time Factors | 2003 |
[Comparison of cisplatin combined with gemcitabine versus cisplatin combined with vinorelbine regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2003 |
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2003 |
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Lung Neoplasms; Male; Membrane Proteins; Microtubule Proteins; Middle Aged; Paclitaxel; Phosphoproteins; Predictive Value of Tests; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Stathmin; Survival Rate; Transcription, Genetic; Tubulin; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2003 |
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2003 |
Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2003 |
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Vinblastine; Vinorelbine | 2003 |
A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Time Factors; Treatment Outcome | 2003 |
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Quality of Life; Survival Rate; Time Factors; Vinblastine | 2003 |
Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis | 2003 |
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Spain; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Effectiveness of Gemzar-Cisplatin therapy in stage IIIA-N2, IIIB and IV non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Survival Analysis; Treatment Outcome | 2003 |
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2003 |
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Analysis; Survival Rate; Treatment Outcome | 2003 |
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Prospective Studies; Treatment Outcome | 2003 |
Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2003 |
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation; Receptor, ErbB-2; Trastuzumab | 2004 |
[Phase II clinical trial on gemcitabine in the treatment of stage IIIB-IV non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2003 |
Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Taxol plus gemcitabine and vinorelbine given every other week in advanced chemo-naïve non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Survival Rate | 2003 |
Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 2004 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 2004 |
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Enzyme Inhibitors; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Staurosporine | 2004 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing d
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Up-Regulation | 2004 |
[Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2004 |
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Thrombocytopenia | 2004 |
Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytokines; Deoxycytidine; Female; Gemcitabine; Granulocytes; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Superoxides | 2004 |
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Female; Gemcitabine; Genes, Tumor Suppressor; Genotype; Homocysteine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2004 |
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Helicases; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Picibanil; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dietary Supplements; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Analysis; Time Factors; Vitamins | 2004 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Forecasting; Gemcitabine; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Italy; Kinetics; Lymphoma, Non-Hodgkin; Vinblastine; Vinorelbine | 2004 |
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides, Antisense; Oligonucleotides; Oligonucleotides, Antisense; Protein Kinase C; Protein Kinase C-alpha; Thionucleotides; Treatment Outcome | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
[Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Fever; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Primary Health Care; Prospective Studies; Vinblastine; Vinorelbine | 2004 |
[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2004 |
Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 2004 |
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2005 |
[Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Tirapazamine; Triazines | 2004 |
Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2005 |
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2005 |
A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Vinblastine | 2005 |
First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2005 |
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2005 |
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Time Factors | 2005 |
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nuclear Proteins; Pneumonectomy; RNA, Messenger; Survival Analysis; Transcription Factors; Treatment Outcome | 2005 |
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2005 |
Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides | 2005 |
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Control; Deoxycytidine; Gemcitabine; Health Care Costs; Health Services; Humans; Italy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Vinblastine; Vinorelbine | 2005 |
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Macrophages; Male; Middle Aged; Prognosis; Stromal Cells; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome | 2005 |
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Frail Elderly; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Risk Factors; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; International Agencies; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2005 |
Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
[A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2005 |
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
GRiN: a trial and tribulation in respiratory radiotherapy research.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2005 |
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Turkey | 2005 |
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Adducts; Dose-Response Relationship, Drug; Floxuridine; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Platinum; Treatment Outcome | 2005 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Prospective Studies; Survival Analysis | 2005 |
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2005 |
Biweekly administration of cisplatin/gemcitabine in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate | 2005 |
Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytosis | 2005 |
Chemotherapy for metastatic NSCLC: current status and future direction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Sweden | 2005 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Prognosis; Remission Induction; Survival Analysis; Vomiting, Anticipatory | 2006 |
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Prospective Studies | 2005 |
Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Singapore | 2006 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Protein Kinase C; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Pulmonary Embolism; Radiopharmaceuticals; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel | 2006 |
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Survival Analysis | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2006 |
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2006 |
Improvement of quality of life with Shenfu injection in non small cell lung cancer patients treated with gemcitabine plus cisplatin regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2006 |
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life | 2006 |
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Respiratory Function Tests; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2007 |
Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2006 |
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Rate; Treatment Outcome | 2006 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Quality of Life | 2006 |
Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Time Factors; Treatment Outcome; Vindesine | 2006 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2006 |
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Vinblastine; Vinorelbine | 2007 |
[A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2006 |
[Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Remission Induction; Survival Rate | 2006 |
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2006 |
Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Treatment Outcome | 2006 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2007 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2007 |
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase I
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Survival Rate | 2007 |
Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Neoplasm Staging; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2007 |
[Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids | 2006 |
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate | 2007 |
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2007 |
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2006 |
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate | 2006 |
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sulindac; Survival Analysis; Treatment Outcome; Vomiting | 2006 |
Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Esophagus; Female; Forced Expiratory Volume; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Radiotherapy Dosage; Thorax | 2006 |
Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids | 2006 |
A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Survival Rate | 2006 |
A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Sulindac; Survival Rate | 2006 |
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Treatment Outcome | 2007 |
A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2007 |
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed | 2007 |
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiation-Sensitizing Agents | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Failure | 2007 |
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lactones; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Sulfones; Survival Rate | 2007 |
Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Asian People; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2007 |
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Probability; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Burden; Vinblastine; Vinorelbine | 2007 |
Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Staging; Patient Selection; Pleural Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2007 |
Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Demography; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2008 |
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2007 |
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gemcitabine; Humans; Hypoxia; Leukocytes, Mononuclear; Lung Neoplasms; Male; Methemoglobinemia; Middle Aged; Pyridines; Thiosemicarbazones; Treatment Outcome | 2008 |
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids; Treatment Outcome | 2007 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Leukopenia; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2007 |
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Lung Neoplasms; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Patient Selection; Pharmacogenetics; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2007 |
Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil | 2008 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2008 |
Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2008 |
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2008 |
[Efficacy of gemcitabine with concurrent radiotherapy on stage III,inoperable non-small cell lung cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Esophagitis; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, High-Energy; Remission Induction; Survival Rate | 2007 |
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2007 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; HIV Infections; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organ Transplantation; Paclitaxel | 2008 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Analysis; Taxoids | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy | 2008 |
Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome | 2008 |
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed | 2008 |
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1994 |
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Remission Induction; Survival Rate; Vomiting | 1994 |
Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical | 1996 |
Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Parapsoriasis | 1996 |
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors | 1996 |
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Middle Aged | 1996 |
Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis | 1996 |
Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Savings; Deoxycytidine; Direct Service Costs; Drug Costs; Etoposide; Female; Gemcitabine; Health Services Research; Hospital Costs; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Models, Economic; Monte Carlo Method; Oncology Service, Hospital; Sensitivity and Specificity; United States | 1996 |
Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1995 |
[A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase II].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies | 1997 |
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1997 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1997 |
Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases | 1997 |
Single-agent gemcitabine in non-small cell lung cancer: the French experience.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Survival Rate | 1997 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Ribonucleotide Reductases; Treatment Outcome; Vomiting | 1997 |
Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia; Treatment Outcome | 1997 |
Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Treatment Outcome | 1997 |
Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases | 1997 |
Gemcitabine plus radiotherapy for non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ribonucleotide Reductases | 1997 |
[A phase II multicenter study of gemcitabine in non small cell lung cancers].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1997 |
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1997 |
Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Phase II study of weekly gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 1997 |
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Salvage Therapy; Survival Analysis | 1997 |
Phase II trial of gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Treatment Outcome | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1998 |
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1998 |
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 1998 |
Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1998 |
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 1998 |
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Vindesine | 1999 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia | 1999 |
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1999 |
A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1999 |
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine | 1999 |
[Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged | 1999 |
[Gemcitabine in the treatment of non-small cell lung cancer for elderly patients].
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Nausea; Survival Rate; Vomiting, Anticipatory | 1999 |
[Phase I study of gemcitabine hydrochloride (LY 188011) combination therapy with cisplatin in the patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting, Anticipatory | 1999 |
A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platinum Compounds; Salvage Therapy; Survival Rate | 1999 |
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 1999 |
Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Peripheral Nervous System Diseases; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Italy; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Sample Size; Survival Rate | 1999 |
Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 1999 |
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 1999 |
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; In Vitro Techniques; Infusions, Intravenous; Leukocytes, Mononuclear; Linear Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Statistics, Nonparametric | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors; Vinblastine; Vinorelbine | 1999 |
Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Professional Staff Committees; Treatment Outcome | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia | 1999 |
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Survival Analysis; Time Factors | 2000 |
Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion, Malignant; Remission Induction; Survival Rate; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Survival Analysis; Treatment Outcome | 2000 |
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2000 |
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2000 |
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Etoposide; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic | 2000 |
A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Israel; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Vinblastine; Vinorelbine | 2000 |
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.com.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2000 |
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2000 |
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis | 2000 |
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Patient Compliance; Quality of Life; Survival Analysis | 2000 |
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2000 |
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Proportional Hazards Models; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Pemetrexed | 2000 |
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2000 |
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Allowable Concentration; Middle Aged; Paclitaxel; Pneumonia | 2000 |
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Phase II study of regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2000 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine for the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Treatment Outcome | 2001 |
Optimizing chemoradiation in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyponatremia; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Nervous System Diseases; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 2001 |
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2001 |
A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis | 2001 |
Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Thrombocytosis; Treatment Outcome; Vincristine | 2001 |
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vinblastine; Vinorelbine | 2001 |
Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Thorax | 2001 |
A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Activity of the combination of high-dose epirubicin with gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis | 2001 |
Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Treatment Outcome | 2002 |
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2001 |
A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Incidence; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Survival Rate; Treatment Outcome | 2001 |
A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Rate; Time Factors | 2002 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2002 |
Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; Prospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2002 |
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |
Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platelet Count; Thrombocytopenia; Vomiting | 2002 |
Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2002 |
Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Vinblastine; Vinorelbine | 2002 |
First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival; Treatment Outcome; Vinblastine | 2002 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fever; Gemcitabine; Hematologic Diseases; Humans; Kidney; Liver; Lung Neoplasms; Nausea; Neoplasm Staging; Tegafur; Uracil | 2002 |
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate | 2002 |
Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate | 2002 |
642 other study(ies) available for deoxycytidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Curcumin enhances drug sensitivity of gemcitabine-resistant lung cancer cells and inhibits metastasis.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Deoxycytidine; Gemcitabine; Lung Neoplasms; Mice; Mice, Nude | 2021 |
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Neoplasms; Neutropenia; Sweden | 2022 |
Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Deoxycytidine; DNA; DNA Repair; Gemcitabine; Humans; Lung Neoplasms; RNA, Messenger | 2022 |
MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Proteins; RNA, Long Noncoding | 2022 |
CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Disulfides; Gemcitabine; Humans; Hyaluronan Receptors; Lung; Lung Neoplasms; Methoxyhydroxyphenylglycol; Micelles; Prodrugs | 2022 |
HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression.
Topics: Animals; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heme; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice | 2022 |
Elevated PAF1-RAD52 axis confers chemoresistance to human cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Rad52 DNA Repair and Recombination Protein; Transcription Factors | 2023 |
Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
Topics: Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Ribonucleoside Diphosphate Reductase; Survivin; Tubulin; Tumor Suppressor Proteins | 2023 |
First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2019 |
Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gamma Rays; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Proportional Hazards Models; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Taxoids; Tumor Burden; Vinorelbine | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA; Female; Gemcitabine; Genome-Wide Association Study; Hematopoiesis; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thrombocytopenia | 2020 |
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins p21(ras); Sequence Analysis, DNA; Tomography, X-Ray Computed; Tumor Suppressor Protein p53 | 2019 |
EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Reply to A. Tateishi et al.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Lung Neoplasms; Metal Nanoparticles; Platinum | 2020 |
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate | 2019 |
Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Cycle Checkpoints; Cell Death; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; G1 Phase; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Resting Phase, Cell Cycle; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; RNA, Messenger | 2020 |
The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Lung Neoplasms; Mitochondria; Signal Transduction | 2020 |
A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanostructures; Oxidation-Reduction; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Lipids; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polymers; Rats; Rats, Sprague-Dawley | 2020 |
Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Humans; Lecithins; Lung Neoplasms; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
Comparative clinical study on microwave ablation combined with gemcitabine and cisplatin or combined with pemetrexed and cisplatin in treatment of advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Microwaves; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2020 |
Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Systematic Review as Topic | 2020 |
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Exome Sequencing; Gemcitabine; Genome-Wide Association Study; Humans; Leukopenia; Lung Neoplasms; Neutropenia | 2020 |
Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; RNA, Circular; RNA, Long Noncoding | 2021 |
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Topics: A549 Cells; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Pilot Projects; Tumor Cells, Cultured; Xanthones; Xenograft Model Antitumor Assays | 2020 |
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Topics: Ankyrins; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Small Cell Lung Carcinoma; Tyrosine | 2020 |
Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
Topics: Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Regulatory Networks; Humans; Lung Neoplasms; Whole Genome Sequencing | 2020 |
Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Aloe-emodin induces autophagy and apoptotic cell death in non-small cell lung cancer cells via Akt/mTOR and MAPK signaling.
Topics: A549 Cells; Anthraquinones; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Oncogene Protein v-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Troponin C | 2020 |
Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2020 |
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum Compounds; Retrospective Studies | 2020 |
Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors | 2020 |
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Interactions; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Lung Neoplasms; Nucleotides; Prodrugs | 2021 |
Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Lung Neoplasms; Metal Nanoparticles; Mice; Xenograft Model Antitumor Assays; Zinc Oxide | 2020 |
Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; PTEN Phosphohydrolase; RNA, Long Noncoding; Signal Transduction; Tumor Cells, Cultured | 2021 |
Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Cisplatin; Dendritic Cells; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; RNA-Seq; Transcriptome; Treatment Outcome; Tumor Burden; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide | 2021 |
Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2021 |
Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).
Topics: Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Humans; Lung Neoplasms | 2021 |
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Mechanistic Target of Rapamycin Complex 2; Phosphorylation; Protein Binding; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Signal Transduction | 2021 |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Topics: A549 Cells; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; EGF Family of Proteins; Endothelial Growth Factors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2017 |
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Proto-Oncogene Proteins p21(ras); Republic of Korea; Retrospective Studies; Treatment Outcome | 2017 |
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Pemetrexed; Platinum; Retrospective Studies; Taxoids | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Signal Transduction; Smad4 Protein; Topoisomerase I Inhibitors; Transforming Growth Factor beta | 2017 |
Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.
Topics: 3' Untranslated Regions; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Exosomes; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local | 2017 |
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Topics: Adenocarcinoma; AMP-Activated Protein Kinase Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mice, Nude; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Thiophenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2017 |
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Patient Reported Outcome Measures; Pemetrexed; Proportional Hazards Models; Prospective Studies; Quality of Life; Registries | 2017 |
Biodistribution study of
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Stability; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Microscopy, Electron, Transmission; Organotechnetium Compounds; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2017 |
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Polymers; Prodrugs; Xenograft Model Antitumor Assays | 2017 |
Variations in gene expression of lung macromolecules after induction chemotherapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Extracellular Matrix Proteins; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Lung Neoplasms; Membrane Proteins; Pneumonectomy; Preoperative Care; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Proliferation; Cell Transformation, Neoplastic; Chemokine CXCL10; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesenchymal Stem Cells; Mice; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, CXCR3; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
Topics: Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Lung Neoplasms; Mice; Paclitaxel; Thiosemicarbazones; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2018 |
Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Fatty Acids, Omega-3; Gemcitabine; Humans; Lung Neoplasms; Tumor Cells, Cultured | 2018 |
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Maintenance Chemotherapy; Resorcinols; Treatment Outcome | 2018 |
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.
Topics: Administration, Metronomic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Models, Theoretical; Pharmacokinetics | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Diamines; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Receptor, Notch3; Signal Transduction; Thiazoles | 2018 |
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Commerce; Decision Making, Organizational; Deoxycytidine; Drug Costs; Gemcitabine; Health Policy; Humans; Incidence; Insurance, Health; Lung Neoplasms; Medicare; Models, Economic; Treatment Outcome; United States | 2018 |
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies | 2018 |
Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Adducts; DNA Breaks, Double-Stranded; DNA Repair; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Proliferating Cell Nuclear Antigen; Ubiquitination; Up-Regulation | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
[The Relationship of Clinicopathology of p16 in Non-small Cell Lung Cancer and 5-nitrogen impurity-2'-deoxycytidine-nitrogen Impurity on the Influence of p16 Expression in Lung Cancer A549 Cells].
Topics: A549 Cells; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Promoter Regions, Genetic | 2018 |
Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Republic of Korea; Survival Analysis; Treatment Outcome | 2018 |
Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Survival Rate; Transcription Factors; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2019 |
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2019 |
Pectoralis major radiation recall.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pectoralis Muscles; Radiation Injuries | 2019 |
Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy.
Topics: Animals; Autophagy; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Sirtuins | 2018 |
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies | 2018 |
Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2020 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Activation; Prognosis; Retrospective Studies | 2018 |
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis | 2019 |
Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Cullin Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; MicroRNAs; Pneumonectomy | 2019 |
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; Drug Design; Female; Gemcitabine; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Models, Molecular; Protein Structure, Tertiary; Receptors, CXCR4; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors | 2019 |
Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2019 |
Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen species‑induced autophagic death.
Topics: Adenine; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Microwaves; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Taxoids | 2019 |
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytidine Kinase; Drugs, Chinese Herbal; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Rats | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Deoxycytidine; Drug Delivery Systems; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2013 |
A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Sleeve lobectomy compared with pneumonectomy after induction therapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Reply to N. Singh et al.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single Nucleotide; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Sequence‑dependent effect of gemcitabine and cisplatin on A549 non‑small‑cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms | 2013 |
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2013 |
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Genetic Therapy; Humans; Lung Neoplasms; Mice; Nanoparticles; Neovascularization, Pathologic; RNA, Small Interfering; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pyrazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Female; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate | 2013 |
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genotype; Humans; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; RNA, Messenger | 2013 |
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dichloroacetic Acid; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Proteins; Prodrugs; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Random Allocation; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2013 |
[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Respiratory Mucosa; RNA, Small Interfering | 2013 |
Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Gemcitabine; Lung Neoplasms; Mice; RNA, Messenger; Survival Rate; Tumor Burden | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Vinblastine; Vinorelbine | 2014 |
Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Killer Cells, Lymphokine-Activated; Lung Neoplasms | 2014 |
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Treatment Outcome | 2013 |
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Urea | 2014 |
Effects of chemotherapy on global gene expression in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Pneumonectomy; Retrospective Studies; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deglutition Disorders; Deoxycytidine; Gemcitabine; Humans; Interpersonal Relations; Lung Neoplasms; Multicenter Studies as Topic; Nausea; Paclitaxel; Pain; Palliative Care; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Surveys and Questionnaires; Survival Analysis | 2014 |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Xeroderma Pigmentosum Group D Protein | 2014 |
Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Deoxycytidine; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Female; Flow Cytometry; Gemcitabine; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Micrometastasis; Neoplastic Cells, Circulating; Pilot Projects; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2014 |
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Treatment Outcome; Tubulin; Tumor Suppressor Proteins; X-ray Repair Cross Complementing Protein 1 | 2014 |
Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
[Lung cancer: is surgery an option for persisting N2 after induction therapy?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome | 2015 |
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Feasibility Studies; Female; Gemcitabine; Humans; Image-Guided Biopsy; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Ribonucleoside Diphosphate Reductase; Tomography, X-Ray Computed; Treatment Outcome; Tubulin; Tumor Suppressor Proteins | 2014 |
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Epithelial Cells; Eukaryotic Initiation Factor-4E; Gemcitabine; Green Fluorescent Proteins; Humans; Hydrazones; Lung; Lung Neoplasms; Measles Vaccine; Measles virus; Membrane Cofactor Protein; Mice; Oncolytic Virotherapy; Phosphoproteins; Sirolimus; Thiazoles; Tumor Burden; Virus Replication | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.
Topics: Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2014 |
Clinical trials in thoracic radiation oncology: as easy as 1, 2, 3.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Organs at Risk; Radiation-Sensitizing Agents; Research Design; Survival Rate; Treatment Failure | 2014 |
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Immunohistochemistry; Postoperative Period; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2014 |
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids | 2014 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Computational Biology; Deoxycytidine; DNA Polymerase I; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Models, Molecular; Mutation; Polymorphism, Single Nucleotide; Prognosis; Protein Conformation; Survival Analysis | 2014 |
Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppression Therapy; Killer Cells, Natural; Lung Neoplasms; Male; Middle Aged; T-Lymphocytes, Regulatory | 2015 |
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2015 |
Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microarray Analysis; Neoadjuvant Therapy | 2015 |
Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Lipids; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Mice, Nude; Mice, SCID; Nanocapsules | 2015 |
Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Transforming Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Platinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Topics: Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Probability; Radiotherapy Dosage; Regression Analysis; Severity of Illness Index; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, Gel; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice, Inbred BALB C; Pemetrexed; Pinocytosis; Polyethylene Glycols; Proton Magnetic Resonance Spectroscopy; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical | 2015 |
[Sequential Treatment of Advanced Squamous Lung Cancer:
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Response Evaluation Criteria in Solid Tumors; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Transfusion; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hematinics; Hemoglobins; Humans; Incidence; Iron; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Prevalence; Retrospective Studies; Small Cell Lung Carcinoma; Spain; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2015 |
WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Nuclear Proteins; Organoplatinum Compounds; Polymorphism, Genetic; Protein-Tyrosine Kinases | 2015 |
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Oligopeptides | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2015 |
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hemoglobins; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Treatment Outcome | 2015 |
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthritis; Protein Kinase Inhibitors; Pyrazoles; Pyridines | 2015 |
Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Oligonucleotides, Antisense; Osteopontin; Vascular Endothelial Growth Factor A | 2015 |
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lung Neoplasms; Male; Mice, Nude; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Time Factors; Transfection; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiation Pneumonitis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2015 |
A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Prognosis | 2015 |
Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Stilbenes; Up-Regulation | 2014 |
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Thrombocytopenia | 2016 |
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; ras Proteins; Retrospective Studies; Taxoids | 2015 |
Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobutanes; Deoxycytidine; Docetaxel; Drug Administration Schedule; Endostatins; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Perfusion Imaging; Recombinant Proteins; Taxoids; Tomography, Emission-Computed | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cellular Senescence; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Indoles; Lung Neoplasms; Mice, Nude; Morpholines; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Sulfonamides; Sulfoxides; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lung Neoplasms; Nanoparticles; Oligodeoxyribonucleotides; Polyesters; Polyethylene Glycols; Polymers | 2016 |
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Macrophage-Activating Factors; Male; Pemetrexed; Treatment Outcome; Ultrasonic Therapy; Vitamin D-Binding Protein | 2016 |
Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Turkey | 2016 |
The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Antineoplastic Agents; Asian People; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mutation; Neoplasm Metastasis; Pemetrexed; Philippines; Reactive Oxygen Species; Treatment Outcome | 2016 |
Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Hepatocyte Growth Factor; Humans; Interleukin-22; Interleukins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Treatment Outcome | 2016 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.
Topics: 3' Untranslated Regions; A549 Cells; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Phenotype; RNA Interference; Transcription Factors; Up-Regulation | 2016 |
Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cation Transport Proteins; Copper Transporter 1; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide | 2016 |
Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxyribonucleotides; Dose-Response Relationship, Drug; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Resting Phase, Cell Cycle; Ribonucleotides; S Phase Cell Cycle Checkpoints | 2016 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Thrombocytosis; Treatment Outcome | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2017 |
Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.
Topics: A549 Cells; Administration, Inhalation; Aerosols; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemistry, Pharmaceutical; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gelatin; Gemcitabine; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Viscosity; X-Ray Diffraction | 2017 |
Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Stability; Endocytosis; Galactose; Gemcitabine; Humans; Inhibitory Concentration 50; Lipids; Lung Neoplasms; Mice; Nanostructures; Paclitaxel; Polymers | 2017 |
Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Retrospective Studies; Singapore; Treatment Outcome | 2009 |
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Peptide Synthases; Pleural Neoplasms; Reduced Folate Carrier Protein; RNA, Messenger; Thymidylate Synthase; Time Factors | 2008 |
[Economic evaluation of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patient in an outpatient setting].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Allocation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Outpatients | 2008 |
Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Deoxyguanosine; Disease Progression; DNA Damage; DNA, Mitochondrial; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxidative Stress; Pneumonectomy; Retrospective Studies; Treatment Outcome | 2008 |
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Prostatic Neoplasms; Transplantation, Heterologous | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Galectin 3; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tissue Array Analysis; Tumor Suppressor Protein p53 | 2008 |
Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Evidence-Based Medicine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Tegafur; Uracil | 2008 |
[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2008 |
Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Retrospective Studies; Treatment Outcome; Vinblastine | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Research Design | 2008 |
Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Population Surveillance; Retrospective Studies; Taxoids; United States | 2009 |
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Tumor Suppressor Proteins | 2008 |
Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Still's Disease, Adult-Onset | 2009 |
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Statistics, Nonparametric; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Paclitaxel; Radiography; Retrospective Studies; Vascular Endothelial Growth Factor A | 2009 |
Cutaneous vasculitis associated with gemcitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Lung Neoplasms; Male; Skin Diseases, Vascular | 2009 |
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic | 2009 |
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Pleural Effusion, Malignant; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
[Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors | 2009 |
[Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden | 2008 |
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphoglycerate Kinase; Response Elements; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Positron-Emission Tomography; Tegafur | 2009 |
Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Observation; Platinum; Prospective Studies | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Treatment Outcome | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neovascularization, Pathologic; Xenograft Model Antitumor Assays | 2009 |
Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.
Topics: Antimetabolites, Antineoplastic; Bioreactors; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Microscopy, Electron; Protein Biosynthesis; RNA, Messenger | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
"The best-laid plans ... often go awry ...".
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; Mammalian orthoreovirus 3; Oncolytic Virotherapy; Paclitaxel; Poly(ADP-ribose) Polymerases; ras Proteins; Vinblastine; Virion | 2009 |
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; ErbB Receptors; Gemcitabine; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; In Situ Nick-End Labeling; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Particle Size; Proliferating Cell Nuclear Antigen; Random Allocation; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 2009 |
Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Contraindications; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Retrospective Studies; Survival Analysis | 2010 |
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Sex Factors; Treatment Outcome | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2009 |
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.
Topics: Aged; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy | 2009 |
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Approval; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; United States; United States Food and Drug Administration | 2009 |
Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
IR spectroscopy reveals effect of non-cytotoxic doses of anti-tumour drug on cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Spectrophotometry, Infrared | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Weekly cetuximab and gemcitabine plus cisplatin as salvage therapy for unresectable non-small cell lung cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Salvage Therapy; Treatment Outcome | 2009 |
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
Topics: 5'-Nucleotidase; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Suppressor Proteins | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Quality of Life; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Proteomics; Spectrometry, Mass, Electrospray Ionization; Survival Rate; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2010 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Precision Medicine; Taxoids; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2010 |
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; PTEN Phosphohydrolase; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2010 |
RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Saliva | 2010 |
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Protein Kinase C; Ribonucleotide Reductases; Staurosporine | 2010 |
Hand-foot hyperpigmentation skin lesions associated with combination gemcitabine-carboplatin (GemCarbo) therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Foot; Gemcitabine; Hand; Humans; Hyperpigmentation; Lung Neoplasms; Male | 2011 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Analysis of chemiotherapeutic protocols efficiency in therapy of advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2010 |
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adenine; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; Cytidine Deaminase; Cytosine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Research Design | 2010 |
Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2011 |
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Gemcitabine-induced acute eosinophilic pneumonia.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Pulmonary Eosinophilia; Radiation Tolerance | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Low dose fractionated cisplatin plus gemcitabine for elderly patients with advanced non small cell lung cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies | 2010 |
In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Interactions; Drug Synergism; Flow Cytometry; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; In Vitro Techniques; Lung Neoplasms; Pemetrexed; Radiotherapy Dosage; Tumor Cells, Cultured | 2010 |
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Markov Chains; Models, Economic; Pemetrexed; Quality of Life | 2010 |
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Costs; Gemcitabine; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Pemetrexed | 2010 |
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; European Union; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2010 |
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gemcitabine; Gene Expression; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Introns; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Minisatellite Repeats; Neoplasm Staging; Nitric Oxide Synthase Type III; Paclitaxel; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome | 2010 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Health Care Surveys; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 2011 |
Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2011 |
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.
Topics: Analysis of Variance; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Necrosis; Radiation Tolerance; Radiation-Sensitizing Agents; Resting Phase, Cell Cycle; S Phase; Tumor Suppressor Protein p53 | 2011 |
[Cerebral infarction after cisplatin-gemcitabine chemotherapy: probable cause-effect].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cerebral Infarction; Cisplatin; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Intracranial Thrombosis; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Radiography; Seizures | 2012 |
Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed; Young Adult | 2011 |
[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Predictive Value of Tests; RNA, Messenger; Treatment Outcome; Tubulin; Tumor Suppressor Protein p53 | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
[Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; ras Proteins; Remission Induction; Survival Rate; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2011 |
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Deletion; Glutathione Transferase; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies | 2012 |
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crizotinib; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Amplification; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Treatment Outcome | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; DNA Repair; ErbB Receptors; Female; Gemcitabine; Glutathione; Glutathione Peroxidase; Humans; Lung Neoplasms; Male; Platinum; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-raf; Taxoids | 2011 |
Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; DNA, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nucleoside-Phosphate Kinase; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
[Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2011 |
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Neoplasm Staging; Platinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; ROC Curve | 2012 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study.
Topics: Aerosols; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Forced Expiratory Volume; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2011 |
Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Risk Factors | 2011 |
Combination chemotherapy for older adults with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Minor Histocompatibility Antigens; NF-kappa B; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Molecular Mimicry; Paclitaxel; RNA Interference; Tumor Burden; Tumor Necrosis Factor-alpha; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Xeroderma Pigmentosum Group D Protein | 2011 |
Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antitussive Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Noscapine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.
Topics: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Differentiation; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome | 2011 |
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Genotype; HapMap Project; Humans; Lung Neoplasms; Polymorphism, Genetic; Signal Transduction | 2012 |
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Pneumonectomy; Postoperative Complications; Psychosurgery; Retrospective Studies; Thoracic Surgery, Video-Assisted; Thoracotomy; Treatment Outcome | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromogranins; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genotype; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prognosis; Proportional Hazards Models | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymerase Chain Reaction; Polymorphism, Genetic; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2012 |
[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Constipation; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomatitis; Vinblastine; Vinorelbine | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 2012 |
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hemorrhage; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pulmonary Embolism; Retrospective Studies; Risk Factors; Survival Rate | 2012 |
UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Conjugating Enzymes | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Bronchoesophageal fistula in a patient with stage IIIB non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Fistula; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Tomography, X-Ray Computed | 2012 |
Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Gene Frequency; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Survival Rate | 2012 |
Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Period; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diffusion; Gemcitabine; Humans; Lung Neoplasms; Models, Biological; Viscosity | 2012 |
IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatin Immunoprecipitation; Cohort Studies; Deoxycytidine; DNA Modification Methylases; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Interleukin-23; Lung Neoplasms; Macrophages; Neoplasm Staging; Tumor Cells, Cultured | 2013 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine | 2013 |
Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Survival Rate; Young Adult | 2012 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-akt; Repetitive Sequences, Nucleic Acid | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Old drugs: new complications.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infarction; Kidney; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Splenic Infarction; Tomography, X-Ray Computed | 2013 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxyuridine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; HCT116 Cells; Humans; Lung Neoplasms; Mice; Prodrugs; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Chemotherapy of advanced non-small cell lung cancer with the combination of gemcitabine and cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
Treatment of advanced non-small-cell lung cancer with two-drug combinations.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Patient Selection | 2002 |
[Gemcitabine in the treatment of advanced non-small cell lung cancer: report of one case].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Decision Making; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life | 2002 |
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Combined platinum containing treatment in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis | 2002 |
The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Quality of Life | 2002 |
[Severe interstitial pneumonitis related to Gemcitabine].
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Respiratory Distress Syndrome | 2002 |
[Weekly administration of gemcitabine in outpatient clinic for non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Ambulatory Care Facilities; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Timing is everything, or could be.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2003 |
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Design; Drug Stability; Esterases; Female; Fluorouracil; Humans; Lung Neoplasms; Mice; Oxidoreductases; Prodrugs; Thymidine Phosphorylase; Tissue Distribution; Uracil; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2003 |
Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Injections, Spinal; Lung Neoplasms; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Ribonucleotide Reductases; Tomography, X-Ray Computed | 2003 |
Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Successful treatment with chemotherapy of vinorelbine and gemcitabine for an elderly patient with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Vinblastine; Vinorelbine | 2003 |
[Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Middle Aged; Ribonucleotide Reductases | 2003 |
[Combination therapy with vinorelbine and gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2003 |
Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Smoking | 2003 |
[Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Etoposide; Feasibility Studies; Female; Gemcitabine; Hospital Mortality; Humans; Lung; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiotherapy Dosage; Survival Analysis | 2003 |
Supportive care in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Vinblastine; Vinorelbine | 2003 |
[Gemcitabine-cisplatin combination in the first line treatment of non-small cell lung cancer. Our experience and analysis of safety].
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Constipation; Creatinine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Eruptions; Dyspnea; Female; Gemcitabine; Hemoglobins; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies; Severity of Illness Index; Taste Disorders; Thrombocytopenia; Treatment Outcome | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
[Two cases of radiation myositis probably induced by recall phenomenon].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Myositis; Radiation-Sensitizing Agents; Radiotherapy | 2003 |
Special patients, special treatments.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Fever; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Population Dynamics; Taxoids | 2003 |
A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
[Home chemotherapy for lung cancer: a five year retrospective study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hospital Bed Capacity; Humans; Lung Neoplasms; Male; Medication Errors; Middle Aged; Quality of Life; Retrospective Studies; Safety; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2003 |
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Home Care Services; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Treatment Outcome | 2003 |
[Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2003 |
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Costs and Cost Analysis; Deoxycytidine; Drug Costs; Europe; Gemcitabine; Hospital Costs; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies | 2004 |
Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2004 |
Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Vinblastine; Vinorelbine | 2004 |
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2004 |
High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycins; Phlebitis; Retrospective Studies; Risk Factors; Vinblastine; Vinorelbine | 2004 |
Multidisciplinary management of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 2004 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Carbon-Nitrogen Ligases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytosine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
[Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Resistance, Multiple; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Survival Rate; Vault Ribonucleoprotein Particles; Vinblastine; Vinorelbine | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Topics: Affinity Labels; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thioinosine; Tumor Cells, Cultured | 2004 |
Treatment of advanced non-small-cell lung cancer in special populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Combination chemotherapy of gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Health Status; Humans; Lung Neoplasms; Quality of Life; Reproducibility of Results; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 2004 |
Symptom-free T4 lung cancer with bilateral pulmonary artery infiltration.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pulmonary Artery; Radiography | 2005 |
Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin.
Topics: Anti-Asthmatic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Separation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Flow Cytometry; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Propidium; Proto-Oncogene Proteins c-bcl-2; Resting Phase, Cell Cycle; Theophylline | 2005 |
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Embolism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Thrombosis; Time Factors | 2005 |
Gemcitabine, pemetrexed, and novel agents in the treatment of thoracic cancer. Selected presentations from the 10th World Congress on Lung Cancer. Vancouver, Canada.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed | 2004 |
[Cisplatin schedule in combination with gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Length of Stay; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia | 2005 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Fragmentation; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topotecan | 2005 |
Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspases; Cell Line, Tumor; Deoxycytidine; DNA Fragmentation; fas Receptor; Female; Gemcitabine; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, SCID; Transplantation, Heterologous | 2005 |
Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Approval; Drug Combinations; France; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vindesine | 2005 |
[Acute myocardial infarction induced by lung cancer chemotherapy after radiation of left lung].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction | 2005 |
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Glutamates; Growth Inhibitors; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2005 |
Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 2005 |
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: pharmacoeconomic considerations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2005 |
Chemotherapy for non-small cell lung cancer in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Thrombosis | 2005 |
The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Utilization; Drugs, Investigational; Evidence-Based Medicine; Female; Financing, Government; Gemcitabine; Humans; Male; Middle Aged; National Health Programs; Ontario; Practice Guidelines as Topic; Vinblastine; Vinorelbine | 2005 |
Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Postoperative Complications; Radiotherapy, Adjuvant; Survival Analysis; Thoracotomy; Vinblastine; Vinorelbine | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
A phase I study of moderate-dose radiation therapy and weekly gemcitabine in patients with locally advanced non-small cell lung cancer not suitable for radical chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiation Pneumonitis; Radiotherapy; Radiotherapy Dosage; Time Factors | 2005 |
Synergistic interaction of hyperthermia and Gemcitabine in lung cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms | 2005 |
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Lung Neoplasms; NF-kappa B; Transcription, Genetic; Vorinostat | 2005 |
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Prognosis; Quality of Life; Vinblastine; Vinorelbine | 2005 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Pyrazoles; Sulfonamides; Thalidomide | 2005 |
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Survival Rate | 2005 |
Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine | 2005 |
Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate | 2005 |
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Using translational research to tailor the use of chemotherapy in the treatment of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Drug Delivery Systems; Endonucleases; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2005 |
The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 2005 |
Incorporating novel agents with gemcitabine-based treatment of NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2005 |
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Enzyme Activation; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases | 2005 |
Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2006 |
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Topics: 14-3-3 Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Drug Administration Schedule; Exonucleases; Exoribonucleases; Female; Gemcitabine; Gene Silencing; Genes, cdc; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Prospective Studies | 2005 |
Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 2006 |
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; Gemcitabine; Genotype; Humans; Lung Neoplasms; Polymorphism, Genetic; Survival Analysis | 2006 |
Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Croatia; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2005 |
Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Lung Neoplasms; Male | 2006 |
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 2006 |
Relationship between cisplatin administration and the development of ototoxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Audiometry; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hearing; Hearing Loss; Hearing Loss, High-Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 2006 |
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity.
Topics: Aged; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dihematoporphyrin Ether; Dose-Response Relationship, Drug; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Resting Phase, Cell Cycle | 2006 |
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatin Immunoprecipitation; Cisplatin; Deoxycytidine; Dihydro-beta-Erythroidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Nicotine; Paclitaxel; Promoter Regions, Genetic; Receptors, Nicotinic; Retinoblastoma Protein; Survivin; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2006 |
[A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Phosphoproteins; Protein Biosynthesis; RNA Caps; Transfection | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; MutL Protein Homolog 1; MutL Proteins; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
[Maintenance chemotherapy in advanced NSCLC].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Karnofsky Performance Status; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Time Factors; Vinblastine; Vinorelbine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Gemcitabine-cisplatin chemotherapy before lung resection: a case-matched analysis of early outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Critical Care; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Length of Stay; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Postoperative Complications; Retrospective Studies; Selection Bias; Statistics, Nonparametric; Treatment Outcome | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Europe; Gemcitabine; Humans; Japan; Lung Neoplasms; Platinum; Retrospective Studies; Survival Rate; Taxoids; United States; Vinblastine; Vinorelbine | 2006 |
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2006 |
Intramedullary metastases due to non microcytic lung carcinoma.
Topics: Adenocarcinoma; Bone Marrow Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Docetaxel; Frontal Lobe; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Taxoids; Thoracic Vertebrae; Vinblastine; Vinorelbine | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Tolerance; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunologic Factors; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotides; Pemetrexed; RNA, Messenger; Toll-Like Receptor 9; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Glutamates; Guanine; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Pemetrexed; Phosphodiesterase Inhibitors; Purinones; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Suppressor Proteins | 2006 |
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2006 |
[Myositis as a 'radiation-recall phenomenon' following palliative chemotherapy with carboplatin-gemcitabin for non-small-cell pulmonary carcinoma].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiation-Sensitizing Agents | 2006 |
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2006 |
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2006 |
Metastatic non-small-cell lung carcinoma successfully treated with pre-operative chemotherapy and bilateral adrenalectomy.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Splenectomy | 2006 |
Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2007 |
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy.
Topics: Aged; Analysis of Variance; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Europe; False Positive Reactions; Female; Gemcitabine; Hemoglobins; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Palliative Care; Platinum Compounds; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2007 |
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Middle Aged | 2006 |
An unusual case of gemcitabine-induced radiation recall.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiodermatitis | 2006 |
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Deoxycytidine; DNA Methylation; DNA Primers; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Proportional Hazards Models; Tumor Suppressor Proteins | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
Chemotherapy induced reversible posterior leukoencephalopathy syndrome.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalography; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Ribonucleotide Reductases; Tomography, X-Ray Computed | 2007 |
Operative complications and early mortality after induction therapy for lung cancer.
Topics: Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Postoperative Complications; Preoperative Care; Radiation-Sensitizing Agents; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome | 2007 |
Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Vinblastine; Vinorelbine | 2007 |
Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Attitude to Health; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Patient Compliance; Patient Satisfaction; Physician-Patient Relations; Prospective Studies; Ribonucleotide Reductases; Surveys and Questionnaires | 2007 |
Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fingers; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged | 2007 |
Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Probability; Retrospective Studies; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2007 |
Pick the winner designs in phase II cancer clinical trials.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Gemcitabine and carboplatin chemotherapy safely administered to a patient with homocystinuria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Homocystinuria; Humans; Lung Neoplasms; Male; Middle Aged | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Risk Factors | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Nude; Retinoid X Receptors; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2007 |
A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Proliferation; Cells, Cultured; Deoxycytidine; DNA; Drug Resistance; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Tissue Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.
Topics: Apoptosis; Bioreactors; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Time Factors; Tumor Stem Cell Assay | 2007 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
[Consideration of preventive free-flowing IV infusion method for vinorelbine].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Phlebitis; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Second; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Taxoids; Tomography, X-Ray Computed | 2008 |
Chemotherapy improves low performance status lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2007 |
[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Thrombocytopenia | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis | 2008 |
[Non-small-cell bronchial carcinoma--induction--combined with radiochemotherapy--a more certain alternative].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids | 2007 |
Bilateral renal infarction in a patient with lung carcinoma treated with cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infarction; Kidney; Lung Neoplasms; Middle Aged; Tomography, X-Ray Computed | 2007 |
Bevacizumab: optimal dose, schedule, and duration of therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Macrophages, Alveolar; Receptors, CXCR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2008 |
[Non-small cell lung neoplasms--weekly taxane combinations are possible].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2007 |
Does saturable formation of gemcitabine triphosphate occur in patients?
Topics: Adipose Tissue; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Body Weight; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Creatinine; Cytidine Triphosphate; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Prodrugs; Prospective Studies; Randomized Controlled Trials as Topic | 2008 |
Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2008 |
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2008 |
[Combination of carboplatin and gemcitabine is a safe and feasible regimen in adjuvant therapy for stage II and IIIA NSCLC].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2008 |
Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lung Neoplasms; Methotrexate; Transcription Factors | 2008 |
Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bronchial Neoplasms; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Fanconi Anemia; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Pulmonary Artery; Whole-Body Irradiation | 2008 |
A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Gemcitabine: current status of phase I and II trials.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Research | 1994 |
Gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1995 |
Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Receptor, ErbB-2; Regression Analysis; Tumor Cells, Cultured | 1996 |
Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasms | 1995 |
Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Etoposide; Gemcitabine; Germany; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging | 1995 |
Treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1996 |
Gemcitabine for lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Lung Neoplasms; Survival Rate | 1996 |
An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging | 1996 |
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Cytarabine; Daunorubicin; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Software; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Comment: vinorelbine and gemcitabine--new antineoplastic drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 1996 |
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Stem Cell Assay | 1996 |
Gemcitabine: safety profile unaffected by starting dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Kidney Function Tests; Liver Function Tests; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Ribonucleotide Reductases; Vomiting | 1996 |
Gemcitabine shows promise as combination agent in NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Survival Rate | 1996 |
Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1997 |
More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1997 |
The emerging role of gemcitabine in lung cancer: part I.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 1997 |
In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Models, Theoretical; Ribonucleotide Reductases; Tumor Cells, Cultured | 1997 |
Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Topics: Antimetabolites, Antineoplastic; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Health Care Costs; Health Resources; Humans; Lung Neoplasms; Models, Economic; Neoplasm Staging; Ribonucleotide Reductases; Survival Rate | 1997 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Organoplatinum Compounds; Taxoids; Vinca Alkaloids | 1997 |
Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Tolerance; Edema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Safety | 1997 |
Gemcitabine-induced hemolytic uremic syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged | 1997 |
Gemcitabine-associated autonomic neuropathy.
Topics: Antimetabolites, Antineoplastic; Autonomic Nervous System Diseases; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Daunorubicin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Gemcitabine; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1998 |
Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Nucleoside Deaminases; Pancreatic Neoplasms; Thymidine Kinase; Transplantation, Heterologous | 1998 |
Effects of gemcitabine on renal function in patients with non-small cell lung cancer.
Topics: Adult; Aged; Albuminuria; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erythrocytes; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Renal Plasma Flow, Effective | 1998 |
Veno-occlusive disease of the liver induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Budd-Chiari Syndrome; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatic Encephalopathy; Humans; Lung Neoplasms; Middle Aged | 1998 |
[New cytostatics in the therapy of non-small cell bronchial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Lung Cancer Experts' Symposium. Proceedings. Stresa, Italy, October 1997.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Sweden; Treatment Outcome | 1998 |
Gemcitabine--a major advance?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Pancreatic Neoplasms | 1998 |
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytosine Nucleotides; DNA Damage; Drug Synergism; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured | 1999 |
Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 1999 |
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Commentary on "Gemcitabine: single-agent and combination therapy in non-small cell lung cancer". The Oncologist 1999;4:241-251.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Practice Guidelines as Topic; Research; Treatment Outcome | 1999 |
Gemcitabine--a new agent in the treatment of non-small cell lung cancer. A commentary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life | 1999 |
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphokines; Male; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Oxidative Stress; Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vindesine | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Immunohistochemistry; Lung Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Lung Neoplasms; Mice; Neoplasm Transplantation | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Gemcitabine-containing regimens in non-small cell lung cancer: are these standard therapies or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Necrosis; Retinal Diseases; Skin Diseases, Vascular; Vasculitis | 2000 |
Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Nude; Mitomycin; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Mice; Paclitaxel; RNA, Neoplasm; Tumor Cells, Cultured | 2000 |
Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Deoxycytidine; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; NF-kappa B; Tumor Cells, Cultured | 2000 |
Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged; Peripheral Vascular Diseases | 2000 |
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Rapid reduction of platelet numbers in thrombocytosis.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Platelet Count; Plateletpheresis; Thrombocytosis; Time Factors | 2000 |
Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; DNA Fragmentation; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
A fatal case of cholestatic liver failure probably related to gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Failure; Lung Neoplasms; Male; Multiple Organ Failure | 2000 |
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Topics: Antineoplastic Agents; Blood Platelets; Body Fluid Compartments; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Hematologic Diseases; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Models, Biological; Neutropenia; Neutrophils; Platelet Count | 2000 |
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Chloromethyl Ketones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cisplatin; Cytochrome c Group; Cytosol; Deoxycytidine; DNA, Complementary; Fas-Associated Death Domain Protein; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Jurkat Cells; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Spectrometry, Fluorescence; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings.
Topics: Antimetabolites, Antineoplastic; Brain; Brain Injuries; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Syndrome | 2001 |
Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life | 2001 |
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mucous Membrane; Neutropenia; Thrombocytopenia; Treatment Outcome | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
[Gemcitabine and cisplatin as induction therapy for patients with histologically proven stage IIIA-N2 non-small-cell bronchial cancer: a phase-II study of the EORTC Cooperative Group (EORTC 08955)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Treatment Outcome | 2001 |
Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drosophila Proteins; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Insect Proteins; Lung Neoplasms; Tumor Cells, Cultured | 2001 |
Chemotherapy and quality of life in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Placebos; Quality of Life; Randomized Controlled Trials as Topic | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Genes, p53; Genes, Retinoblastoma; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Prognosis | 2001 |
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
Drug resistance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Proteins; Survival Analysis | 2001 |
Gemcitabine-induced systemic capillary leak syndrome.
Topics: Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cytochrome c Group; Deoxycytidine; DNA Fragmentation; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; NF-kappa B; Tumor Cells, Cultured | 2002 |
Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Eruptions; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2001 |
Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bronchi; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Transformed; Cisplatin; Cyclin-Dependent Kinases; Deoxycytidine; DNA; DNA, Neoplasm; Drug Interactions; Enzyme Inhibitors; Epithelial Cells; Fibroblasts; Flavonoids; Gemcitabine; Humans; Lung Neoplasms; Piperidines; S Phase; Tumor Cells, Cultured | 2002 |
[An elderly patient with advanced non-small-cell lung cancer that responded remarkably to combination chemotherapy of vinorelbine and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Vinblastine; Vinorelbine | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Vasculitis due to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Muscles; Muscular Diseases; Necrosis; Treatment Outcome; Vasculitis | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |